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ABSTRACT 
 
This PhD project sets out to investigate the role of genetic factors associated with fetal 
growth restriction and recurrent miscarriage (RM), two of the most common complications of 
pregnancy. This work studied large cohorts of patients collected from specialist clinics in 
West London with the aim of better understanding their underlying molecular aetiology.  
The first part of this project focused on the paternally expressed, maternally imprinted 
gene, IGF2, which is a key growth hormone critical for in utero growth in mice. Its role in 
human fetal growth has remained ambiguous, as it has only been studied in term tissues. 
mRNA expression levels of IGF2 and other genes were investigated in 260 chorionic villus 
samples collected at 11-13 weeks’ gestation. Transcript levels of IGF2 revealed a significant 
positive correlation with birth weight (P=0.009). Critically, small for gestational age neonates 
had significantly lower IGF2 levels than appropriate for gestational age neonates    
(P=3.6x10
-7
).  
Next a study was undertaken to investigate a potential role for disturbed imprinting in 
products of conception (POC). This work first involved a detailed analysis of the POC DNA 
to establish levels of maternal cell contamination. POCs could then be more accurately 
evaluated to investigate the status of known imprinted genes. Interestingly, in a number of 
POCs, known maternally expressed genes were found to be paternally expressed and vice 
versa. This suggested that some miscarriages might be associated with or even caused by 
abnormal imprinting. 
        Two approaches were then used to study genetic factors associated with RM. The 
first involved a genetic association study with a placental anti-coagulant protein Annexin A5 
that contains four nucleotide substitutions (M2 haplotype) in its promoter. Patient and control 
haplotypes were determined and compared in 500 White European pairs that had RMs and 
250 control trios. Carriers of the M2 haplotype were found to exhibit higher RM risk than 
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non-carriers, which was in agreement with previous studies. However, this is only true for the 
patients who suffered with early miscarriages.  
The second study involved analysis of a single family where the patient had 
experienced a total of 29 miscarriages but had no successful pregnancies. Next-generation 
exome sequencing was carried on family members to search for a potential rare genetic 
variant gene causative of the RM phenotype. Two candidate genes with potentially damaging 
mutations were investigated in more depth by sequencing them in cohorts of Asian RM 
patients (n=100) and White European RM patients (n=120). In one of the genes, three novel 
variants and one very rare SNP, which were all predicted to be damaging by different 
prediction programs, were identified in a total of four Asian patients. Future studies to further 
investigate these potential mutations, involves functional analysis of each variant such as site-
directed mutagenesis and protein-protein interactions.   
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CHAPTER 1 – INTRODUCTION 
The research in this PhD investigates genetic factors associated with complications of 
pregnancy (Fig. 1-1), in particular fetal growth restriction (FGR) and recurrent miscarriage 
(RM), with the latter including both early and late miscarriage. The first part of the 
introduction focuses on normal fetal growth, FGR and a class of genes (imprinted genes) that 
are involved in fetal growth. The second part of the introduction describes miscarriage and 
the currently known causes of RM. 
 
Figure 1-1: Stages of onset of common pregnancy complications.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1st trimester 2nd trimester 3rd trimester 
Early miscarriage  Late miscarriage  FGR 
Pre-eclampsia Prematurity 
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1.1 Fetal growth and intrauterine restriction 
1.1.1 Normal fetal growth 
Growth is defined as the progressive increase in size. It is a complex process of 
multifactorial origin, as both genes and environment are involved. The normal growth of a 
fetus is dependent upon the balanced interaction between the mother, the fetus and the 
placenta, the latter being responsible for the blood flow and nutrient transportation from the 
mother to the fetus. Any deviation from this normal interaction can have a detrimental effect 
on fetal growth (Abu-Amero et al., 2006). 
The pattern of normal human fetal growth can be divided into three consecutive 
stages, often referred to as trimesters. The first trimester (weeks 0-12) is associated with rapid 
cell mitosis and thus an increase in cell numbers. At this stage, the fetus grows at 
approximately 5 g/day. The second trimester (weeks 13-27) includes hypertrophy and 
hyperplasia and during this stage the fetus has a growth rate of 15-20 g/day. The third 
trimester and final stage, which occurs from 28 weeks of gestation until term, has a fetal 
growth rate of 30-35 g/day and involves an increase in both cell number and size with 
accumulation of muscle, fat and connective tissues (Williams et al., 1982; Pollack and Divon, 
1992; Monk and Moore, 2004). 
Each baby has a unique growth potential in utero due to both length of the pregnancy 
and physiological variations, which include the baby's gender, parity, ethnicity and maternal 
characteristics such as weight, height and smoking status as well as gestational age (GA). 
Therefore, all of these factors need to be taken into account when assessing fetal growth. 
GA is considered to be the most influential marker of birth weight, and its accurate 
measurement is critical for the correct estimation of fetal birth weight centiles (Wilcox et al., 
1993). Gender also contributes to fetal growth variation, as on average, males are bigger in 
size and have a higher average birth weight of about 145 g than females (Hindmarsh et al., 
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2002). It is also reported that the first pregnancy for a mother is on average 184 g smaller in 
birth weight than subsequent pregnancies (Hindmarsh et al., 2002) therefore the influence of 
parity has also to be considered. This may be attributed to an improved uterine environment 
in subsequent pregnancies, such as a stretched uterine wall with a better circulatory system.  
There is also variability in the mean birth weight among different ethnic groups. For 
example, the average birth weight of babies of mothers of Indian origin was found to be 
approximately 260 g smaller than those of European origin (Wilcox et al., 1993). Fetal 
growth is further affected by maternal physical characteristics such as weight and height, with 
positive correlations being observed for heavier and taller mothers (Mongelli and Gardosi, 
1995). Cigarette smoking during pregnancy has been associated with a reduction in birth 
weight in a dose dependent manner (Bernstein et al., 2005; Cliver et al., 1995). A reduction 
has been observed of approximately 12 to 27 g in birth weight for every cigarette per day 
consumed during the third trimester (Bernstein et al., 2005; England et al., 2001). The 
underlying mechanism is likely to include decreased oxygen delivery to the fetus due to 
increased carbon monoxide concentration and narrowing of the uterine blood vessels caused 
by nicotine (Pollack and Divon, 1992). 
 
1.1.2 Fetal growth restriction  
FGR (also known as intrauterine growth restriction, IUGR) is defined as the failure of 
a fetus to attain its expected growth potential at any gestational stage, and it is one of the 
most common phenotypes resulting from a disruption to the balanced interaction between the 
mother, the fetus and the placenta (reviewed in Abu-Amero et al., 2006). Despite the 
established clinical significance of growth restriction, standard parameters used to describe its 
condition may still vary. FGR is commonly defined as an estimated birth weight being below 
the 10th percentile at a given GA (Resnik, 2002).  
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Although not synonymous, there is considerable overlap between the terms low birth weight 
(LBW), small for gestational age (SGA) and FGR. According to the World Health 
Organization, LBW is defined as a birth weight below 2500 g irrespective of the GA. SGA 
refers to the condition where the growth parameter of a baby falls below the 10
th
 percentile 
for their GA. However, these babies have a normal growth velocity in utero, and therefore are 
simply constitutionally small rather than pathologically growth restricted (Wilcox, 1983). 
Therefore, FGR babies can be classified as SGA, but not all SGA babies are growth 
restricted. It has been estimated that about 50 to 70% of SGA babies are constitutionally 
small (Ott, 1988). Developments in Doppler ultrasound of the maternal and fetal circulation, 
fetal heart rate analysis, and biophysical profile have improved the diagnosis of both FGR 
and SGA. SGA pregnancies often exhibit a normal fetal Doppler test, whilst FGR, due to 
placental disease, exhibit characteristic maternal and fetal Doppler abnormalities (Ott, 2000). 
The incidence of FGR is estimated to be approximately 5-7% (Brodsky and Christou, 
2004). The most common form of FGR results in asymmetric growth restriction (70-80%) 
and refers to a disproportionate decrease in the fetal abdominal size relative to the head; this 
is likely to result if growth is impaired during the last trimester (Lin et al., 1991). The 
etiology for asymmetric FGR is mostly extrinsic and includes maternal and placental vascular 
factors e.g. placental insufficiency. Symmetric growth restriction (20-30%) is characterised 
by the proportionate decrease in both fetal head and abdominal circumference. This is likely 
to occur if fetal growth is impaired during the first or second trimester, thereby disturbing the 
cellular hyperplasia phase, leading to a proportionate reduction in all fetal organ sizes. The 
etiology for symmetric growth restriction is mostly intrinsic including chromosomal 
abnormalities and congenital malformations. Infants with symmetric FGR have a higher 
morbidity and mortality rate than asymmetric FGR infants (Pollack and Divon, 1992; 
Brodsky and Christou, 2004). 
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FGR is of clinical interest because it is associated not only with immediate medical 
problems such as hypoglycaemia, hypothermia (Doctor et al., 2001) and neurological delay, 
but because it influences later life and is associated with common adult-onset diseases such as 
hypertension, type 2 diabetes (T2D) and cardiovascular disease (Barker, 1992; Ong and 
Dunger, 2002; Simmons, 2009). The majority of FGR infants usually demonstrate catch-up 
growth during the first two years of life, with most of them achieving this growth in the first 
six months (Hediger et al., 1998). Infants with LBW have a 10 times higher risk of mortality 
than infants with normal birth weight (10 to 90th percentile) (McCormick, 1985; McIntire et 
al., 1999). 
 
1.1.3 Anthropometric measurements to predict birth weight 
Accurate determination of in utero fetal weight is crucial. Measuring fetal body 
parameters allows assessment of the growth pathway of the fetus and helps in predicting and 
managing FGR and other pathological conditions (Brodsky and Christou, 2004). Ultrasound 
has been used since the 1960s as a tool for determining fetal size. Measurements are normally 
taken in the first trimester and these include crown-rump length (CRL), measured usually 
between 7 to 13 weeks. CRL is also used to provide an accurate estimation of GA. The fetal 
biparietal diameter that refers to the diameter between the two sides of the head, the femur 
length that reflects the longitudinal growth of the fetus as this is the measurement of the 
longest bone in the body and the fetal abdominal circumference and head circumference are 
also taken (Stetzer et al., 2002; Loughna et al., 2009). The weight of the fetus can then be 
estimated at any gestation with great precision through the use of equations containing 
different combinations of these anthropometric measurements (Stetzer et al., 2002; Mu et al., 
2008; Loughna et al., 2009). 
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1.1.4 Causes of FGR 
FGR is a multifactorial disease with both genetic and environmental factors playing 
variable roles. The major cause of FGR in the Western world is placental insufficiency, 
whereas in developing countries, malaria infections and inadequate maternal nutrition play a 
larger role (Brodsky and Christou, 2004). In addition, there is a strong association between 
FGR and chromosomal abnormalities, as fetuses with chromosomal disorders such as trisomy 
13, 18 and 21 are often growth impaired. Oxygen deprivation, as well as other maternal 
environmental factors such as smoking, drug abuse and alcohol consumption, are also known 
causes of FGR (Brodsky and Christou, 2004; Aagaard-Tillery et al., 2008; Miller et al., 
2008). Known factors associated with FGR are summarized in Table 1-1. 
 
Table 1-1: Maternal, Placental and Fetal Etiologies of FGR.  
(table adapted from Brodsky and Christou, 2004; Monk and Moore, 2004). 
 
Maternal Placental Fetal 
Vascular disorders 
-Hypertension 
-Diabetes mellitus 
Partial placental separation Chromosomal abnormality 
-Aneuploidy 
High-altitude pregnancy 
-Hypoxia 
Abnormal trophoblast 
invasion 
Multifactorial congenital 
malformations 
Hypercoagulable states 
-Thrombophilia 
-Antiphospholipid antibody 
syndrome 
Placental infarction Intrauterine infection 
-Malaria 
-Cytomegalovirus 
-Rubella 
Substance abuse 
-Smoking 
-Alcohol 
-Drugs 
Placenta previa  
 
Aberrant genomic 
imprinting 
-Uniparental Disomy 
-Epimutations 
Malnutrition Small placenta Multiple gestation 
Constitutionally smaller 
mother 
Uteroplacental 
insufficiency 
 
Lack of second-trimester 
weight gain 
Umbilical-placental 
vascular anomalies 
 
 Pre-eclampsia  
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The aforementioned potential factors that may lead to FGR can influence the function 
of the placenta, the maternal supply of nutrients and oxygen to the fetus as well as the ability 
of the fetus to use this supply (Brodsky and Christou, 2004). Although many factors have 
been implicated in the process of fetal growth and development, the underlying molecular 
and cellular mechanisms regulating normal fetal growth are still poorly understood. There are 
many genes involved in fetal growth and development, but of particular interest in 
understanding fetal growth is the group of genes found in Eutherian (placental) mammals, 
known as imprinted genes.  
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1.2 Genomic Imprinting 
In diploid mammals, most autosomal genes are expressed equally from the paternal 
and maternal alleles, resulting in biallelic expression. However, there is a small subset of 
genes, termed imprinted genes that show parent-specific expression. The differential 
expression of a gene, according to its parental origin of inheritance, is defined as genomic 
imprinting. That is, although both parental alleles are present, only one of them is active 
while the other is switched off, i.e. if the paternal allele is expressed, the maternal allele is 
imprinted (silenced) and vice versa (Fig. 1-2) (Hitchins and Moore, 2004; Abu-Amero et al., 
2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2: Genomic Imprinting (adapted from Hitchins and Moore, 2004). 
a) As with most genes, a biallelic gene is expressed from both parental copies. 
b) A maternally expressed gene is expressed specifically from the maternal allele and 
silenced on the paternal allele.   
c) A paternally expressed gene is expressed specifically from the paternal allele and 
silenced on the maternal allele. 
 
 
 
1.2.1 The discovery of imprinting  
Evidence of genomic imprinting was first provided by mouse pronuclear 
transplantation experiments, where diploid mouse embryos were created but with the nuclear 
material derived solely from one parental genome (McGrath and Solter, 1984; Surani et al., 
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1984; Barton et al., 1984). These embryos contained either the paternal (androgenetic) 
genome or the maternal (gynogenetic) genome only. All of these embryos failed to develop 
post-implantation, demonstrating that diploidy is not sufficient for normal development. 
Moreover, both parental genomes are required, since the maternal and the paternal 
contributions to the embryo are not equivalent. In fact, the paternal genome appears essential 
for normal development of the trophoblast and the embryonic membrane, whereas the 
maternal genome is critical for embryogenesis (Barton et al., 1984; McGrath and Solter, 
1984). Subsequent mouse studies revealed that the parental origin effect was localised to 
specific chromosomal regions (Cattanach and Kirk, 1985; Searle and Beechey, 1990). The 
regions containing parent-of-origin effects were further narrowed down to clusters of genes, 
and in some cases to single genes, which are now known as imprinted genes.  
 
1.2.2 The “parental conflict hypothesis” 
The most widely accepted explanation for genomic imprinting is the “parental conflict 
hypothesis” put forward by Moore and Haig. This hypothesis is based on the conflicting 
interests of the two parental genomes during the offspring’s growth and development. The 
father’s contribution is concerned primarily with the development of his offspring, ensuring 
that it gets maximal growth and that it is the fittest, allowing the paternal genome to pass on 
to successive generations. The mother meanwhile, is concerned with distributing equal 
resources to each individual within her litter and at the same time, restricting fetal growth to 
ensuring her own survival and ability to reproduce in the future. This theory is strongly 
supported by the fact that genomic imprinting is common in placental animals, while 
imprinted genes are frequently monoallelically expressed specifically in the placenta, a tissue 
which plays a major role in the allocation of resources from the mother to the fetus (Moore 
and Haig, 1991).  
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The behaviour of several imprinting genes support this model, with the most striking 
example being the complementarity of the mouse genes insulin-like growth factor II (Igf2) 
and insulin-like growth factor II receptor (Igf2r) which show reciprocal imprinting effects in 
embryos. Igf2 is paternally expressed and encodes an embryonic growth factor and Igf2r in 
mice is maternally expressed and its product inhibits Igf2 function (Willison, 1991). Loss of 
function of Igf2 results in a 40% reduction in birth weight (DeChiara et al., 1991), whereas 
mutation of Igf2r on the maternal allele produces non-viable, over-sized mice (Lau et al., 
1994) (more details about human IGF2 and IGF2R are given in Chapter 2). Another example 
supporting this model comes from mice with uniparental disomy (UPD). Mice with maternal 
UPD11 have LBW (70%) compared to their wild littermates, whereas mice with paternal 
UPD11 are larger (130%) (Cattanach and Kirk, 1985). 
 
1.2.3 Uniparental disomy 
UPD occurs when both homologues of a particular chromosome are inherited from a 
single parent. Therefore, paternal UPD can occur when there are two copies of the paternal 
allele and no copy of the maternal allele or vice versa. In cases of UPD for the whole 
chromosome, individuals appear to be cytogenetically normal, as they have a balanced 
number of chromosomes (Hitchins and Moore, 2004). Such UPD cases are associated with 
clinical disorders in humans and provide further evidence for genomic imprinting. For 
example, Prader-Willi syndrome can be caused by paternal UPD for chromosome 15 
(pUPD15) (Robinson et al., 1991), Silver-Russell syndrome (SRS) can be caused by maternal 
UPD for chromosome 7 (mUPD7) (Kotzot et al., 1995) and Beckwith-Wiedemann Syndrome 
(BWS) can be caused by segmental pUPD11 (Slatter et al., 1994). Both, SRS and BWS 
provide examples of where disrupted imprinting is associated with growth phenotypes, either 
growth restriction or overgrowth respectively.  
29 
 
SRS is a growth disorder characterised by pre- and postnatal growth retardation, limb 
and truncal asymmetry, lack of subcutaneous fat and macrocephaly. mUPD7 occurs in about 
10% of SRS cases (Preece et al., 1997). Overexpression of a growth inhibitor that is active on 
the maternal chromosome 7, or lack of a functional growth-promoting gene that is active on 
the paternal allele, could be causing SRS.  Cases of SRS have been reported that have a 
maternal duplication of region 7p11.2-p13, a region that is homologous to the mouse-
imprinted region on chromosome 11 (Monk et al., 2000). Mice with maternal disomy for that 
region have FGR and mice with paternal disomy are overgrown. The most prevalent 
molecular explanation for SRS, however, is loss of methylation at the H19 differentially 
methylated region (DMR), which is found in some 30-50% of SRS cases (Gicquel et al., 
2005). In these patients, it seems most likely that the growth restriction could be caused by a 
decrease in IGF2 expression, which is linked to H19 methylation although the exact 
mechanism is yet to be fully understood (Frost and Moore, 2010). 
BWS is an overgrowth disorder characterised by pre- or postnatal overgrowth, 
macroglossia, facial dysmorphisms and in some cases organomegaly and Wilms’ tumour. 
Like SRS, the genetics of BWS is complex, and imprinting defects were implied as 
pUPD11p15.5 has been observed in 20% of sporadic cases (Maher and Reik, 2000). This is 
the same region implicated in SRS and it is known to be rich in imprinted genes (Verona et 
al., 2003). Reciprocal to SRS, IGF2 overexpression is strongly implicated in BWS, as in 
some patients it is expressed from both parental alleles. The increase in IGF2 expression 
could be due to hypermethylation of H19 DMR, which is found in about 30% of BWS cases 
(Cooper et al., 2005). In fact, loss of imprinting (LOI) of IGF2 is the most common 
molecular defect seen in sporadic BWS patients (Maher and Reik, 2000). 
 
 
30 
 
1.2.4 Imprinted Genes and their Characteristics 
It is estimated that there are about 200 imprinted genes in the mammalian genome and 
so far about 100 have been identified in mouse and 50 in human (www.otago.ac.nz/IGC). A 
great number of imprinted genes tested so far, exhibit imprinted expression in the placenta 
and yolk sac (Coan et al., 2005; Frost and Moore, 2010). Imprinted genes have three primary 
characteristics: they show monoallelic expression; they are clustered in imprinted domains 
that are evolutionary conserved and show an association with parental-allele-specific 
methylation (Hitchins and Moore, 2004) (for a list of imprinted genes highly expressed in 
human placenta, see Appendix A). 
 
a) Monoallelic expression: 
The major characteristic of imprinted genes is monoallelic expression and refers to the 
transcription of a gene from one parental allele. However, some imprinted genes have 
complex expression patterns, as there are some that are monoallelically expressed only in a 
particular organ or tissue, whereas they are biallelically expressed in other parts of the body. 
Moreover, imprinted genes can be monoallelically expressed during a particular 
developmental stage. For example, human IGF2 is expressed specifically from the paternal 
allele in most fetal tissues such as the liver, but its expression during infancy becomes 
biallelic, so in the adult liver IGF2 is expressed from both parental alleles (Davies, 1994). 
 
b) Clustering into evolutionary conserved domains: 
Imprinted genes tend to occur in clusters in the genome, because their silencing within 
a cluster is regulated by a cis-acting element referred to as the “imprinting centre”. These 
regions as well as the imprinted genes are conserved between humans and mice, indicating 
the importance of imprinting in mammals (Hitchins and Moore, 2004). One of the most well 
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studied clusters in humans is at the proximal end of chromosome 11p15.5. This region shares 
homology to the mouse distal chromosome 7 region (Reik and Walter, 2001; Verona et al., 
2003). 
 
c) Parental-allele-specific methylation: 
Genomic imprinting does not depend on the DNA sequence itself, but on factors that 
regulate the activity of DNA such as the attachments of methyl groups. Thus genomic 
imprinting is an epigenetic phenomenon (Hitchins and Moore, 2004). CpG (cytosine 
phosphate diester guanine) islands are dinucleotide pairs found within DNA. Methyl groups 
can attach to cytosine residues within specific CpG islands and this can modify DNA. CpG 
islands at the 5’end of genes are usually unmethylated so that constitutive expression of the 
genes is allowed.  Methylation of an allele is correlated with its transcriptional inactivation 
and thus methylation is a hallmark of imprinted genes (Neuamann and Barlow, 1996). For 
example, the Igf2r and H19 promoters are methylated on the paternal allele and are thus 
expressed from the maternal allele (Ferguson et al., 1993; Stoger et al., 1993). However, 
exceptions do exist, as IGF2 that is paternally expressed, is methylated on the paternal allele 
(Reik et al., 1994). Modification is most likely taking place during gametogenesis as this is 
the only period when the parental genomes are separated (Barlow, 1993). For more 
information on IGF2 methylation see Chapter 2 and more information on the imprinting 
cycle see Chapter 3.  
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1.3 Miscarriage 
Miscarriage is the commonest complication of pregnancy and it is the spontaneous 
loss of a fetus before it has reached viability (Stirrat, 1990). Hence, the term miscarriage 
includes all the losses between the time of conception to the 24
th
 week of gestation. There are 
two types of miscarriages: sporadic and recurrent. Sporadic miscarriages are experienced by 
at least 25% of all women and this risk increases with increasing maternal age. In fact, the 
risk of fetal loss increases after the age of 35 and the rate of miscarriage can reach up to 75% 
in women who are 45 years and older at the time of conception (Nybo Andersen et al., 2000). 
RM is defined as three or more consecutive pregnancy losses and it affects about 1% of 
couples trying to conceive (Stirrat, 1990). Unlike sporadic miscarriages, RM can occur even 
if the fetus has no chromosomal abnormalities (Sullivan et al., 2004). 
Environmental factors that have been shown to affect pregnancy outcomes include 
cigarette smoking (Lindbohm et al., 2002) and caffeine consumption (Rasch, 2003) which are 
both associated with a dose-dependent risk of miscarriage, the use of cocaine (Ness et al., 
1999) and alcohol consumption (Kesmodel et al., 2002). In addition, evidence suggests that 
obesity is a risk factor for infertility, miscarriage (Clifford et al., 1994; Lashen et al., 2004) 
and late pregnancy complications (Sebire et al., 2001). 
Studies have shown that the risk of miscarriage increases after each successive 
pregnancy loss and it can reach 45% after three consecutive losses (Regan et al., 1989). RM 
has been attributed to a) genetic causes, b) anatomical disorders, c) infective, d) endocrine, e) 
immune, f) thrombophilic disorders or unexplained causes.  
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1.3.1 Genetic causes 
The most important cause of miscarriage before the 10
th
 week of gestation is fetal 
aneuploidy, a deviation from the normal number of 46 chromosomes in humans (Jacobs and 
Hassold, 1987). At least half of all miscarriages are associated with cytogenetic 
abnormalities, where chromosome trisomies are the most frequent ones (Kalousek et al., 
1993). Most aneuploidies in humans arise from errors in the first meiotic division of the 
oocyte and an increased rate of sperm chromosomal abnormalities have been reported in 
couples with RM (Giorlandino et al., 1998). 
In addition, in about 4% of couples with RM, one partner carries either a balanced 
reciprocal translocation or a Robertsonian translocation (Clifford et al., 1994).  In the former, 
there is an exchange of two terminal segments from different chromosomes and in the latter 
there is a centric fusion of two acrocentric chromosomes. Although carriers of a balanced 
reciprocal translocation are phenotypically normal, 50-70% of their gametes and as a 
consequence, embryos are unbalanced.  
Genetic defects in RM relate to skewed X chromosome inactivation in couples with a 
history of RM. Inactivation of the X chromosome occurs randomly early in embryogenesis 
where one of the parental X chromosomes becomes inactivated. Skewed X chromosome 
inactivation is defined as the preferential expression of the maternal or paternal X 
chromosome in more than 90% of peripheral leukocytes. It has been reported to occur 
significantly more often amongst women with RM compared with controls (Lanasa et al., 
1999).  
 
1.3.2 Anatomical disorders 
The frequency of congenital uterine abnormalities in the general population is 
unknown, but in women with RM it is estimated to be between 6% and 38%. This wide range 
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reflects differences in imaging techniques used and differences in diagnostic criteria (Salim et 
al., 2003). Most uterine anomalies relate to defects in the development or fusion of the paired 
Müllerian ducts during embryogenesis. The septate uterus is the most common structural 
uterine anomaly, as approximately 20%-60% of women have a septate uterus that is 
associated with reproductive failure in the first and second trimester of pregnancy.  The 
bicornuate uterus is another important uterine anomaly associated with reproductive failure 
(Grimbizis et al., 2001).   
 
1.3.3 Infection 
Infective causes of RM remain speculative, as for any infective agent to be 
implicated, it has to be capable of being persistent and undetected in the genital tract and 
must cause few maternal symptoms. Rubella, toxoplasmosis, cytomegalovirus and herpes 
infection do not meet these criteria and routine screening for these diseases has now been 
abandoned (Regan et al., 2001). However, the presence of bacterial vaginosis during the first 
trimester of pregnancy has been reported as a risk factor for late miscarriage in the second 
trimester and for early preterm birth (Hay et al., 1994). 
 
1.3.4 Endocrine abnormalities 
Abnormalities in the endocrine system have been hypothesized to cause RM, but few 
reports withstand scrutiny. Studies have shown that well-controlled diabetes is not a risk 
factor for RM (Mills et al., 1988). Hyperprolactinaemia on the other hand, which is the 
increase of prolactin that plays a role in ovulation and endometrial maturation has been 
reported to cause RM. Treatment with bromocriptene that suppresses the secretion of 
prolactin, reduces the rate of miscarriage (Hirahara et al., 1998). 
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The incidence of polycystic ovaries is significantly higher in women with RM (40%) 
than women who had no history of pregnancy complications (22%) (Rai et al., 2000). 
Miscarriage in women with polycystic ovaries syndrome (PCOS) has been associated with 
the plasminogen activator inhibitor 1 (PAI-1) 4G/4G genotype (Glueck et al., 2000a) and 
with high levels of the PAI-1 gene product and activity (Glueck et al., 2000b; Glueck et al., 
2004). 
PAI-1 inhibits plasminogen activators in the fibrin degradation pathway, hence is an 
inhibitor of fibrinolysis, the physiological process that degrades blood clots. Elevated levels 
of PAI-1, due to 4G/5G polymorphisms in the PAI-1 gene promoter, result in deficient 
plasminogen activation and are associated with predisposition to thrombosis. Hence, plasma 
concentrations of fibrin, which is important in remodelling of the tissue that accompanies 
embryonic implantation, are also affected by the polymorphism. Women with PCOS are 
more likely to have PAI-1 4G/4G or 4G/5G genotypes than normal control women and 
women with PCOS have higher PAI-1 levels compared to controls (Diamanti-Kandarakis et 
al., 2004; Glueck et al., 2006). Moreover, the occurrence of the 4G/4G or 4G/5G genotypes 
in pregnant women has been shown to be clinically significant for the pathogenesis of venous 
thromboembolism in pregnancy, but not for early miscarriage (Schenk et al., 2008).   
 
1.3.5 Immune abnormalities 
In pregnancy, hemiallogenic fetal cells remain spared from attack by the maternal 
immune system, posing a great unsolved enigma of immunology. From an immunological 
perspective, survival of the hemiallogenic fetus depends on suppression of the maternal 
immune response. However, no such suppression has been recorded. The current 
understanding of reproductive immunology, suggests a cooperative interaction between the 
maternal immune system and fetal antigens (Moffett-King, 2002).  
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Natural killer (NK) cells are the main type of maternal immune cell that populate the 
uterine mucosa during formation of the placenta. NK cells are lymphocytes, and although 
their function is not fully clear, their abundance at the time of implantation suggests that they 
are important for pregnancy establishment (Moffett-King, 2002).  
There is a link between NK cells and pregnancy loss. Women with RM have more 
CD56+ NK cells in their uterine mucosa than controls and those with the highest levels, if 
remain untreated, have a higher rate of miscarriage in subsequent pregnancies (Clifford et al., 
1999; Koopman et al., 2003). In addition, it has been demonstrated that women with RM 
have more CD16+ uterine NK cells than fertile controls. These NK cells are associated with 
an increased cytotoxic response and their increased number in women with RM may play a 
role in the rejection of the conceptus (Maybin et al., 2010).   
However, uterine NK cells are phenotypically different from the peripheral blood NK 
cells (Koopman et al., 2003) and therefore testing women with RM for levels of NK cells is 
questionable, as no association was observed between levels of NK cells in uterine mucosa 
and peripheral blood and levels of NK in peripheral blood is not predictive of pregnancy 
outcome in women with RM (Moffett et al., 2004). 
 
 
1.3.5.1 Antiphospholipid syndrome 
 
Antiphospholipid syndrome (APLS) is an established cause of RM and it is an 
autoimmune disease caused by the presence of circulating maternal antiphospholipid 
antibodies (aPL) such as anticardiolipin antibodies (IgG, IgM) and lupus anticoagulant (LA) 
that are directed against proteins that bind to phospholipids on plasma membranes (Rai and 
Regan, 2006). The prevalence of APLS in women with RM is 15% (Rai et al., 1995) and 
women with APLS have a miscarriage rate of 90% in subsequent pregnancies if untreated 
(Creagh et al., 1991; Rai et al., 1995).  
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The clinical criteria used for diagnosis of APLS are a) three or more consecutive 
unexplained miscarriages before the 10
th
 week of gestation, or b) one or more unexplained 
deaths of a morphologically normal fetus at 10 week’s gestation or older or c) one or more 
premature births of a morphologically normal fetus at 34 week’s gestation or younger 
associated with severe pre-eclampsia (Wilson et al., 2001). Laboratory criteria include a) the 
presence of LA detected according to the guidelines of the International Society of 
Thrombosis and Haemostasis, or b) the presence of aPL of IgG and/or IgM isotype in 
medium or high titer, or c) presence of anti-β2-glycoprotein-1 antibody of IgG and/or IgM 
isotype, present in titer greater than the 99
th
 percentile (Lim, 2009).  
Antiphospholipid antibodies cause thrombosis of the placental vessels, which in turn 
lead to fetal loss (Salafia and Cowchock, 1997).  It is suggested that the primary underlying 
event is platelet aggregation and maternal fibrin deposition around chorionic villi within the 
intervillous space (Sebire et al., 2002). In addition, antiphospholipid antibodies can reduce 
the levels of the anticoagulant Annexin V on trophoblast cells, thus leading to 
hypercoagulable state in the placenta (Rand et al., 1997). 
Studies in vitro have shown that antiphospholipid antibodies interfere with the signal 
transduction mechanisms controlling endometrial cell decidualisation (Mak et al., 2002), 
decrease trophoblast fusion (Di Simone et al., 2002; Bose et al., 2005), promote trophoblast 
apoptosis and impair trophoblast invasion (Bose et al., 2004; Bose et al., 2005). These effects 
of antiphospholipid antibodies on trophoblast function are reversed in vitro by low-
molecular-weight heparin to reduce the risk of further episodes of thrombosis (Di Simone et 
al., 1999; Bose et al., 2004; Quenby et al., 2004). However, a meta-analysis has shown that 
the best treatment for women with RM and APLS includes a combination of heparin and 
aspirin. This combination can significantly reduce pregnancy loss by 54% (Empson et al., 
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2002), but such pregnancies may have an increased risk of developing later complications 
such as pre-eclampsia and IUGR (Backos et al., 1999).  
 
 
1.3.6 Thrombophilic disorders  
 
Thrombophilia, which is defined as a tendency to thrombosis, can be inherited or 
acquired. The most common thrombophilia is acquired and about 40% of thrombophilic cases 
are inherited. Whilst the causative role of acquired thrombophilia manifest by elevated 
circulating antiphospholipid antibodies is widely accepted, the contribution of specific 
inherited thrombophilic genes is controversial (Coulam et al., 2006).  The first studies of the 
prevalence of coagulation abnormalities in women with pregnancy complications appeared in 
the mid-1990s, where women with familial thrombophilia, especially those with combined 
defects, had an increased risk of fetal loss, particularly still birth (Preston et al., 1996). 
Although 10 thrombophilic genes have been investigated, three of these genes significantly 
correlated to RM <20 weeks gestation when compared with controls (Coulam et al., 2006; 
Goodman et al., 2006). These include mutations in Factor V Leiden (FVL), Factor II 
prothrombin and methylene tetrahydrofolate reductase (MTHFR), which are described in 
more detail below.  
 
 
1.3.6.1 Factor V Leiden  
 
Activated protein C (APC) is a serine protease with anticoagulant properties, which 
during normal haemostasis limits clot formation by inactivating clotting factors V and VIII. 
However, a mutation in factor V gene leads to the synthesis of a factor V molecule that is not 
properly inactivated by APC. APC resistance is a result of a single point mutation in factor V 
gene at nucleotide 1691 that codes for the APC cleavage site. This is known as the FVL 
mutation (G1619A) and it is the most common genetic predisposition to thrombosis (Bertina 
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et al., 1994). The FVL mutation causes slower cleavage (10-fold) of the factor V 
(Arg506Gln) by APC and therefore an increased level of thrombin gene and hence 
predisposition to clot formation (Kalafatis et al., 1994).  
Research suggests that the thrombotic state results in an exaggerated haemostatic 
response during pregnancy that is associated to an increased risk of systemic venous 
thrombosis (Dahlbäck, 1995) and can also lead to placental infarction and as a consequence 
fetal loss (Dizon-Townson et al., 1997). The FVL mutation, which is transmitted in an 
autosomal dominant fashion, is common, as it is reported in about 6% of healthy Caucasian 
population. Heterozygosity and homozygosity of the FVL mutation is associated with a 5-10 
and a 50-100 fold increased risk of thrombosis, respectively (Bloomenthal et al., 2002). Case-
control studies found a significant association between APC resistance/FVL carriers and late 
second-trimester pregnancy loss (Rai et al., 1996; Grandone et al., 1997). 
 
1.3.6.2 Factor II prothrombin 
The second most common inherited thrombophilia is the prothrombin (Factor II) 
mutation. Prothrombin is the precursor of thrombin. A nucleotide change at position 20210 
(G20210A) in the 3’untranslated region (UTR) of prothrombin gene was identified in 18% of 
patients with familial thrombophilia. This mutation in the prothrombin gene was associated 
with increased prothrombin levels and a 2.8-fold increased risk of venous thrombosis (Poort 
et al., 1996).  The relative risk for early miscarriage before the 12
th
 week of gestation has 
been reported between two to eight times in carriers compared with controls (Coulam et al., 
2006).  
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1.3.6.2 Methylene tetrahydrofolate reductase  
MTHFR catalyzes remethylation of homocysteine to methionine. Increased levels of 
homocysteine can result from several mutations in MTHFR that have been identified as risk 
factors for thrombosis. Homozygosity of the C677T variant of MTHFR, which converts an 
alanine to a valine residue, is the commonest mutation, and individuals homozygous for the 
mutation have significantly increased levels of plasma homocysteine (Frosst et al., 1995; 
Kluijtmans et al., 1996). 
However effects of the C677T mutation on early RM are conflicting. Researchers 
have shown that homozygosity for the C677T mutation was associated with a 2 to 3-fold of 
RM (Nelen et al., 1997), whereas others have shown no significant difference in prevalence 
between early RM patients and controls (Kutteh et al., 1999). In others, the MTHFR mutation 
seemed to significantly increase the risk of miscarriage, when considered in combination with 
other thrombophilic factors (Tranquilli et al., 2004).  
  A large meta-analysis has confirmed an association between FVL and both early and 
late RMs, with an odds ratio (OR) of 2.01 and 1.73, respectively, as well as an association 
with late non-recurrent pregnancy losses (OR=3.26). The same meta-analysis confirmed an 
association between the prothrombin mutation with early RM (OR=2.56) and late non-
recurrent fetal loss (OR=2.30). However, MTHFR mutation was not significantly associated 
with fetal loss (Rey et al., 2003). 
Nevertheless, studies have shown that although some of the specific thrombophilic 
gene mutations appear not to be a risk factor for RM, when taken together, the total number 
of mutations is a significant risk. It looks like the additive effect of different thrombophilic 
mutations superimpose on the hypercoagulable state of pregnancy and this increases the risk 
of clotting. 
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1.4 Aims and Hypotheses 
Chapter 2 focuses on imprinting and the role of imprinted genes on FGR. Five 
candidate genes, three of which are imprinted, were selected to investigate their roles on fetal 
growth. These consisted of the paternally expressed gene IGF2, two maternally expressed 
genes IGF2R and pleckstrin homology-like domain, family A, member 2 (PHLDA2) and 
genes IGF1 and IGF1R. Previous studies performed by our research group have shown that 
PHLDA2 expression in normal human term placentas negatively correlates with fetal growth, 
but no correlation was found with IGF2 and IGF2R (Apostolidou et al., 2007). Thus, the aim 
of this study was to address the role of these genes in early pregnancy on term birth weight. 
This was done by using real-time quantitative PCR to investigate the expression levels of 
IGF1, IGF2, IGF1R, IGF2R and PHLDA2 in 260 chorionic villus samples, collected at 11-13 
week’s gestation. Since a maternally expressed gene (PHLDA2) controls fetal growth late in 
pregnancy as shown by the expression levels in term placenta, our hypothesis was that a 
paternally expressed gene such as IGF2 might play an important role early in pregnancy.  
Chapter 3 focuses again on imprinted genes, but this time on their potential role on 
miscarriage. This study involved 104 couples that had a miscarriage and whose product of 
conception (POC) was available. POC is tissue that is present in a fertilized gestation in a 
pregnancy that ended in a miscarriage. The aim of our study was to firstly detect maternal 
contamination levels in the 104 POCs available and then investigate the imprinting status of 
known imprinted genes. Genes investigated included the maternally expressed HLA-C, H19, 
PHLDA2 and the paternally expressed IGF2, PEG3 and DLK1. These genes were sequenced 
in the non-contaminated POCs from which DNA from both parents was available so we 
could detect which parental allele was expressed in these genes. Our hypothesis is that a 
proportion of miscarried POCs that are cytogenetically normal will have abnormal expression 
profiles at imprinted loci, which may be the cause of the embryonic lethality. 
42 
 
Chapter 4 focuses on the placental anti-coagulant protein Annexin A5 (ANXA5) and 
RMs. ANXA5 contains four consecutive nucleotides substitutions (M2 haplotype) in its 
promoter. The frequency of M2 was found to be significantly higher in female RM patients 
than among controls (Bogdanova et al., 2007). The aim of this study was to further 
investigate this gene in both males and females by genotyping 500 White European pairs that 
had more than three consecutive miscarriages. These include 300 patient couples that had 
early miscarriages (before 12 week of gestation) and 200 couples that had late miscarriages 
(after 12 week of gestation). A cohort of 250 White European control trios (mum, dad and 
placenta) was also genotyped. Based on previous studies, the M2 haplotype should be 
associated with a higher risk of RM, but our aim here was to use a larger cohort to investigate 
the hypothesis that the ANXA5 M2 haplotype influences the timing of miscarriages, interacts 
with known risk factors, such as APLS and FVL and is also associated with the father’s 
haplotype. 
Chapter 5 focuses on identifying new candidate genes for RMs. This study involves a 
Bangladeshi family where the patient suffered a total of 29 early RMs. The aim of this study 
was to carry out next generation exome sequencing on available samples from this family 
pedigree to find a potential rare genetic variant gene causative of the RM phenotype. Our 
hypothesis is that the cause of miscarriages in this family is genetic, as the patient had three 
different partners but no successful pregnancies so far. Two genes, FK506 binding protein 4 
(FKBP4) and Serpin peptidase inhibitor clade B member 2 (SERPINB2), with potential 
damaging mutations were investigated in more depth by sequencing them in 100 RM Asian 
patients, 120 RM White European patients and 100 Bangladeshi controls. Three novel 
variants and one very rare SNP in FKBP4 were identified in a total of 4 Asian RM patients, 
which were all predicted to be damaging by different prediction programs. Future work 
involves functional studies to test pathogenicity of these variants. 
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CHAPTER 2 – IGF2 EXPRESSION IN CVS 
2 INTRODUCTION  
As briefly described in the overview presented in Chapter 1, in Chapter 2, I will 
describe studies investigating the correlation between 11-13 weeks GA chorionic villus 
sample (CVS) mRNA levels of paternally expressed IGF2, maternally expressed PHLDA2, 
the polymorphic maternally expressed IGF2R and genes IGF1 and IGF1R with birth weight. 
I performed all of the experiments involving the role of IGF2, IGF2R and IGF1R, whereas 
MSc students Lara Al-Olabi and Lydia Leon contributed experiments involving the role of 
PHLDA2 while MSc student Jaime Stafford performed experiments involving IGF1 under 
my supervision.  
 
2.1 The IGF growth axis 
The IGF growth axis includes many endocrine factors that are important for pre- and 
postnatal growth. These factors include insulin, insulin-like growth factors I and II (IGFI and 
IGFII), their corresponding receptors (IGFIR and IGFIIR) and six binding proteins (IGFBPI-
VI) (Fant and Weisoly, 2001). Insulin is a hormone important for metabolism as it regulates 
the uptake of sugars, such as glucose by body cells. The insulin receptor is a transmembrane 
tyrosine kinase receptor that is activated by insulin, as well as both growth factors IGFI and 
IGFII (Rechler et al., 1980). The proteins encoded by IGF1 and IGF2 are ligands that closely 
resemble the molecular structure and function of insulin. They constitute a functionally 
interrelated family of proteins referred to as the “IGF axis” which are critically linked to 
growth and metabolism (Fant and Weisoly, 2001). 
Both IGFI and IGFII are expressed by the blastocyst at early stages of development, 
suggesting a role during fetal development. They circulate in fetal serum and rise throughout 
gestation (Bennett et al., 1983; Rappolee et al., 1992). Increasingly, evidence suggests that 
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IGF axis genes are likely to be involved in the regulation of placental nutrient transfer and 
fetal growth including key genes within this group that are imprinted, most notably IGF2 
(Fant and Weisoly 2001). Although both IGFI and IGFII have been detected in fetal plasma 
early in gestation in many species, plasma concentrations of IGFII are found to be several 
fold higher than those of IGFI (Gluckman and Butler, 1983). The high concentrations of 
IGFII in fetal serum decline within days after birth, whereas serum concentrations of IGFI 
rise in the postnatal period (Gluckman and Butler, 1983; Daughaday et al., 1982).   
The first three endogenous imprinted genes were identified in the mouse in 1991. 
These were the reciprocally imprinted genes Igf2r (Barlow et al., 1991) and Igf2 (DeChiara et 
al., 1991), as well as H19 (Bartolomei et al., 1991). Igf2 is found on the distal domain of 
mouse chromosome 7 and Igf2r on the proximal domain of mouse chromosome 17. These 
two genes confer reciprocal function in fetal growth as IgfII is a growth promoter and IgfIIr is 
responsible for IgfII’s sequestration from the circulation, thus a negative regulator of IgfII 
(reviewed by Coan et al., 2005). A number of animal studies support the role of insulin 
growth factors in intrauterine growth and some of these studies are summarised below. 
Baker et al. showed that Igf1
-/-
 mutant mice are infertile and have a retarded growth 
rate. Their relative size was 60% of normal at the end of gestation and their retarded growth 
continued after birth as they were still only 30% of normal adult weight. Three other classes 
of mutant embryos also had distinct differences in size. The relative weight of Igf2
p-
/Igf1r
-/- 
double mutants was approximately 30% of normal and the relative weight of Igf1r
-/- 
mutant 
and Igf2
p-
 mutant were 45% and 60% of normal, respectively.  It is worth mentioning that 
these mutations affected the embryos’ growth after embryonic day 10.5, since younger 
mutant embryos did not differ in size from their wild-type (WT) littermates (Baker et al., 
1993). 
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Wang et al. showed that mice carrying maternal inheritance of an Igf2r null allele as 
well as mice homozygous for the inactive allele are generally lethal at birth and these mutants 
are about 30% larger compared to their WT littermates. Observations from mice lacking both 
Igf2r and Igf2 suggest that the overgrowth phenotype was due to an excess of IgfII, as the 
introduction of an Igf2 null allele rescued the Igf2r mutant mice (Wang et al., 1994). 
Expression of Igf2 in mice is driven from four distinct promoters. The fetal promoters 
P1-P3, that control expression of Igf2 in fetal tissues and the placental-specific promoter (P0) 
that is specifically expressed in the labyrinthine trophoblast of the placenta (Moore et al., 
1997). Humans also have an IGF2 P0 promoter but this is not placental-specific, indicating 
only a partial conservation of imprinting regulation of Igf2/IGF2 between humans and mice 
(Monk et al., 2006a). 
Constancia et al. reduced IgfII action specifically in the placenta by deleting Igf2 
(P0). Mice that inherited the deletion paternally had placental growth restriction and the 
degree of deficiency remained constant throughout the gestational stages; at birth mutant P0 
mutant mice were 69% of normal birth weight. They also showed that the deletion reduced 
the growth of the placenta and that the supply of nutrients across the placenta was influenced, 
as the mean weight of P0 mutant placenta was 68% of WT placentae at late gestation and the 
permeability for nutrients was decreased (Constancia et al., 2002). Therefore, disruption of 
the Igf2 (P0) in mice is associated with both late gestation IUGR and placental growth 
restriction.  
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2.1.1 IGF2 
 
The first evidence for the imprinted role of Igf2 in embryonic growth came from the 
work of DeChiara and his colleagues in 1990, when mutations at the Igf2 gene locus were 
introduced in the mouse germ line. Heterozygous mice that inherited the inactive copy of the 
Igf2 gene from the father were about 40% smaller than their WT littermates and remained 
smaller throughout their lives. Moreover, homozygous mutants, in whom both alleles were 
disrupted, appeared to have no phenotypic differences in size when compared to 
heterozygous growth-deficient mice. When the inactive Igf2 was transmitted maternally, 
heterozygous mice were phenotypically normal (DeChiara et al., 1990).  
The difference in size between those mice that inherited the mutated allele maternally 
(M-heterozygotes) and those that inherited the mutated allele paternally (P-heterozygotes) 
can be attributed to genomic imprinting.  Igf2 is paternally expressed as M-heterozygotes that 
carry the intact paternal allele are of normal size, whereas P-heterozygotes that carry the 
intact maternal allele are growth-deficient (DeChiara et al., 1991). Two years after DeChiara 
provided evidence that mouse Igf2 is paternally expressed, it was shown that the human IGF2 
is also expressed paternally (Giannoukakis et al., 1993). Imprinting mechanism regulating 
IGF2 are shown in Figure 2-2. 
Observations of pUPD11 in some patients with BWS provided indirect evidence that 
human IGF2 is subject to parental imprinting, as a double dose of IGF2 could explain some 
of the syndromes’ characteristics. In addition, overgrowth in BWS occurs only in the tissues 
where IGF2 is expressed. Sparago et al. (2004) reported that microdeletions in the human 
H19 DMR on chromosome 11p15.5 inherited maternally, resulted in hypermethylation and 
hence silencing of the H19 DMR. This in turn resulted in upregulation of IGF2 due to the 
loss of IGF2 imprinting, showing that IGF2 is important in the overgrowth and tumour 
predisposition of BWS. On the other hand, in SRS that is characterised by growth retardation, 
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loss of methylation at the H19 DMR is observed in 30-50% of cases (Gicquel et al., 2005). 
Growth restriction in these patients could be caused by a decrease in IGF2 expression, which 
is linked to H19 methylation, again suggesting a role of IGF2 in human growth. 
 
2.1.2 IGF2R 
IGF2R/M6P (insulin-like growth factor 2 receptor/mannose 6-phosphate) maps to 
human chromosome 6q24.1- 24.3. IGFIIR is a multifactorial receptor involved in intracellular 
lysosomal enzyme trafficking and IGFII degradation, cell growth and signal transduction 
(Jirtle, 1999). Igf2r deficiency in mice causes increased levels of Igf2 and results in 
abnormalities including cleft palate, cardiac abnormalities and fetal overgrowth. Epigenetic 
changes in gene regulation that result in decreased levels of Igf2r, lead to large offspring 
syndrome, thus suggesting an important role in growth (Young et al., 2001). 
Mice embryos that inherit a mutated Igf2r gene from their fathers are viable and 
develop into normal adults. However, mice that have inherited the non-functional Igf2r from 
their mothers, do not express IgfIIr in their tissues, have increased levels of IgfII, are larger 
than their littermates and die around birth. Therefore Igf2r is maternally expressed and 
paternally imprinted (Lau et al., 1994).  
However, IGF2R is not imprinted in humans, as both paternal and maternal alleles are 
expressed early in fetal development (Killian et al., 2001). This is was the first demonstration 
for the presence of differential imprinting between mouse and human genes. One explanation 
for this might be due to the structural differences between the mouse and human IGF2R locus 
or more likely imprinting was lost during evolution (Kalscheuer et al., 1993). The current 
consensus is that imprinting of IGF2R is demonstrated in less than 10% of individuals and 
even this may not be functionally relevant for those individuals (Monk et al., 2006b). 
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2.1.3 IGF1 
Insulin-like growth factor 1 (IGFI) located on chromosome 12, stimulates cell growth 
and proliferation, and inhibits apoptosis via activation of the AKT signaling pathway. 
Downstream elements of this pathway regulate various crucial cell processes such as 
proliferation, differentiation, apoptosis, and metabolic homeostasis. IGFI exerts its growth 
properties on almost every cell in the body (Klammt et al., 2008). As previously mentioned, 
IGFI is structurally related to insulin, and is able to bind to the insulin receptor although with 
a lower affinity than insulin itself. IGF1 and its primary binding receptor IGF1R are not 
imprinted. A homozygous partial deletion of Igf1r in mice results in stunted height and 
weight, as well as disruption to the pubertal growth spurt. A complete inactivation of Igf1r is 
lethal in the neonatal period (Klammt et al., 2008). In contrast to Igf2 deficient mice, growth 
restriction continued into the postnatal period in the Igf1 mutants (Le Roith et al., 2001).  
 
2.1.4 IGF1R 
IGF ligand signalling is mediated by IGFIR. IGF1R gene is located on chromosome 
15 and encodes a cell surface tyrosine kinase that shares amino acid (aa) sequence homology 
with the insulin receptor (Le Roith et al., 2001). IGFIR is recognised by both IGFI and IGFII, 
although IGFI is binding with a 15-20 fold higher affinity. IGFIIR does not appear to share 
any homology to IGFIR as they differ in structure and peptide binding specificity. IGFIIR 
strongly binds IGFII but rarely recognizes IGFI (Kornfeld, 1992). In fact, IGFII can bind to 
all three cell surface receptors (insulin receptor, IGFIR and IGFIIR), but it binds to IGFIIR 
with the highest affinity (Rechler and Nissley, 1985; Filson et al., 1993).  
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2.2 PHLDA2 
PHLDA2 is a maternally expressed, paternally imprinted gene in both humans and 
mice (Qian et al., 1997). It is located on the imprinting cluster of human chromosome 
11p15.5, and its orthologous region on distal chromosome 7 in mice (Paulsen et al., 1998). 
PHLDA2 is highly conserved among vertebrates and consists of two exons and a single 223 
bp intron and encodes a small protein consisting of 152 aa with a Pleckstrin-homology 
domain (Qian et al., 1997). PHLDA2 expression is highly tissue specific. Its expression is the 
highest in the placenta, and is expressed throughout gestation in human placenta correlating 
with its continuous growth (Qian et al., 1997; Frank et al., 1999).  
Involvement of Phlda2 in growth and development of the placenta was demonstrated 
by knockout mouse models with a maternal germline deletion that was associated with a 
significant increase in placental size during mid to late gestation (Frank et al., 2002). Studies 
that have investigated the human placental expression of PHLDA2 report increased 
expression in SGA pregnancies and a negative association with birth weight (McMinn et al., 
2006; Apostolidou et al., 2007; Ishida et al., 2012). Collectively, this indicated that Phlda2 is 
a putative growth suppressor, consistent with the role of maternally expressed genes in the 
parental conflict hypothesis (Moore and Haig, 1991). 
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2.3 Imprinted gene clusters  
2.3.1 Human chromosome 11p15.5: KCNQ1 domain 
An imprinting control region (ICR) is a specialized region of DNA that is 
differentially methylated in parental alleles. The imprinted expression of the paternally 
expressed IGF2 gene alongside the co-localised maternally expressed H19 has been 
extensively investigated. Expression of both genes is controlled by the ICR1 located 
upstream of the H19 gene on chromosome 11p15.5. This region contains one of the most 
intensely studied imprinted gene clusters, which is divided into two regulatory independent 
domains. The centromeric KCNQ1 (potassium voltage-gated channel, KQT-like subfamily, 
member 1) domain that contains several imprinted genes including PHLDA2 (Fig. 2-1) and 
the telomeric IGF2/H19 domain (Fig. 2-2) (reviewed by Ishida and Moore, 2013). 
Figure 2-1: Schematic representation of imprinted gene clusters on human chromosome 
11p15.5. Maternally expressed genes are indicated as red boxes with arrows showing 
transcription and direction. Paternally expressed genes are indicated as blue boxes. PHLDA2 
lies on chromosome 11p15.5 KCNQ1 domain, which is under control of the kvDMR1. Black 
circle represents methylated KvDMR1 and white circle represent unmethylated KvDMR1. 
 
 
51 
 
2.3.2 Human chromosome 11p15.5: IGF2/H19 domain 
 ICR1 which is methylated exclusively on the paternal allele, works as an insulator 
and binds to a CCCTC-binding factor (CTCF) in a parent-specific manner. CTCF binds the 
unmethylated ICR1 on the maternal allele and this prevents the IGF2 gene promoter from 
interacting with enhancers found upstream from the H19 gene. This result in silencing of the 
maternal IGF2 gene while H19 gene is expressed (Fig. 2-2A). Therefore the insulator is 
unmethylated and active on the maternal chromosome. On the paternal allele, DNA 
methylation prevents CTCF from binding, the enhancer acts beyond its previous boundary 
and this allows continued expression of IGF2, while at the same time it prevents expression 
of H19 (Fig. 2-2B). Thus, the insulator is methylated and inactive in the paternal 
chromosome (reviewed by Miozzo and Simoni, 2002; Demars et al., 2010; Shi et al., 2011).   
 
Figure 2-2: The imprinting mechanism of maternally expressed H19 and paternally 
expressed IGF2 in humans (figure taken from Charalambos Demetriou MSc thesis). 
The two genes H19 and IGF2 share an enhancer region, downstream of H19.  
     A) The CTCF protein binds to the unmethylated maternal ICR (white circles). This 
prevents the promoters located in the IGF2 gene from interacting with the enhancers so IGF2 
transcription is silenced. H19 is transcriptionally active in this case. 
     B) The paternal ICR is methylated (black circles) and this prevents binding of CTCF. 
Enhancers can now contact the promoters of IGF2, allowing this gene to be transcribed. H19 
is silenced in this case.  
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2.3.3 Mouse chromosome 17: Igf2r domain 
Another related and notable mechanism of imprinting involves the mouse Igf2r gene. 
Igf2r is maternally expressed and encodes insulin-like growth factor II receptor. An intronic 
CpG island (iCGi) located within intron 2 of the Igf2r gene helps to maintain the imprinting 
signal. On the maternal chromosome, the promoter of Igf2r is unmethylated and active when 
the iCGi is methylated (Fig. 2-3A). On the paternal chromosome, the promoter is methylated 
and thus inactive, and the iCGi is unmethylated leading to the production of an antisense 
transcript. Thus Igf2r is paternally imprinted (Fig. 2-3B). The fact that deletion of the iCGi 
leads to absence of the antisense transcript and biallelic expression of Igf2r, demonstrates that 
iCGi is not required for production of Igf2r but for the synthesis of the antisense strand (Wutz 
et al., 1997; Biliya and Bulla, 2010). 
 
Figure 2-3: The imprinting mechanism of maternally expressed Igf2r in mice (figure 
taken from Charalambos Demetriou MSc thesis). 
      A) The promoter of the Igf2r gene on the maternal chromosome is active when iCGi is 
methylated and hence Igf2r is expressed maternally. 
      B)  iCGi is unmethylated on the paternal chromosome, leading to the production of an 
antisense transcript. The promoter of the Igf2r gene is methylated and inactive and thus Igf2r 
is paternally imprinted. 
 
Note: A description of the mechanism of imprinting of mouse Igf2r is described here instead 
of human IGF2R, because as described in section 2.1.2 above, IGF2R is not imprinted in 
90% of humans. 
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2.4 Previous work  
 
The analyses of human placental expression of IGF1, IGF1R, IGF2 and IGF2R have 
previously been confined to term placental samples obtained at the time of birth. IGF1 under-
expression was observed in term placental samples from FGR pregnancies (Koutsaki et al., 
2011), while mutations in the IGF1R gene led to abnormalities in the function of IGF1 
receptors that may also slow down intrauterine growth in humans (Abuzzahab et al., 2003). 
Studies on IGF2 in term placenta have reported conflicting results. Some 
demonstrated no correlation between IGF2 expression and birth weight (Apostolidou et al., 
2007) whereas others have variably shown that in FGR pregnancies compared to controls, 
IGF2 expression is either increased (Abu-Amero et al., 1998), decreased (McMinn et al., 
2006; Koukoura et al., 2011), or similar (Street et al., 2006; Antonazzo et al., 2008), 
including at the protein level (Laviola et al., 2005). Moreover, studies have either shown no 
significant relationship between IGFII cord serum levels and size at birth (Klauwer et al., 
1997), or a positive effect on birth weight (Smerieri et al., 2011). In others, IGFII cord blood 
levels were significantly correlated with birth weight only when its interaction with IGFIIR 
was taken into account (Ong et al., 2000). 
Although the precise roles by which fetal growth is promoted by insulin are not 
completely defined, it is clear that insulin can stimulate growth via multiple mechanisms. 
These include promoting transport of nutrients, storage of fat and an influence on cellular 
proliferation by its interaction with other growth factors and hormones (Fant & Weisoly, 
2001). 
 
  
 
 
54 
 
2.5 Aims 
The profound role of the IGFI and IGFII pathways in the regulation of fetal growth 
have been established largely based on experiments using the mouse as a model (DeChiara et 
al., 1990; Wang et al., 1994; Klammt et al., 2008). Analysis in humans has been hampered 
by the lack of available tissue to study during the course of pregnancy and has therefore 
relied on the use of term placenta, at a time when this tissue has become redundant and 
therefore the levels of gene expression may no longer reliably reflect the needs of the in utero 
growth of the baby. To fully assess the role of these growth factors and their receptors, we 
have focused on an earlier developmental time point when these genes are much more likely 
to measure functionally relevant expression levels. 
The aim of this study was to measure the mRNA levels of IGF1, IGF2, IGF1R, 
IGF2R and PHLDA2 in a large collection of CVS (n=260) using real-time quantitative PCR 
technology. Chorionic villi are tiny finger-shaped growths found in the placenta. The genetic 
material in chorionic villus cells is fetal in origin so by analysing CVS, which were collected 
at 11-13 weeks’ of gestation, direct information about the fetus can be obtained. A critical 
time period for fetal growth occurs at the end of first trimester and progresses through the 
second trimester of pregnancy. CVS was a convenient sampling method as it is the only route 
that directly allows early access to first trimester placental genome and it is in regular use for 
the purposes of prenatal testing for genetic abnormalities (Evans and Andriole, 2008).  
The expression levels of the genes of interest were calculated relative to L19, a 
housekeeping gene, expression of which does not change throughout gestation in term 
placentae and were then correlated with birth weight. Confounding factors such as fetal sex, 
GA, parity, maternal body-mass index (BMI) and smoking status were taken into 
consideration when the statistical analysis was carried out.   
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2.6 MATERIALS AND METHODS 
2.6.1 Subjects 
CVS was performed at 11-13 weeks of gestation in 260 singleton pregnancies that 
subsequently resulted in normal live births at term. The samples were collected from women 
undergoing CVS for prenatal diagnosis of chromosomal defects at King’s College Hospital 
London. The excess tissue samples used for this study were obtained from women agreeing 
to participate in research, which was approved by the Hospital’s Ethics Committee. 
Demographic characteristics were recorded including maternal age, racial origin, 
smoking status, parity and BMI as well as pregnancy outcomes such as gestational age at 
delivery, sex and birth weight (full data in Appendix B). Other birth parameters such as 
placental weight were not available, nor were blood or tissue samples from the newborn 
baby. The pregnancies were subdivided according to the birth weight of neonates into SGA 
with birth weight <10
th
 percentile, large for GA (LGA) with birth weight >90
th
 percentile and 
appropriate for GA (AGA). Information to define these pregnancies as pathological FGR was 
not available, so for this study they were all considered as SGA. 
 
2.6.2 Preparation of DNA and RNA from chorionic villus samples  
DNA and RNA were extracted using the iPrep Purification Instrument (Invitrogen), 
either by use of the iPrep™ ChargeSwitch® gDNA Tissue Kit, or iPrep™ PureLink™ Total 
RNA and Trizol
®
 Plus RNA kit including DNAse treatment, according to the manufacturer’s 
instructions. These kits are for use specifically with the iPrep™ Purification Instrument. They 
are based on charge dictated by the pH of the surrounding medium, which allows selective 
binding of nucleic acids to magnetic beads. Purification is achieved through a three-step bind-
wash-elute procedure. The kits provide prefilled cartridges containing all of the necessary 
reagents for isolating DNA or RNA from tissue samples.  
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2.6.3 DNA and RNA concentration 
Concentrations of DNA and RNA of samples were measured using the NanoDrop™ 
1000 Spectrophotometer (Thermo Scientific). The Nanodrop verifies the concentration and 
the purity of the samples by adding 1 μl of the DNA. Nucleic acid absorbs at a wavelength of 
260 nm, and the ratio of absorbance at 260 nm and 280 nm was used to examine the purity of 
DNA and RNA samples. A ratio of ~1.8 and ~2.0 for DNA and RNA, respectively, indicated 
a high level of purity. RNA integrity can have an important influence on experiments 
designed to measure mRNA expression levels, and it has been suggested that samples with a 
260/280 ratio higher than 1.8 are most suitable for gene expression measurement (Becker et 
al., 2010). Therefore, only RNA samples with the 260/280 ratio in the range of 2 ± 0.2 were 
used for this analysis. 
 
2.6.4 Primer design  
Primer sequences for the genes of interest were obtained using National Centre for 
Biotechnology Information (NCBI) reference sequences (http://www.ncbi.nlm.nih.gov/gene). 
The primers were designed using the Primer3 software (://frodo.wi.mit.edu/primer3/). The 
size of each primer was between 18 to 22 nucleotides long, GC content was between 40 to 
60% and annealing temperatures did not differ by more than 10 
0
C. Primer annealing 
temperatures were optimised using gradient polymerase chain reaction (PCR). 
 
2.6.5 Polymerase Chain Reaction 
PCR is a method used for the selective amplification of a specific target DNA 
sequence (Mullis et al., 1986). PCR requires a pair of oligonucleotide primers approximately 
18-22 bp in length that are complementary to the specific sequences on each DNA strand 
flanking the target region. The double stranded template DNA is initially separated by high 
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temperatures, and subsequent cooling allows the primers to anneal to complementary 
sequences. These primers are extended by a thermostable DNA polymerase to form the 
opposite strand. The new double stranded DNA (dsDNA) is then denatured and the process 
repeated, resulting in the exponential amplification of the specific DNA fragment. A standard 
Bioline PCR reaction is shown in Table 2-1. 
 
Table 2-1: Standard Bioline PCR reaction mix. 
Reagent Volume (μl) per reaction 
NH4 Reaction Buffer (10x) 2 
MgCl2 (50 mM) 0.75 
dNTPs (2.5 mM) 1.8 
Forward primer (50 ng/μl) 1 
Reverse primer (50 ng/μl) 1 
Taq DNA polymerase 0.2 
Betaine (5 M) 6 
DEPC-treated water 6.25 
DNA or cDNA template (50-100 ng)  1 
 
All reactions were carried out in a Veriti® 96-Well Thermal Cycler (Applied 
Biosystems - ABI) with a heated lid set at 100 °C to prevent evaporation. A standard PCR 
cycle consisted of an initial denaturation at 94 °C for 5 minutes, and 35-40 cycles of: 
denaturation at 94 °C for 30 seconds, annealing at 58-62 °C for 30 seconds and extension at 
72 °C for 30 seconds, and a final extension at 72 °C for 2 minutes. 5 μl of PCR products were 
used to confirm product size and quality on an agarose gel. 
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2.6.6 Agarose gel electrophoresis  
Agarose gel electrophoresis is used to estimate the size and integrity of PCR products. 
It involves the migration of DNA fragments depending on their molecular weight/size.  As 
DNA molecules have an overall negative charge, in the presence of an electric field they 
move towards the positively charged anode. 1 g of UltraPure
TM
 agarose powder was mixed 
with 100 ml of TAE buffer (1% agarose gel). The solution was microwaved until the agarose 
powder had completely dissolved and 1 µl of ethidium bromide (10 mg/ml) was added to the 
solution once it had cooled down and no vapour was visible.  The solution was then poured 
into a gel tray and left to solidify. 5 µl of commercially available Blue/Orange Loading Dye 
(Promega) was mixed with 5 µl of PCR product and loaded on the gel. 5 µl of a 100 bp DNA 
ladder (Promega) was used as a size marker. The gel tank was run at 90 volts for 30 minutes 
and the gels visualised on a Genosmart ultraviolet machine.  
 
2.6.7 Reverse transcription PCR   
In order to synthesise complementary DNA (cDNA) for real-time expression analysis 
and imprinting analysis, reverse transcription PCR (RT-PCR) was performed. RT-PCR uses 
the enzyme reverse transcriptase to catalyse the formation of cDNA from an RNA template. 
A first strand of cDNA was synthesised by reverse transcription of the total RNA extracted 
from CVS with Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT). 100 
ng of each RNA sample was diluted with DEPC-treated water to a total volume of 10.25 μl. 
The mix was initially heated at 72 °C for 5 minutes to melt any secondary structures of the 
single stranded RNA (ssRNA) and then cooled to 37 °C in a thermal cycler. The mixture that 
was then added for reverse transcription is shown in Table 2-2. 
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Table 2-2: Standard reverse transcription reaction mix. 
Reagent Volume (μl) per reaction 
M-MLV RT Buffer (5x) 4 
dNTPs (10 mM) 2 
Random Primers (500 μg/ml) 1 
M-MLV Reverse transcriptase (200 units/μl) 0.5 
RNasin RNase inhibitor (40 units/μl) 0.25 
DEPC-treated water 2 
 
9.75 μl of the RT reaction mix was added to each sample followed by incubation at 37 
°C for one hour before heating at 80 °C for 10 minutes to stop the reaction by denaturing the 
enzyme. A negative control was used in each run, where water was used in the place of RNA.  
1 μl of cDNA samples was used to confirm the conversion of RNA to cDNA by performing 
PCR with beta-actin (ACTB) housekeeping gene primers. ACTB primers (shown in Table 2-3 
below) were designed to amplify both genomic DNA (product size: 407 bp) and cDNA (273 
bp) by flanking a relatively short intron (134 bp) in order to detect any genomic 
contamination in the RNA samples, as well as to confirm the conversion of RNA to cDNA.  
 
Table 2-3: Control primers designed for PCR to check the integrity of cDNA. 
 
Gene Primer sequence 5’ to 3’ Tm 
(°C) 
Product 
size (bp) 
Accession 
number 
Notes 
ACTB F: gtcttcccctccatcgtg 
R: ggtcatcttctcgcggttg 
60 273 NM_001101 for cDNA 
  
PCR products were then electrophoresed to check for the presence of good quality 
products and the absence of genomic contamination. cDNA samples were then stored at -20 
°C for future use. 
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2.6.8 Real-time quantitative PCR 
Real-time quantitative PCR (RTqPCR) is a technique that detects and quantifies an 
amplified PCR product in 'real time'.  This can be achieved by the incorporation of a 
fluorescent reporter dye; Power SYBR Green (ABI) was used in this experiment. SYBR 
Green binds to dsDNA but not to ssDNA. When it is bound to dsDNA it fluoresces brightly, 
so as more DNA is synthesised, more dye will bind and the fluorescence will increase (Ma et 
al., 2006). This increase in the fluorescence is then measured by a sensitive detector that 
monitors the fluorescence in each well of the plate and therefore this enables the expression 
of a gene to be quantified at any time during amplification.  
Relative quantification allows relative target quantity comparisons between the 
samples, with expression of each sample normalised to that of an endogenous control gene. 
The "comparative Ct method" was used in this study, which relies on the assumption that the 
amplification of the target and endogenous control genes are equally efficient. The PCR 
efficiency of the primers was tested by producing a standard curve for each pair by 
performing an RTqPCR using five serial 1:10 dilutions of CVS cDNA pool as a template. 
The RTqPCR reactions were run in triplicate on 96-well plates (microAmp Fast Optical 96-
well reaction plates) (ABI). Each reaction contained 10 µl of template and 15 µl of SYBR 
Green master mix (Table 2-4). 
 
Table 2-4: Standard SYBR Green reaction mix. 
Reagent Volume (μl) per reaction 
Power SYBR® Green PCR Master Mix 12.5 
Forward primer (50 ng/μl) 1 
Reverse primer (50 ng/μl) 1 
DEPC-treated water 0.5 
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For this experiment a cDNA pool was also prepared by mixing 1 µl from each of the 
cDNA samples. This was used for inter-calibration control between plates.  The template 
contained either a 10-fold dilution of the cDNA sample of interest, a 10-fold dilution of the 
cDNA pool or DECP-treated water (acting as a blank). The quantitative expression analysis 
of the genes of interest, IGF1, IGF1R, IGF2, IGF2R and PHLDA2 as well as the endogenous 
control gene ribosomal protein L19 (RPL19), was determined by RTqPCR in the 260 CVSs. 
Primers used for quantitative analysis are shown in Table 2-5.  
 
Table 2-5: Primers designed for RTqPCR in chorionic villus samples. 
 
Gene Primer sequence 5’ to 3’ Tm 
(°C) 
Product 
size (bp) 
Accession 
number 
Notes 
IGF1 F: ggaggctggagatgtattgc 
R: acttgcttctgtcccctcct 
60 197 NM_000618 for cDNA 
IGF1R F: ccaagggtgtggtgaaagat 
R: tccatgatgaccagtgttgg 
60 187 NM_000875 for cDNA 
IGF2 
 
F: cgagagggacgtgtcgacc 
R: ggactgcttccaggtgtcata 
60 97 NM_000612 
 
for cDNA 
IGF2R F: ccggcgtgctctgga 
R: ccagagggtcacagtggaaga 
60 189 NM_000876 for cDNA 
PHLDA2 F: ccatccccgcagcccaaacc 
R: ccacgtcctagcctcggtcc 
60 83 NM_003311 for cDNA 
RPL19 F: gcggaagggtacagccaat 
R: caggctgtgatacatgtggcg 
60 140 NM_000981 for cDNA 
 
All primer sets were free of primer-dimer products. The RTqPCR assays were run in 
triplicate for each sample, with the gene of interest and housekeeping gene run on the same 
96-well plates.  A control pool of CVS cDNA was also included on each plate. The plates 
were sealed with Optical Adhesive Covers (ABI) and spun briefly to remove air bubbles, then 
placed in the StepOne Plus™ Real-Time PCR Systems (ABI) to be analysed. The 
amplification reaction was programmed for an initial incubation at 50 °C for two minutes, 
polymerase activation at 95 °C for 10 minutes, and 40 cycles of denaturation at 95 °C for 15 
seconds, and annealing and extension step at 60 °C for 1 minute. Each real time PCR reaction 
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was subjected to melt curve analysis in order to confirm the fidelity of the target sequence 
amplification. 
After amplification, quantitative expression levels were obtained using the StepOne 
software (version 2.1). The software measures the cycle number at which the fluorescence 
crosses an arbitrary line, the threshold. This crossing point gives the CT value (cycle 
threshold). The increment of fluorescent signal at each cycle point is measured as ΔRn, which 
is calculated as: ΔRn (cycle) = Rn (cycle) - Rn (baseline), where normalised reporter (Rn) is 
the fluorescence of the reporter dye divided by that of passive reference which produces 
consistent fluorescent signal.  
The threshold is automatically set by the machine and it is set high enough so that the 
reaction crosses the line due to amplification rather than noise. When seen in the logarithmic 
view the threshold is on the linear part of the reaction (Fig. 2-4A). In the regular view the 
threshold is close to the bottom of the curve (Fig. 2-4B). The same threshold is used for all 
the samples in each plate.  
  
Figure 2-4: Graphical representation of RTqPCR threshold data. The exponential phase 
in (B) corresponds to the linear phase of the amplification plot in (A). In the log view (A) the 
threshold is on the linear part of the reaction, whereas in the regular view (B) the threshold is 
close to the bottom of the curve. Cycle number is shown on the x-axis and ΔRn is shown on 
the y-axis. 
Threshold 
Exponential 
phase 
CT 
B A 
Amplification Plot (Log view) Amplification Plot (Regular view) 
Cycle number Cycle number 
Linear 
phase 
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When determining the difference in the CT values (ΔCT), the control CT value is 
subtracted from the target CT value.  
ΔCT = average target CT (gene of interest) – average control CT (endogenous gene)  
Although the CT value for each sample triplicate should be the same, variations do 
occur mainly to pipetting errors. CT values for each sample were individually checked and 
any CT value that was not within one cycle of the other two repeats, was excluded from the 
analysis. The relative quantity of the target gene was calculated using the formula 2^
-ΔCt
. 
 
2.6.9 RPL19 endogenous control gene  
To accurately compare mRNA expression levels of genes of interest between each 
sample, these expression levels need to be normalised to that of a stable, endogenous control 
gene. This procedure provides a relative expression level. Housekeeping genes are often used 
as endogenous controls since their expression is assumed to be constant in most tissues. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is one of the most frequently used 
endogenous control gene for RTqPCR. However, in placental tissues, GAPDH levels have 
been found to vary considerably during the pregnancy (Patel et al., 2002). In this study we 
used the RPL19 housekeeping gene as an RTqPCR endogenous control as data from our 
group has previous demonstrated consistent results with placental tissues. We chose not use a 
second endogenous control gene since the amount of CVS tissue was extremely limiting. 
 
2.6.10 Sequencing  
PCR products were sequenced by the dideoxy chain termination method (Sanger et 
al., 1977). In a Thermo-Fast® 96-well PCR plate, 3-4 μl of PCR products were purified and 
precipitated by adding an equal volume of microCLEAN. The plate was covered with 
MicroAmp® Clear Adhesive Film, vortexed and left for 5 minutes at room temperature, 
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followed by centrifugation step at 4000 rpm for 40 minutes at room temperature. The 
microCLEAN was removed by centrifugation of the plate set upside down on a tissue at 600 
rpm for 1 minute. Sequencing mixture was then added to the precipitate (Table 2-6). 
 
Table 2-6: Standard Big Dye Terminator sequencing reaction mix. 
Reagent Volume (μl) per reaction 
BigDye® Terminator v1.1 1 
BigDye® Terminator v1.1 Buffer (5x) 2 
Betaine (5 M) 2 
Forward or Reverse primer (50 ng/μl) 0.5 
DEPC-treated water 4.5 
 
The sequencing program consisted of an initial incubation step at 96 °C for 1 minute, 
and 34 cycles of: incubation at 96 °C for 30 seconds, 53 °C for 15 seconds, 60 °C for 4 
minutes and at 20 °C for 2 minutes. The sequencing products were then precipitated by 
adding 50 μl of precipitation mix (5 ml of 3M sodium acetate (NaAc) at pH 5.2, 125 ml of 
100 % Ethanol (EtOH) and 40 ml of Milli-Q water) in each sample. The plate was left at 
room temperature for 20 minutes and it was then centrifuged at 3000 rpm for 40 minutes at 
10 °C. The solution was removed and the pellets were washed with 50 μl of 70% EtOH and 
spun at 3000 rpm for 10 minutes at 10 °C. The EtOH was removed by spinning the plate 
upside-down at 300 rpm for 1 minute and the resulting pellets were resuspended in 10 μl of 
1:10 1x TE Buffer. The plate was then run on the ABI 3730xl DNA Analyzer by staff in the 
Regional Diagnostic Laboratories (Barclay House). The read-out was then analysed by me 
using Sequencher™ v4.8 (Gene Codes Corporation). 
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2.6.11 Imprinting analysis  
Imprinting analysis of IGF2, IGF2R and PHLDA2 in CVS was carried out by DNA 
sequence analysis of expressed single nucleotide polymorphisms (SNP) in CVS genomic 
DNA after amplification using specific primers shown in Table 2-7. 
 
Table 2-7: Primers designed for sequencing genomic DNA and cDNA in CVS for 
imprinting analysis. 
 
Gene Primer sequence 5’ to 3’ Tm 
(°C) 
Product 
size (bp) 
Accession 
number 
Notes 
IGF2 
 
F: aacaccccacaaaagctcag 
R: tgcatggattttggttttca 
58 425 NM_000612 
 
for both gDNA 
and cDNA 
IGF2R F: gaaacacaaaacctacgacc 
R: agaacccaaaagagccaacc 
60 163 NM_000876 for gDNA 
IGF2R F: gaaacacaaaacctacgacc 
R: cctttggagtacgtgacaac 
60 242 NM_000876 for cDNA 
PHLDA2 F: caaaccccgcacgccatgag 
R: gatttatttgcaatgggcacag 
60 483 NM_003311 for both gDNA 
and cDNA 
 
 
Informative DNA samples were heterozygous for IGF2 A/G (rs680), IGF2R A/G 
(rs1805075) or PHLDA2 A/G (rs1056819) SNPs (http://www.ncbi.nlm.nih.gov/projects 
/SNP/), where one allele is inherited from the mother and the other inherited from the father. 
Corresponding cDNA from the informative samples was then screened. If a single peak was 
detected in the cDNA sequence, the gene must be monoallelically expressed, with one of the 
parental alleles silenced (imprinted). If both alleles were detected in the resulting sequence, it 
was biallelically expressed and therefore not imprinted.  
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2.6.12 Statistical analysis 
Standard multiple linear regression models were used to examine the correlation of 
IGF1, IGF1R, IGF2, IGF2R and PHLDA2 relative expression values to birth weight after 
adjustment for gestational age at delivery, sex, parity, maternal age, smoking status and 
maternal BMI. Any outliers more than 2 standard deviations from the mean were removed. 
The analysis of variance (one-way ANOVA) was used to compare the gene expression means 
between the three different categorical birth weight groups (SGA, AGA, LGA) taking into 
consideration any confounding factors. Statistical package “R” (version 2.13.0) was used for 
the analyses and for calculating adjusted R-squared (R
2
) values. Significance was defined as 
p<0.05. 
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2.7 RESULTS 
2.7.1 Subjects 
A total of 260 CVSs from King’s College Hospital were used in this study. The 
clinical details about the pregnancy from both the mother and the baby at term are shown in 
Table 2-8.  
 
Table 2-8: Medical details of participants in the CVS cohort. 
 
Maternal information:  
Pre-pregnancy weight (Kg) 
Height (cm) 
Maternal BMI 
Maternal age (years) 
Smoking  
 
Parity 
63 ± 7 
153.4 ± 8.6 
27.3 ± 6 
34.3 ± 10.3 
Yes: 24 (9 %) 
No: 236 (91%) 
0: 90 (35 %) 
>1: 170 (65 %) 
Baby’s information:  
Birth weight (g) 
Gestational age at birth (days) 
Sex  
 
3,515 ± 690 
279.4 ± 9  
Males: 142 (55%) 
Females: 118 (45 %) 
Ethnicity:  
White European 
Black 
Asian 
Oriental 
Unknown 
226 (87 %) 
13 (5 %) 
10 (4 %) 
8 (3 %) 
3 (1%) 
   
Mean ± standard deviations.  
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2.7.2 Analysis of mRNA levels in CVS cohort 
In order to perform quantitative expression analysis using RTqPCR, RNA was first 
isolated from each CVS and reversed transcribed to cDNA. The housekeeping gene ACTB 
was used to confirm the presence of cDNA and the absence of genomic contamination, as the 
band size (incorporating an intron) would be much larger if genomic DNA was present (Fig. 
2-5).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5: ACTB cDNA amplification.  
Lane 1: 100 bp DNA marker; lane 2: sample 2593; lane 3: sample 2454; lane 4: sample 2457; 
lane 5: sample 2512; lane 6: sample 2522; lane 7: sample 2567; lane 8: sample 2570; lane 9: 
sample 2588; lane 10: sample 2611; lane 11: sample 2670; lane 12: sample 2697; lane 13: 
sample 2702; lane 14: sample 2713; lane 15: sample 2715; lane 16: RT negative control; lane 
17: PCR blank. 
 
 
Next, the relative mRNA levels of IGF1, IGF2, IGF1R, IGF2R, PHLDA2 and L19 
were quantified in the 260 CVSs using the StepOnePlus Real-Time PCR system and analysed 
by the StepOne software (version 2.1). In order to determine the relative expression of the 
genes of interest in each sample, levels of each gene were compared to the ubiquitously 
expressed housekeeping gene L19 (Fig. 2-6). L19 was chosen as an endogenous control 
because it encodes a ribosomal protein that has a constant expression in all cell types (Thellin 
et al., 1999). 
 
 
 
 1     2     3    4    5     6    7     8    9   10   11  12   13  14  15   16   17 
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Figure 2-6: Amplification plots.  
Plots are shown for two out of the five genes tested. (A) IGF2 and L19, sample 3400; (B) 
IGF2R and L19, sample 1885. The amplification plots shown are representative of the sample 
selection as all CVSs consistently showed relatively higher expression of IGF2 compared to 
L19; CVSs also showed relatively lower expression of IGF2R compared to L19. The Rn 
(normalised reported) value is the fluorescent signal from SYBR Green normalized to the 
signal of the passive reference dye. The y-axis represents the ΔRn (delta Rn) value, which is 
the Rn value of an experimental reaction minus the Rn value of the baseline signal generated 
by the instrument. The x-axis represents the cycle number. 
L19 
IGF2 
L19 
IGF2R 
A 
B 
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2.7.3 Confounding factors – The influence of GA, maternal BMI, sex, parity and 
smoking status on fetal birth weight 
In this study, we have investigated the relationship between IGF1, IGF2, IGF2R, 
IGF1R and PHLDA2 mRNA levels in first-trimester placental tissue with the birth weight of 
the resultant term new born babies. We correlate this data taking into account the carefully 
recorded birth parameters that may have a confounding effect (GA, sex, parity, maternal BMI 
and smoking status; Fig. 2-7).  
As expected by Wilcox et al., 1993, there was a strong positive association between 
GA at term and birth weight, as babies that are born at a later GA are heavier (P=4.8×10
−15
; 
Fig. 2-7A). In addition, maternal BMI was positively correlated to fetal birth weight, which is 
in agreement with Mongelli and Gardosi (1995) who showed that heavier and taller mothers 
give birth to heavier offspring (P=0.0012; Fig. 2-7B). There was also an association between 
fetal sex and birth weight, as males had a higher birth weight than females (P=1.4×10
−7
; Fig. 
2-7C). In addition, parity showed a significant association with birth weight, as women that 
had previous pregnancies (multiparous) had heavier babies than those women that had their 
first pregnancy (nulliparous) (P=7.5×10
−5
; Fig. 2-7D). These associations between birth 
weight and sex or parity are all in agreement with Hindmarsh et al., 2002.  
Although studies have shown that cigarette smoking during pregnancy is associated 
with a reduction in birth weight (Bernstein et al., 2005), in our cohort we did not find a 
significant association between birth weight and maternal smoking status (P=0.33; Fig. 2-
7E). This could be due to the low percentage (9%) of smokers in this cohort. Moreover, no 
association was observed between birth weight and different ethnic groups, probably because 
87% of the samples used were of the same ethnic group (White-Europeans). 
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Figure 2-7: Confounding factors. 
Correlation of birth weight with GA (P=4.8×10
−15
; Fig. 2-7A), with maternal BMI 
(P=0.0012; Fig. 2-7B), with sex (P=1.4×10
−7
; Fig. 2-7C), with parity (P=7.5×10
−5
; Fig. 2-7D) 
and with maternal smoking status (P=0.33; Fig. 2-7E) (Figure from Demetriou et al., 2014). 
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2.7.4 Correlation between expression of genes of interest in CVS and birth weight 
Regression analysis was performed after standardization to the endogenous control 
gene L19, in relation to birth weight corrected for confounding factors. Significant 
associations were observed for expression of IGF2 (P=0.009) (Fig. 2-8A) and IGF2R 
(P=0.04) (Fig. 2-8B) between CVS tissue and birth weight. Importantly the range of IGF2 in 
relative expression units was from 1.5-12 with one relative expression unit being equivalent 
to a change in birth weight of 63 g. No association was found for PHLDA2 (P=0.73) (Fig. 2-
8C), IGF1 (P=0.48) (Fig. 2-8D) or IGF1R (P=0.08) (Fig. 2-8E) between CVS tissue and birth 
weight. 
As both IGF1 and IGF2 bind to the receptor IGF1R but only IGF2 binds to IGF2R we 
decided to look at this relationship between the ligands and their receptors and any 
correlation they might have with birth weight. No association was found for the ratio of IGF1 
to IGF1R (P=0.76) (Fig. 2-9A) or the ratio of IGF2 to IGF2R (P=0.93) (Fig. 2-9B) between 
CVS tissue and birth weight. However, the ratio of IGF2 to IGF1R (P=0.005) (Fig. 2-9C) 
was significantly associated with birth weight. 
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Figure 2-8: mRNA expression levels of IGF2, IGF2R, PHLDA2, IGF1 and IGF1R in 
chorionic villi. The expression levels of IGF2, IGF2R, PHLDA2, IGF1 and IGF1R after 
standardization to the control gene L19, in relation to birth weight corrected for parity, sex, 
GA at term, maternal BMI and smoking status. Significant associations were observed for 
CVS expression of A) IGF2 (P=0.009) and B) IGF2R (P=0.04). No significant association 
was found for C) PHLDA2 (P=0.73), for D) IGF1 (P=0.48) or for E) IGF1R (P=0.08) (Figure 
from Demetriou et al., 2014). 
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Figure 2-9: mRNA expression levels of IGF1/IGF1R, IGF2/IGF2R and IGF2/IGF1R in 
chorionic villi.  The expression levels of IGF1/IGF1R, IGF2/IGF2R and IGF2/IGF1R after 
standardization to the endogenous control gene L19, in relation to birth weight corrected for 
parity, sex, GA at term, maternal BMI and smoking status. No significant association was 
found for A) the ratio of IGF1 to IGF1R (P=0.76), or for B) the ratio of IGF2 to IGF2R 
(P=0.93). Significant association was observed for CVS expression of C) the ratio of IGF2 to 
IGF1R (P=0.005) and birth weight (Figure from Demetriou et al., 2014). 
 
To investigate the whole growth spectrum pregnancies were subdivided into small for 
gestational age (SGA; n=50) with birth weight <10
th
 percentile, large (LGA; n=65) with birth 
weight >90
th
 percentile and appropriate (AGA; n=145) (Table 2-9). 
Table 2-9: Samples subdivided into groups according to the birth weight centile. 
BW Centile Class Sample Number Mean BW (g) P-value 
<10
th
 SGA 50 2564 P <2x10
-16***
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th
 – 90th AGA 145 3455 P <2x10-16*** 
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th
 LGA 65 4382  
SGA: small for gestational age (GA); AGA: appropriate for GA; LGA: large for GA 
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In the SGA group compared to the AGA group, IGF2 expression was reduced by 
statistically significant amounts (P=3.6x10
-7
), despite no significant differences in the 
expression levels of individual receptors (IGF2R, P=0.76 or IGF1R, P=0.15). In the LGA 
group IGF2R expression was found to be higher than in the AGA group (P=0.02) and IGF1R 
expression was lower than in the SGA group (P=0.05) (Fig. 2-10). 
 
 
 
 
 
 
 
Figure 2-10: mRNA expression levels of IGF2, IGF2R, and IGF1R in chorionic villi 
according to BW centile. Relative IGF2, IGF2R, and IGF1R expression levels in the 
pregnancies with SGA, AGA and LGA neonates. In the SGA group, compared to the AGA 
group, A) IGF2 expression was lower (P=3.6x10
-7
), but there was no significant difference in 
the expression levels of B) IGF2R (P=0.76) or C) IGF1R (P=0.15). In the LGA group B) 
IGF2R expression was higher than in the AGA group (P=0.02) and C) IGF1R expression was 
lower than in the SGA group (P=0.05) (Figure from Demetriou et al., 2014). 
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2.7.5 Imprinting analysis in CVS 
Given that IGF2 and PHLDA2 are both imprinted in mouse and human (DeChiara et 
al., 1990; Qian et al., 1997; Giannoukakis et al., 1993), we wanted to confirm that 
monoallelic expression was maintained in CVS material, since reversion to biallelic 
expression may have an impact on mRNA levels. Furthermore, in contrast to the mouse, 
where it is fully imprinted (Monk et al., 2006), IGF2R is reported to be monoallelically 
expressed in only 10% of individuals in the human population. We therefore wished to 
investigate for any potential skewing. The transcribed SNPs rs680 (IGF2), rs1805075 
(IGF2R) and rs1056819 (PHLDA2) were used to report on allele-specific expression and thus 
determine imprinting status of IGF2, IGF2R and PHLDA2.  
Genomic DNA extracted from the CVS from 200 patients were tested for 
heterozygosity at these SNPs, with 40 samples found to be informative at rs680 for IGF2, 24 
samples at rs1805075 for IGF2R and 21 samples at rs1056819 for PHLDA2. The 40 
informative IGF2 individuals and the 21 informative PHLDA2 individuals were all found to 
be monoallelically expressed. For the 24 samples informative for IGF2R, 21 (88%) were 
biallellically expressed for IGF2R and 3 (12%) were monoallelic, which is similar to the 
expected population frequency (Fig. 2-11). Thus, skewed monoallelic/biallelic expression 
was unlikely to be a factor reflected in the relative expression levels associated with birth 
weight. 
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Figure 2-11: Imprinting analysis of IGF2, PHLDA2 and IGF2R.  
Representative Sanger sequencing chromatograms are shown from one of the 40 informative 
CVS samples for the IGF2 A/G polymorphism (rs680) (A, B), one (from 21) for the 
PHLDA2 A/G polymorphism (rs1056819) (C, D) and two (from 24) for the IGF2R A/G 
polymorphism (rs1805075) (E, F, G, H). Heterozygous genomic CVS DNA sequence is 
shown in A), C), E) and G). While monoallelic expression from the corresponding cDNA 
samples are shown in B), D) and H).  Monoallelic expression in cDNA was found in all 
informative IGF2 and PHLDA2 samples as well as 12% of IGF2R samples. Biallelic 
expression, as shown in F), was found in the majority (88%) of informative cDNA samples 
for IGF2R (Figure from Demetriou et al., 2014). 
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2.8 DISCUSSION 
Previous studies that have linked IGF2 expression to birth weight have shown that 
IGF2 in term placenta is decreased in FGR pregnancies compared to controls (Koukoura et 
al., 2011), as well as in SGA pregnancies (Guo et al., 2008). However, the first trimester 
IGF2 expression data reported in this study, provides the first evidence for the role of this 
paternally expressed imprinted gene as an in utero fetal growth enhancer this early in human 
pregnancy (Demetriou et al., 2014). This is in agreement with results previously described in 
animal studies (DeChiara et al., 1990; Constancia et al., 2002). In mouse experiments, for 
example, paternally expressed Igf2 was reported to control 40% of fetal growth, while the 
maternally expressed gene Igf2r limited growth (Wang et al., 1994; Lau et al., 1994). In 
humans, IGF2 is maternally imprinted and thus a paternal-expression driven growth 
promoter. However, in humans, IGF2R is polymorphic for its imprinting status as 90% of 
individuals show biallelic expression (Monk et al., 2006). This suggests a possible shift in the 
mechanism of its regulation of expression away from that used in the mouse. Interestingly, 
here, the samples showing monoallelic expression of IGF2R had similar levels of expression 
to those showing biallelic expression. 
As fetal size is subject to both positive and negative regulation, IGF2 and IGF2R can 
apply opposite forces on the fetus, thus achieving a fine degree of control over the growth 
process. As levels of IGF2 increase in the fetus, the levels of IGF2R can also increase, 
resulting in clearance of IGFII from tissue fluids and plasma, correcting and maintaining 
levels of IGFII in the circulation. This acts as a fine-tuning rheostat designed to prevent 
babies from overgrowth in order to maintain a normal growth trajectory. This is also 
supported by the fact that no association was observed between the IGF2/IGF2R expression 
levels and birth weight, as the ligand and the receptor work tightly together to regulate 
growth. The same applies for IGF1 and its regulating receptor IGF1R (Fig. 2-9). 
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In this study, expression of IGF1 in chorionic villi was not associated with birth 
weight outcome (Fig. 2-8D) These results directly contradict findings from previous studies 
involving mouse models which highlighted IGF1 in the regulation of both pre- and postnatal 
growth (Le Bouc et al., 2003). A strong possibility that IGF1 is indeed relevant to intrauterine 
growth in the later stages of pregnancy remains, as it is preparing the baby for a postnatal life. 
While fetal chorionic samples in our cohort proved an opportunity to assess correlation 
between gene expression and fetal growth in early gestation (11-13 weeks), this narrow 
window might not be the best to investigate IGF1 expression, as IGFI does not appear in the 
fetal circulation until later (Demendi et al., 2011). 
Although previous studies have shown a negative association of term placental 
PHLDA2 with birth weight (Apostolidou et al., 2007; Ishida et al., 2012), in our study no 
statistically significant association was observed between PHLDA2 expression levels in CVS 
and birth weight (Fig. 2-8C). This suggests that maternally expressed PHLDA2 is suppressing 
the baby’s growth later in pregnancy rather than early on. Previous studies investigating term 
placental IGF2 expression have shown inconclusive results. However, in our study a 
statistically significant association was observed between IGF2 expression levels in CVS and 
birth weight, suggesting that the paternal genome is promoting the baby’s growth earlier in 
pregnancy (Fig. 2-8A).  Therefore, the two parental genomes appear to be acting at different 
times during pregnancy to control fetal weight. This supports the idea that whilst increased 
fetal growth is important early on, it must still require careful regulation by the mother to 
ensure a successful birth. 
In our study, SGA neonates had significantly lower IGF2 expression levels compared 
to AGA neonates, but no differences were observed between the levels of the receptors 
IGF2R and IGF1R (Fig. 2-10). This highlights the importance of the IGF2 ligand rather than 
the receptor level in determining size of the neonate in SGA pregnancies. This is in 
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agreement with previous studies investigating IGF2 mRNA levels in the placentas from SGA 
pregnancies (Guo et al., 2008). However, other studies have reported no differences in IGF2 
expression levels in term placenta between FGR pregnancies and controls (Street et al., 2006; 
Antonazzo et al., 2008) or increased IGF2 levels in FGR pregnancies (Abu-Amero et al., 
1998). Possible explanations for these conflicting results could be the fact that term tissue 
was used or the fact that pathological FGR pregnancies were investigated, whereas in our 
study SGA pregnancies were used. In addition, as previous studies have relied on a smaller 
sample size, for example 16 FGR samples compared to 20 controls (Street et al., 2006), these 
studies may not have had sufficient power to observe significant differences between the two 
different groups.  
To better understand the causes and consequences of FGR as a human pregnancy 
complication, we focused on available tissue from the first trimester, as this time window is 
more likely to accurately reflect the in utero growth potential. We used a larger sample size 
and we investigated the whole growth spectrum including not only SGA but also LGA 
neonates. Extending the investigation of these genes to samples displaying macrosomic birth 
weight revealed further correlations between growth parameters and gene expression. In this 
study, LGA neonates had higher IGF2R expression levels compared to AGA neonates and 
lower IGF1R levels compared to SGA babies. Similar results have been reported in placenta 
tissue for IGF1R mRNA levels alone (Iniguez et al., 2011). This suggests that fetuses with 
high birth weight are producing more IGF2R and correspondingly less IGF1R, which could 
remove the growth promoting effect IGF2. This balance may represent another important 
compensatory mechanism in response to fetal overgrowth (summarised in Table 2-10). This 
is also supported by the fact that a significant association was observed between the ratio of 
IGF2 to IGF1R and birth weight, suggesting that the levels of IGF1R in LGA neonates 
decrease as their IGF2 levels increase, to avoid any further increase in size. 
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Table 2-10: Differences in the expression levels of IGF2, IGF2R and IGF1R in SGA and 
LGA neonates compared to AGA neonates. 
 
 
 
 
 
 
 
 
The “small baby syndrome hypothesis” proposed by Barker et al., (1993) suggests 
that there is an inverse linear relation between birth weight and T2D. This is also supported 
by a large meta-analysis (Whincup et al., 2008). The mechanisms by which birth weight is 
related to T2D is still under debate; some researchers claim that this relationship reflects 
long-term consequences of under-nutrition in utero (Barker et al., 1993), whereas others do 
not see under-nutrition as playing a significant role (Hofman et al., 2004). Interestingly, 
specific fetal IGF2 paternal haplotypes are linked to higher maternal glucose levels that 
increase the risk of gestational diabetes (Petry et al., 2011). Nevertheless the amount of IGF2 
available from the placenta early in the first trimester is likely to be a major factor in 
promoting growth.  
An important aim for antenatal care is the prediction, detection and treatment of 
abnormal fetal growth. It is known that variation in size at birth results from interaction 
between fetal genetic factors and the maternal genetic and uterine environment. In this study 
we also implicate the important role of the father’s genes in fetal growth in utero. 
 
 
Early in pregnancy at 11-13 weeks’ gestation 
SGA neonates LGA neonates 
Reduced IGF2 Similar IGF2 
Similar IGF2R Elevated IGF2R 
Similar IGF1R Reduced IGF1R 
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2.9 FUTURE WORK 
 
IGF2 mRNA levels in adult human peripheral blood leukocytes – a pilot study 
Maternal circulating IGF-proteins increase during pregnancy. IGFII levels are highest 
from the end of the first trimester and persist through the remainder of pregnancy, remaining 
much higher than IGFI (Gargosky et al. 1990). Previous data has shown that imprinted genes 
are not highly expressed in adult blood compared to more relevant fetal tissues. However, 
IGF2 was among those few that could be readily detected (Frost et al., 2010). 
In this pilot study, IGF2 mRNA levels were measured using RTqPCR in peripheral 
blood leukocytes of 23 males, 13 non-pregnant females and 41 pregnant females (samples 
were previously collected by Dr Andy Duncan, UCL). An unpaired two-tailed t-test was used 
to compare the difference in the IGF2 expression levels between the three groups. Pregnant 
females had significantly higher IGF2 expression levels compared to both males and non-
pregnant females (P=0.008 and P=0.02, respectively), suggesting that IGF2 mRNA levels 
are higher during pregnancy (Fig. 2-12).  
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Figure 2-12: Relative expression levels of IGF2 in adult blood. Pregnant females had 
significantly higher IGF2 expression levels compared to both males and non-pregnant 
females (P=0.008 and P=0.02, respectively). 
 
Interestingly, a study in pregnant guinea pigs demonstrated that administration of 
IGFII during early pregnancy increased the volume of the placenta devoted to exchange by 
30%, as well as the transfer of nutrients from the mother to the fetus. Infusion of IGFII 
increased the number of viable fetuses by 26% and fetal weight by 11% but did not affect 
maternal body composition. Moreover, they showed that maternal IGFII in early gestation 
acts in part via the IGFIIR to enhance the functional development of the placenta and nutrient 
delivery and hence promote fetal growth (Sferruzzi-Perri et al., 2006, 2007, 2008). As the 
IGF axis in guinea pigs is thought to function in a very similar way to that of humans, one 
might predict that increasing maternal IGFII abundance in an early pregnancy in humans may 
also enhance fetal growth and viability at term. Therefore, more samples from pregnant 
females are now being collected to investigate whether IGF2 mRNA levels detected in 
maternal blood are correlated with birth weight at term and whether maternal IGF2 can be 
used as a biomarker in predicting SGA neonates. 
Understanding the developmental role, function and parent-of-origin effect of critical 
imprinted genes during human fetal growth will make an important contribution to effective 
clinical evaluation of growth disorders and their association with longer term, metabolically 
related, health risks such as T2D. Determination of paternal IGF2 expression in the first 
trimester, potentially in maternal blood, may act as a predictor of fetal growth trajectory for 
later in the pregnancy. An early growth biomarker could be invaluable to alert Obstetricians 
and Neonatologists towards closer ‘at risk’ pregnancy surveillance. 
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CHAPTER 3 – IMPRINTING ANALYSIS OF MISCARRIED 
PRODUCTS OF CONCEPTION 
3 INTRODUCTION 
Fetal growth involves a complex interaction between genes and the environment. Of 
particular interest is one group of genes that are found almost exclusively in placental 
mammals, known as imprinted genes many of which have growth regulatory functions. As 
described in Chapter 1, genomic imprinting is an epigenetic form of gene regulation that 
gives rise to differential expression or silencing of a given allele, depending upon its maternal 
or paternal inherited origin. The imprinting mechanism is complicated and still not 
completely understood. Although the regulation of imprinted expression is cluster specific, 
several common features shared by imprinting clusters have been described, including 
enrichment of CpG sites which are normally subject to epigenetic modifications. These 
modifications include histone modifications associated with repressive or active chromatin 
conformation, DNA acetylation and DNA methylation (Lewis and Reik, 2006). 
Histone acetylation is the process brought about by histone acetyltransferases (HATs) 
that acetylate the histone tails of the nucleosome, as part of gene regulation. Acetylation 
neutralizes the positively charged lysine residues of the histone N termini, thus decreasing 
their affinity for DNA. As a result, the condensed chromatin is transformed into a more 
relaxed structure that is associated with greater levels of gene transcription (Lee et al., 1993).  
However, of these mechanisms of epigenetic variation the most widely studied and 
best understood is methylation. The difference between an active and an inactive gene is the 
presence of 5’-methylcytosine bases within CpG islands that lie upstream of the gene. Allele 
specific methylation causes certain genes to be only active on one of the two parental 
chromosomes (Lee et al., 1993). 
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The sequences contributing to differences in DNA methylation between the parental 
alleles are known as DMRs. DMRs can have different properties, as some DMRs are 
methylated resulting in an active gene copy, whereas others are methylated causing 
inactivation. In addition, methylation of DNA in some DMRs is introduced in the parental 
germ cells and maintained in all tissues and during all developmental stages, whereas others 
show tissue-specific patterns as well as changes during development. At imprinting loci, two 
types of DMRs have been described. One of them is known as a germline DMR that acquires 
methylation during gametogenesis and the other is known as a somatic DMR that becomes 
methylated after fertilization and depends on the presence of the germline DMR (Lewis and 
Reik, 2006; Edwards and Ferguson-Smith, 2007).  
 
3.1 The imprinting cycle 
Most imprinted genes studied to date are involved in embryonic development and 
fetal growth (Reik and Walter, 2001). Genomic imprints change in characteristic ways during 
the life cycle of an organism and have three major stages in their life cycle: establishment, 
maintenance, and erasure (Fig. 3-1). The paternal and the maternal epigenetic marks are 
heritable to the daughter cells, but must reset in each generation to establish parental specific 
imprints. In mammals, the parental genomes undergo two rounds of genome-wide DNA 
methylation reprogramming during the life cycle of imprints. 
 
Erasure:  
   The first round of reprogramming that occurs in the primordial germ line involves 
sequential demethylation and remethylation steps where the old imprints are erased. These 
steps occur to remove the existing parental methylation patterns and establish new sex-
specific imprints in the gametes (Constancia et al., 1998; Lee at al., 2002). The epigenetic 
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imprints of the new organism are erased, followed by the acquisition of new imprints 
according to the sex of the germ line, making sure that the sex dependent imprints can be 
expressed in later embryonic development (Reik and Walter 2001).  
 
Establishment:  
Establishing epigenetic imprints involves a complex procedure involving 
reprogramming of the entire genome. This reprogramming is very important, as accurate 
imprints must be passed from one generation to the next. All cells contain two sets of 
chromosomes: one from the father, hence male imprints and one from the mother, hence 
female imprints. When these chromosomes are passed on to the next generation, the two sets 
in the specific germ cells are reprogrammed to contain male or female imprints exclusively 
(Biliya and Bulla, 2010). 
Sex-specific imprints are established during the development of germ cells into sperm 
or eggs (gametogenesis). The genomic imprints get implanted into the male and female germ 
line and then go through further development ready to be passed on to the offspring. In males, 
the genomic imprints become fully established and finish developing in prospermatagonia by 
the neonatal stage. In females, the imprints are implanted to the germ line layers of the oocyte 
and then completely established by the time the oocyte is fully developed (Davis et al., 2000; 
Li et al., 2004; Li and Sasaki, 2011). 
The second round of reprogramming occurs after fertilization, and involves genome-
wide demethylation in the early embryo prior to implantation. Post-implantation, global 
remethylation takes place. The somatic methylation patterns for normal development are thus 
created, a process that is essential for the activation and silencing of specific genes (Reik and 
Walter, 2001). Although is not yet clear which enzymes are responsible for de novo 
methylation, in mammals three functional DNA-methyltransferase (DNMT) enzymes have 
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been described; DNMT1, DNMT3a and DNMT3b (Hata et al., 2002; Kaneda et al., 2004).  
 
Maintenance:  
Once the imprints are completely ready to be expressed they are passed on to the 
zygote through fertilization and maintained throughout the development and adult life. The 
methylation imprints at germline DMRs escape from the global epigenetic reprogramming 
that occurs in the pre-implantation embryos. This reprogramming includes the active de-
methylation of the paternal genome and the subsequent passive de-methylation of both 
parental genomes. Only imprinted genes are protected against this demethylation, thus 
maintaining their germline methylation marks and parent-specific activities throughout 
development of the new organism. The mechanism that protects ICRs from genome-wide 
demethylation is not well characterized, but zinc finger protein 57 (Zfp57), has been shown to 
be involved in the post-fertilisation maintenance of DNA-methylation imprints at multiple 
ICRs (Li et al., 2008). In somatic cells, imprints are maintained and are modified during 
development. The imprints are eventually read thus resulting in parent-specific gene 
expression (Reik and Walter 2001, Morgan et al., 2005).  
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Figure 3-1: Life cycle of genomic imprints.  
The maternal and paternal methylation imprints are established during the development of 
germ cells into sperm or eggs (gametogenesis). The two germline genomes are combined at 
fertilization and in the early embryo, parent-specific genome reprogramming takes place. 
Imprints are maintained as chromosomes duplicate and segregate in the developing organism. 
In the germ cells of the new organism, DNA methylation patterns are erased at an early stage. 
This is followed again by establishment at a later stage of germ cell development, thus 
completing the imprinting cycle. In somatic cells, imprints are maintained and modified 
during development. 
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3.2 Genes investigated  
Known imprinted genes include IGF2, PHLDA2, paternally expressed gene 3 
(PEG3), delta-like 1 homolog (DLK1) and H19. IGF2 is paternally expressed, maternally 
imprinted in both mouse (Willison, 1991) and human (Giannoukakis et al., 1993). Studies 
that have investigated the human expression of IGF2 report decreased levels in SGA 
pregnancies and a positive association with birth weight early in pregnancy (Demetriou et al., 
2014). PHLDA2 is maternally expressed, paternally imprinted, in both humans and mice 
(Qian et al., 1997). Studies that have investigated the human placental expression of 
PHLDA2 report increased levels in SGA pregnancies and a negative association with birth 
weight (Apostolidou et al., 2007; Ishida et al., 2012). For more information on IGF2 and 
PHLDA2 see Chapter 2 sections 2.1.1 and 2.2, respectively.  
 
3.2.1 Paternally expressed gene 3 
PEG3 was the first imprinted gene to be discovered in human chromosome 19q13.4 
locus, a region of conserved synteny with mouse proximal chromosome 7 (Murphy et al., 
2001). PEG3 encodes a large Kruppel-type (C2H2) zinc-finger protein, most of which are 
believed to function as transcription factors (el-Baradi and Pieler, 1991; Pieler and Bellefroid, 
1994). Although the overall genomic structure of PEG3 is well conserved between mice and 
humans, some species-specific changes exist. For instance, mouse Peg3 contains two proline-
rich domains whereas human PEG3 lack one of these domains (Kim et al., 2004). PEG3 is 
ubiquitously expressed and imprinted in a wide variety of human fetal tissues including the 
fetal adrenal gland, heart, liver, lung, kidney, brain and fetal and term placenta (Murphy et 
al., 2001). Both male and female mice carrying the disrupted paternal copy of Peg3 are viable 
and fertile but suffer from placental and fetal growth restriction (Li et al., 1999). 
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3.2.2 Delta-like 1 homolog 
DLK1 is a paternally expressed gene located on the human chromosome 14q32 
imprinting cluster, approximately 90 kb away from the reciprocally imprinted, maternally 
expressed gene 3 (MEG3). DLK1 is highly conserved throughout vertebrates with the 
predicted aa sequence of DLK1 sharing 86% identity with mouse DLK1 (Laborda et al., 
1993). DLK1 encodes a transmembrane glycoprotein containing six epidermal growth factor-
like repeat motifs in the extracellular domain (Laborda et al., 1993) involved in adipogenesis 
(Sul, 2009). DLK1 is ubiquitously expressed in fetal tissues, including the fetal kidney, lung, 
liver, adrenal gland, brain and fetal and term placenta, where it is also shown to exhibit 
monoallelic expression (Wylie et al., 2000). Dlk1-null mice show high perinatal lethality, 
pre- and postnatal growth restriction followed by obese phenotype (Moon et al., 2002), 
suggesting its role as a growth promoter.   
 
3.2.3 H19 
H19 is maternally expressed, paternally imprinted and encodes a noncoding RNA in 
humans and mice (Bartolomei et al., 1991). The imprinting manner of H19 was determined 
by inducing H19 mutation in mice. Offspring who inherited the H19 mutation from the 
mother were 27% heavier than those who inherited it from the father. Additionally, there was 
no effect of paternal inheritance, which reflects the paternal silencing of this gene (Leighton 
et al., 1995). Biallelic expression of H19 has been reported in some cases at the early stage of 
normal pregnancy before the 10
th
 week of gestation (Yu et al., 2009).  
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3.3 Human leucocyte antigens in human pregnancy 
Placenta trophoblast cells form the interface between the mother and her conceptus 
and are the primary fetal cells that are exposed to the maternal immune system. The ability of 
the genetically distinct allogeneic fetus to escape immune rejection by avoiding alloreactivity 
has been described as an immunological paradox (Moffett-King, 2002). The main molecules 
involved in allorecognition by T-cells and NK cells belong to the highly polymorphic major 
histocompatibility complex (MHC) (reviewed by Moffett and Loke, 2006).  
The MHC is a 5 Mb region on the short arm of chromosome 6 that contains the most 
highly polymorphic genes in the human genome. The human MHC is named the human 
leukocyte antigen (HLA) complex and genes of this complex are the principal cause of acute 
graft rejection following human transplantation. Rejection is stimulated by HLA differences 
between the transplant recipient and donor. 
There are two HLA classes, class-I and class-II. There are six HLA class I loci that 
express protein products; three classical molecules (HLA-A, HLA-B and HLA-C) and three 
non-classical (HLA-E, HLA-F and HLA-G). The three classical molecules present antigens 
to CD8 T-cells and the three HLA class II (HLA-DP, HLA-DQ and HLA-DR) molecules 
present antigens to CD4 T-cells (Moffett-King, 2002). Class I molecules are expressed on a 
wide range of cells where they serve as ligands for receptors of NK cells (Parham et al., 
2012).  
The two main trophoblast subpopulations are the villous trophoblast that covers the 
villous tree and contacts maternal blood in the intervillous space and the extravillous 
trophoblast (EVT) that invades the decidua and myometrium (Moffett-King, 2002; Moffett 
and Loke, 2006). The villous trophoblast that is exposed to maternal blood lacks both class I 
and class II molecules. The EVT cells of the placenta are the only fetal cells that contact the 
maternal circulation and have the capacity to stimulate maternal lymphocyte responses 
92 
 
against paternal HLA antigenic differences. These cells, express the non-polymorphic HLA-E 
and HLA-G molecules as well as the polymorphic HLA-C molecules (Apps et al., 2009). 
HLA-C molecules are highly polymorphic with 106 different alleles known, encoding 750 
proteins (IPD-HLA database). 
To date, the only potential trophoblast NK-cell ligands that have been found are the 
MHC class-I molecules HLA-C, HLA-E and HLA-G (Ellis et al., 1990; Kovats et al., 1990; 
King et al., 2000). The NK-cell receptors for HLA-C are members of the killer-cell 
immunoglobulin-like receptors (KIR) family. These receptors are encoded by a polymorphic 
family of 15 genes in the leukocyte-receptor complex, and contribute to the immunogenetics 
of human placentation (Moffet and Loke, 2006; Barrow and Trowsdale, 2008). Although all 
three (HLA-C, HLA-E and HLA-G) are ligands for NK cell receptors, it is the interaction 
between HLA-C and KIR that have the greatest immunogenetic potential to vary the course 
of pregnancy (Male et al., 2011). 
In pregnant women, uterine NK (uNK) cells, which represent up to 70% of the 
leukocyte population in first trimester decidua (King et al., 1991), express a higher proportion 
of KIRs that are specific for HLA-C than peripheral blood NK cells do. This suggests that the 
range of the NK-cell receptors is skewed towards recognizing HLA-C in the uterus. This KIR 
expression is highest earlier in gestation and slowly declines over the first trimester (Hiby et 
al., 1997; Verma et al., 1997).  Both KIR and HLA-C are highly polymorphic thus paternally 
derived fetal HLA-C and maternal uNK-cell KIRS should interact during pregnancy. The fact 
that each pregnancy involves different combinations of HLA-C molecules and maternal KIRs 
suggests the possibility that some combinations would not be optimal for implantation and 
that these pregnancies might fail as a consequence.  
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3.3.1 Imprinting of HLA-C  
A recent study by Fogarty et al., (unpublished, manuscript in preparation) showed that 
the HLA-C is temporally imprinted and maternally expressed in CVS at 12 weeks of 
gestation, becoming biallelically expressed in term placenta and adult blood. HLA-C 
expression was also absent in complete hydatidiform mole tissue where only the paternal 
genome is present. Given the genetic diversity of HLA alleles and the advantage associated 
with heterozygosity in HLA loci (Hughes and Yeager 1998), it is highly unlikely that couples 
will have an identical genotype for HLA-C. Therefore, in most pregnancies paternally 
inherited HLA-C alleles will be different from the maternal alleles.  
Classical immunological paradigms describe the rejection of allogeneic tissues due to 
the detection of non-self MHC antigens by circulating immune cells. It is possible that in 
some cases, the conceptus expresses the HLA-C alleles inherited from the father that are 
different from the maternal alleles, and the maternal immune system recognizes the foreign 
paternal HLA-C. Based on this, we decided to investigate the imprinting of HLA-C in our 
POC cohort.  
 
3.4 Aim and Hypothesis 
Miscarriage is the most common pregnancy complication with up to 50% of women 
experiencing one or more early miscarriages (Rai and Regan, 2006). The selective imprinting 
of HLA-C during early human development may have a major functional significance in 
maintaining the human pregnancy and any failures or disruptions of this imprinting could be 
involved in the pathology of miscarriages.  
The aim of our study was to investigate products of conception material, i.e. tissue 
that is present in a fertilized gestation in a pregnancy that ended in a miscarriage, for 
imprinting anomalies. This study focused on investigating the imprinting status of the 
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maternally expressed HLA-C, H19, PHLDA2 genes and the paternally expressed IGF2, PEG3 
and DLK1 genes from which DNA from both parents was available so we could detect which 
parental allele is expressed in these genes. Our hypothesis is that a proportion of miscarried 
POC that are cytogenetically normal will have abnormal expression profiles at imprinted loci, 
possibly causing embryonic lethality. Before this study commenced, it was first necessary to 
investigate the fetal origin of the POC to determine whether maternal tissue contamination 
might interfere with this analysis, and if so to estimate the levels of contamination present in 
each POC sample. 
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3.5 MATERIALS AND METHODS 
3.5.1 Subjects 
Samples were collected from the RM Clinic at St Mary’s Hospital, Imperial College 
London. Ninety-nine trios, consisting of the mother, father and a sample from POCs were 
used in this study. Blood was collected from individuals agreeing to participate in the 
research project approved by the Hospital’s Ethics Committee. Tissues from the POC were 
collected from the uterus of each of these women after miscarriage. Five further trios were 
available from the Baby Bio Bank (Abu-Amero et al., 2014). 
 
3.5.2 Preparation of DNA and RNA from samples  
Parental DNAs were extracted from blood using the iPrep™ PureLink™ gDNA 
Blood Kit using the iPrep Purification Instrument based on the manufacturer’s instructions 
(Invitrogen). DNA from POC tissue was extracted using the iPrep™ ChargeSwitch® gDNA 
Tissue Kit and RNA from the POC was extracted using the iPrep™ Total RNA kit without 
DNAse treatment.  
 
3.5.3 Sex determination of POCs 
A previous study has shown that the majority of POCs are maternal decidua, as 
maternal cell contamination (MCC) was present in 90% of the 46, XX POCs (Jarrett et al., 
2001). The contamination appeared to completely obscure the fetal material in 92% of these 
specimens. Therefore, to exclude possible cases of MCC in POCs, some researchers have 
used only samples with a normal male karyotype for their experiments (Doria et al., 2010).  
We therefore also decided to determine the gender of our 104 POCs and use only 
males for this study. Sex determination was done by PCR analysis of the X-Y homologous 
Amelogenin gene (AMEL) (Akane et al., 1991). The gene has homologous sequences on both 
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the X and the Y chromosome; however, a small deletion in the AMELY homologue makes it 
possible to distinguish between them. Amplification of a segment of this gene using the pair 
of primers shown in Table 3-1 reveals both AMELX- and AMELY-specific bands at the same 
time, with the smaller band being indicative of the Y chromosome (Fig. 3-2).  
 
Table 3-1: Primers designed for sequencing AMEL. 
Gene Primer sequence 5’ to 3’ 
Tm 
(°C) 
Product 
size (bp) 
Accession 
number 
Notes 
AMELX 
AMELY 
    F: ctgatggttggcctcaagcctgtg 
    R: taaagagattcattaacttgactg 
58 
977 
788 
NM_182680 
NM_001143 
for gDNA 
 
 
 
 
 
 
 
 
Figure 3-2: Detection of an X-Y homologous locus by PCR.  
Two bands are observed in males (lanes 7 and 17) and a single band is observed in females 
(lanes 3, 4, 5, 8, 9 10, 11, 14, 15, 16, 18). Lanes 1 and 20 contain DNA marker (1kb) and 
lanes 2 and 19 are water blanks. 
 
Out of the 104 POCs tested, nine failed to amplify, twelve POCs were male and the 
remaining 83 were female. However, we cannot exclude the possibility that those POCs that 
were determined as males were 100% free of MCC or that those POCs that were determined 
as females were 100% maternal decidua. Therefore we decided to use a second test to detect 
which of these POCs were maternally contaminated. 
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3.5.4 Checking for maternal cell contamination in POCs and paternity 
The AmpFISTR Profiler Plus™ ID PCR Amplification kit (ABI) was used to check 
for the presence of MCC in the 104 POCs. This is a fluorescent kit that co-amplifies the 
repeat regions of 9 highly polymorphic short tandem repeat loci: D7S820 (Green et al., 
1991), D21S11 (Sharma and Litt, 1992), FGA (Mills et al., 1992), vWA (Kimpton et al., 
1992), D3S1358 (Li et al., 1993), D8S1179 (Oldroyd et al., 1995), D18S51 (Urquhart et al., 
1995), D5S818 and D13S317 (Hudson et al., 1995). A segment of the AMEL gene is also 
amplified. One primer of each locus-specific primer pair is labelled with the 5-FAM, JOE or 
NED dyes, which are detected as blue, green and yellow, respectively, on the ABI prism 
instruments. The standard AmpFISTR PCR reaction mix is shown in Table 3-2 and 
information on the loci tested using this kit is shown in Table 3-3. 
 
 
Table 3-2: A standard AmpFISTR PCR reaction mix. 
Reagent  Volume (μl) per reaction 
AmpFISTR PCR Reagent Mix 4.2 
AmpFISTR Profiler Plus ID Primer set 2.2 
AmpliTaq Gold DNA polymerase 0.2 
DEPC-treated water 3.6 
DNA (1-3 ng/μl) 0.4 
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Table 3-3: Loci tested using the AmpFISTR Profiler Plus™ ID PCR Amplification kit. 
Locus 
Designation 
Chromosome 
Location 
Number of 
alleles 
Size range (bp) Dye Label 
D3S1358 3p 8 114-142 5-FAM 
VWA 12p12-pter 11 157-197 5-FAM 
FGA 4q28 14 219-267 5-FAM 
AMEL 
X:p22.1-p22.3 
Y:p11.2 
1 
1 
107 
113 
JOE 
JOE 
D8S1179 8 12 128-168 JOE 
D21S11 21 22 189-243 JOE 
D18S51 18q21.3 21 273-341 JOE 
D5S818 5q21-q23 10 135-171 NED 
D13S317 13q22-q31 8 206-234 NED 
D7S820 7q 10 258-294 NED 
 
All reactions were carried out in a Veriti® 96-Well Thermal Cycler (ABI). A standard 
PCR cycle consisted of an initial denaturation at 95 °C for 11 minutes, and 28 cycles of: 
denaturation at 94 °C for 1 minute, annealing at 59 °C for 1 minute and extension at 72 °C for 
1 minute, and a final extension at 60 °C for 45 minutes. A running mix was then prepared 
that included 13.5 μl of Hi-Di formamide (ABI) and 0.5 μl of GeneScanTM 500 ROXTM size 
standard (ABI), per reaction. Using a 96-well plate, 14 μl of running mix was aliquot into 
each well and 1 μl of relevant PCR product was added to each well. Samples were then run 
on an ABI 3130.  
All POCs were tested for maternal contamination. This was performed by 
simultaneously analysing DNA from both the mother and the POC (Fig. 3-3A). POCs that 
were free of contamination or partially contaminated were then tested alongside paternal 
DNA to confirm paternity (Fig. 3-3B and 3-3C).  
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Figure 3-3A: Electropherogram showing the AmpFISTR Profiler Plus ID PCR Amplification kit results, used to detect levels of 
contamination in products of conception. The x-axis is showing the loci tested. This graph is showing three (D8S1179, D21S11 and D18S51) 
out of the nine loci tested using this kit as well as the AMEL gene. The number in the grey box under each peak refers to the allele size and the 
number in the white box above each peak refers to the area under the peak. The y-axis is showing the level of intensity. You can change the 
intensity level and this does not change the allele size or the area under the peak. In this example, this POC is actually maternal decidua (100% 
contamination) as it contains exactly the same alleles as the mother (identical allele sizes). 
 
 
Amelogenin 
POC 
Mother
D8S1179 D21S11 D18S51 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3B: Using the AmpFISTR Profiler Plus ID PCR Amplification kit to detect levels of MCC in the POC as well as paternity. This 
POC is female as it contains only the X allele. This POC is free of maternal contamination, as in the loci shown here (D8S1179, D21S11 and 
D18S51), two peaks are detected, one from the mother (indicated by the red arrows) and one from the father (indicated by the blue arrows).  
Mother 
D21S11 
POC 
D18S51 
Father 
Amelogenin D8S1179 
X   Y 
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Figure 3-3C: Using the AmpFISTR Profiler Plus ID PCR Amplification kit to detect levels of MCC in the POC as well as paternity. This 
POC is male as it contains both X and Y alleles. However it is partially maternally contaminated, as in the loci D8S1179 and D21S11, two peaks 
are detected from the mother (indicated by the red arrows) and one peak is detected from the father (indicated by the blue arrows). The level of 
contamination in this POC was calculated to be around 21%. 
Mother 
POC 
D18S51 Amelogenin D8S1179 D21S11 
X   Y 
Father 
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3.5.5 Results of maternal cell contamination test 
Out of the 104 mothers and POCs tested, nine POCs failed to amplify and six POCs 
did not match the mother. Out of the remaining 89 POCs, 66 were 100% maternally 
contaminated (maternal decidua). Only seven POCs were free of MCC while 16 POCs had an 
average of 47% MCC. The area under the peak was used to calculate the level of MCC in 
these 16 POCs (Thiede et al., 1999). An example is shown in Figure 3-4 below (part of Fig. 
3-3C above). 
 
 
 
 
 
 
 
Figure 3-4: Using the area under the peak to calculate MCC levels in each POC sample. 
The area under the peak of the extra maternal allele (in this case the smaller peak indicated by 
the red arrow) is divided by the sum of the area under the peak of the paternal allele 
(indicated by the blue arrow) and the area under the peak of the extra maternal allele. The 
average contamination level in this specimen is 21.5 % [(20.6+22.3)/2].  
 
Of the 23 POCs that were either free of maternal contamination or were partially 
contaminated, the paternal DNA was used to check for paternity. All 23 fathers matched the 
POCs (Fig. 3-5). The RNA samples of these 23 POCs were also checked for the presence of 
maternal cells as we suspected that the levels of contamination could have been different due 
to the fact that a different part of the POC tissue was used for the RNA extractions. The fact 
that no DNase was used in the RNA extraction, allowed us to test for this as we expected 
some DNA to be present in the RNA. Out of the seven non-contaminated DNA POC 
samples, two had partial maternal contamination (average 17%) in the RNA and five were 
MCC= 100 x [4391/(4391+16885)]=20.6% MCC= 100 x [4853/(4853+16874)]=22.3% 
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free of contamination. Out of the 16 partially contaminated DNA POC samples, one RNA 
sample was fully contaminated and the remaining 15 had an average of 49% contamination. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5: POCs were tested for MCC and paternity. 
Out of the 104 POCs tested, nine did not amplify and six did not match the mother. Out of the 
remaining 89 POCs, 66 were fully contaminated. Only seven POCs (four males and three 
females) were free of MCC and 16 POCs (eight males and eight females) had an average of 
47% contamination. All 23 POCs tested for paternity, matched the father.  
 
 
 
104 sample sets 
(Mothers and POCs) 
95 sample sets 
89 samples sets 
9 POCs  
did not amplify  
6 POCs did not  
match the mother  
7 POCs (8%) had  
no  maternal 
contamination 
 
4 males & 3 females 
16 POCs (18%) had 
partial maternal 
contamination  
(average= 47%) 
8 males & 8 females 
66 POCs (74%) were  
 maternal decidua 
Tested for paternity 
All 23 fathers 
matched the POCs 
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3.5.6 Reverse transcription 
All of the 22 RNA samples from POCs that were free of MCC or were partially 
contaminated, as well as 20 RNA from maternal decidua were reverse transcribed to cDNA. 
For protocol see section 2.6.7 in Chapter 2. 
 
3.5.7 Polymerase Chain Reaction 
Genomic DNA from the 22 trios and the 20 mothers that had their decidua reverse 
transcribed as well as cDNA from the 22 POCs and the 20 maternal decidua were amplified 
by PCR before sequencing. Primers used are shown in Table 3-4 below: 
 
Table 3-4: Primers designed for sequencing gDNA and cDNA for imprinting analysis. 
Gene Primer sequence 5’ to 3’ 
Tm 
(°C) 
Product 
size (bp) 
Accession 
number 
Notes 
HLA-C 
F: cgcttaccatgactgacctg 
R: gaaggttctcaggtctttatttgc 
58 469 NM_002117 for gDNA 
HLA-C 
F: gctctgatgagtctctcatcact 
R: gaaggttctcaggtctttatttgc 
60 450 NM_002117 for cDNA 
IGF2 
F: aacaccccacaaaagctcag 
R: tgcatggattttggttttca 
58 425 
NM_000612 
 
for both gDNA 
and cDNA 
H19 
F: ctcacccaccgcaattcatt 
R: ccctggatgctgtactgtct 
60 340 NR_002196 
for both gDNA 
and cDNA 
PHLDA2 
F: caaaccccgcacgccatgag 
R: gatttatttgcaatgggcacag 
60 483 NM_003311 
for both gDNA 
and cDNA 
PEG3 
F: gaaccctgtcaatatctttttgag 
R: catgagaaccacttcaacaaac 
57 263 NM_006210 
for both gDNA 
and cDNA 
DLK1 
 
F: cacctgcgtggatgatgag 
R: gatggtgaagcagatggcctg 
58 283 NM_003836 
for both gDNA 
and cDNA 
 
For protocol see section 2.6.5 in Chapter 2. 
   
3.5.8 Sequencing 
For protocol see section 2.6.10 in Chapter 2. 
105 
 
3.5.9 Imprinting analysis 
Imprinting analysis of HLA-C in maternal decidua and analysis of HLA-C, IGF2, 
H19, PHLDA2, PEG3 and DLK1 in POC trios was carried out by DNA sequence analysis of 
expressed SNPs. Corresponding cDNA samples were screened in individuals heterozygous 
for SNPs in HLA-C (rs1049853 C/T, rs1049724 G/A, rs1049709 A/G, rs1065711 T/C, 
rs1049650 G/C and rs1094 A/G), IGF2 (rs680 A/G, rs74050124 C/T), H19 (rs2067051 A/G), 
PHLDA2 (rs1056819 A/G), PEG3 (rs1055359 A/G) and DLK1 (rs1802710 C/T) 
(http://www.ncbi.nlm.nih.gov/projects /SNP/).  
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3.6 RESULTS 
3.6.1 Imprinting status of HLA-C in maternal decidua  
Genomic DNA samples extracted from blood from 20 females whose POC sample 
was found to be maternal decidua, were tested for heterozygosity at the HLA-C SNPs. Eight 
of these samples were informative for at least one SNP. Upon sequencing the respective 
cDNA, all samples were biallelically expressed for HLA-C (Fig. 3-6). Therefore, it could be 
confirmed that HLA-C is biallelically expressed in maternal decidua tissue. 
 
 HLA-C 
Lab ID A) Genomic DNA - rs1065711 C) cDNA from decidua - rs1065711 
69 Mother 
  
 B) Genomic DNA - rs1049650 D) cDNA from decidua - rs1049650 
83 Mother 
  
 
 
Figure 3-6: Imprinting analysis of HLA-C in maternal decidua tissue. Representative 
Sanger sequencing chromatograms are shown from two of the eight informative samples for 
the HLA-C T/C polymorphism (rs1065711) (A) and the HLA-C G/C polymorphism 
(rs1049650) (B). Biallelic expression was observed in all the samples tested (C, D). 
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3.6.2 Imprinting status of HLA-C, IGF2, H19, PHLDA2, PEG3 and DLK1 in POCs. 
Genomic DNA extracted from the 22 POCs that had either no maternal contamination 
or had partial contamination was used to test for heterozygosity at the HLA-C, IGF2, H19, 
PHLDA2, PEG3 and DLK1 SNPs. All samples were informative for at least one of these 
genes. Twenty-one samples were informative at different SNPs for HLA-C, fourteen were 
informative for IGF2, twelve were informative for H19, five were informative for PHLDA2, 
seven were informative for PEG3 and nine were informative for DLK1 (Table 3-5).
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Table 3-5: Table showing the 22 informative POCs for the HLA-C, IGF2, H19, PHLDA2, PEG3 and DLK1 SNPs. 
*BBB: samples from Baby Bio Bank 
 HLA-C IGF2 H19 PHLDA2 PEG3 DLK1 
POC No rs1049853 rs1049724 rs1049709 rs1065711 rs1049650 rs1094 rs680 rs74050124 rs2067051 rs1056819 rs1055359 rs1802710 
5 C/T      A/G  A/G    
36 BBB*      A/G A/G  A/G    
43    T/C G/C A/G A/G   A/G   
45    T/C G/C  A/G   A/G   
67    T/C  A/G      T/C 
72     G/C        
84   A/G    A/G    A/G T/C 
102  G/A      C/T A/G    
119 BBB* C/T      A/G  A/G  A/G  
120    T/C   A/G    A/G T/C 
129   A/G   A/G   A/G    
131     G/C  A/G   A/G A/G T/C 
138         A/G  A/G T/C 
145    T/C  A/G       
151    T/C  A/G       
158 C/T    G/C    A/G A/G   
163  G/A       A/G   T/C 
201    T/C  A/G A/G  A/G  A/G T/C 
215   A/G    A/G  A/G    
217   A/G    A/G  A/G    
219  G/A     A/G  A/G A/G  T/C 
220    T/C G/C A/G A/G    A/G T/C 
Total 3 3 4 8 6 8 13 1 12 5 7 9 
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3.6.2.1 Imprinting status of HLA-C in POCs  
All 21 samples that were informative for HLA-C were monoallelically expressed; ten 
were maternally expressed, paternally imprinted and eight were paternally expressed, 
maternally imprinted (Fig. 3-7). The parental origin for three POC samples could not be 
determined as both parents were heterozygotes at the same SNP. 
 
 HLA-C 
Lab ID A) Genomic DNA - rs1065711 C) cDNA from POC - rs1065711 
43 Mother 
 
 
43 Father 
 
 
43 POC 
  
 B) Genomic DNA - rs1094 D) cDNA from POC - rs1094 
43 Mother 
 
 
43 Father 
 
 
43 POC 
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 HLA-C 
Lab ID E) Genomic DNA - rs1065711 G) cDNA from POC - rs1065711 
145 Mother 
 
 
145 Father 
 
 
145 POC 
  
 F) Genomic DNA - rs1094 H) cDNA from POC - rs1094 
145 Mother 
 
 
145 Father 
 
 
145 POC 
  
 
Figure 3-7: Imprinting analysis of HLA-C in POCs. Representative Sanger sequencing 
chromatograms are shown from two of the 21 informative POC samples for the HLA-C T/C 
polymorphism (rs1065711) (A, E) and the HLA-C A/G polymorphism (rs1094) (B, F). 
Monoallelic expression was observed in all of the samples tested. However ten POC samples 
expressed the maternal allele (C, D) while eight samples expressed the paternal allele (G, H). 
The parental origin for three POC samples could not be determined as both parents were 
heterozygotes at the same SNP. 
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However, it was interesting to note that some POC samples gave conflicting 
imprinting results. For example, POC 45 that was informative heterozygous for the two HLA-
C SNPs appeared to be paternally expressed, maternally imprinted at the first SNP and 
maternally expressed, paternally imprinted at the second SNP (Fig. 3-8).  
 
 HLA-C 
Lab ID A) Genomic DNA – rs3176007 C) cDNA from POC – rs3176007 
45 Mother 
 
 
45 Father 
 
 
 
 
45 POC 
 
 
  
 B) Genomic DNA – rs1049650 D) cDNA from POC – rs1049650 
45 Mother 
 
 
45 Father 
 
 
45 POC 
  
 
112 
 
Figure 3-8: Imprinting analysis of HLA-C in POCs that gave conflicting results. 
Representative Sanger sequencing chromatograms are shown for a sample that gave 
conflicting results for the HLA-C T/C polymorphism (rs3176007) (A) and the HLA-C G/C 
polymorphism (rs1049650) (B). Monoallelic expression was observed in both SNPs. 
However, HLA-C in this sample appears to be paternally expressed for the first SNP, as the T 
allele inherited from the father was expressed (C). The same POC appears to be maternally 
expressed at the second SNP, as the G allele inherited from the mother was expressed (D). 
 
 
To investigate this further, we decided to investigate the POC genomic DNA at 
different levels of MCC (Fig. 3-9). 
 
Lab ID A) Genomic DNA – rs3176007 D) Genomic DNA - rs1049650 
45 POC 
 
75% MCC 
  
 B) Genomic DNA – rs3176007 E) Genomic DNA - rs1049650 
45 POC 
 
65% MCC 
  
 C) Genomic DNA – rs3176007 F) Genomic DNA - rs1049650 
45 POC 
 
32% MCC 
  
 
Figure 3-9: POC genomic DNA at different levels of MCC. Sanger sequencing 
chromatograms are shown for POC sample 45 for the HLA-C T/C polymorphism (rs3176007) 
and the HLA-C G/C polymorphism (rs1049650), at different levels of MCC, that is at 75% 
(A,D), 65% (B,E) and 32% (G,F). 
 
At 65% MCC, POC 45 appeared to be heterozygous for rs3176007 (Fig. 3-9B). 
However at higher levels of MCC (75%), the peak of the C allele inherited from the mother 
was higher (Fig. 3-9A), whereas at lower levels of MCC (32%) the peak of the C allele drops 
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(Fig. 3-9C), suggesting that the sample is in fact homozygous T/T for rs3176007 and that the 
C allele from the mother appeared in the chromatogram because of the contamination.   
For rs1049650, at 75% MCC it appeared that this POC inherited a G allele from both 
parents (Fig. 3-9D). However when the levels of contamination drop to 65% a small peak of 
the C allele that was inherited from the father (Fig. 3-9E) was observed and this peak 
becomes even higher when the levels of contamination drop to 32% (Fig. 3-9F), suggesting 
that POC 45 was in fact heterozygous G/C for rs1049650.  Therefore in POC 45, HLA-C was 
maternally expressed, as rs1049650 is the informative SNP. 
Taking this analysis in to consideration, the imprinting status of HLA-C in POCs was 
found to be abnormal, with 38% of the samples demonstrating expression from the paternal 
allele. Given this unexpected result, it was decided to investigate additional imprinted genes 
to establish if this was unique to HLA-C, or a more global imprinting anomaly.  
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3.6.2.2 Imprinting status of IGF2 in POCs  
All fourteen samples that were informative for IGF2 were monoallelically expressed; 
seven were paternally expressed, maternally imprinted and four were maternally expressed, 
paternally imprinted (Fig. 3-10). The parental origin for three POC samples could not be 
determined as both parents were heterozygotes at the same SNP. Therefore, the imprinting 
status of IGF2 in many of the POCs was considered abnormal, with 29% of the samples 
showing expression from the maternal allele. 
 
 IGF2 
Lab ID A) Genomic DNA – rs680 C) cDNA from POC – rs680 
5 Mother 
 
 
5 Father 
 
 
5 POC 
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 IGF2 
Lab ID B) Genomic DNA – rs680 D) cDNA from POC – rs680 
43 Mother 
 
 
43 Father 
 
 
43 POC 
  
 
Figure 3-10: Imprinting analysis of IGF2 in POCs. Representative Sanger sequencing 
chromatograms are shown from two of the fourteen informative POC samples for the IGF2 
A/G polymorphism (rs680) (A, B). Monoallelic expression was observed in all of the samples 
tested. However seven POC samples expressed the paternal allele (C) while four samples 
expressed the maternal allele (D). The parental origin for three POC samples could not be 
determined as both parents were heterozygotes at the same SNP. 
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3.6.2.3 Imprinting status of PHLDA2 in POCs  
All five samples that were informative for PHLDA2 were monoallelically maternally 
expressed (Fig. 3-11).  Therefore, the imprinting status of PHLDA2 in POCs was considered 
normal. 
 
 PHLDA2 
Lab ID A) Genomic DNA – rs1056819 B) cDNA from POC – rs1056819 
43 Mother 
 
 
43 Father 
 
 
43 POC 
  
 
Figure 3-11: Imprinting analysis of PHLDA2 in POCs. Representative Sanger sequencing 
chromatograms are shown from one of the five informative POC samples for the PHLDA2 
A/G polymorphism (rs1056819) (A). Monoallelic expression was observed in all of the five 
samples tested. Three samples expressed the maternal allele (B). The parental origin for two 
POC samples could not be determined as both parents were heterozygotes at the same SNP. 
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3.6.2.4 Imprinting status of H19 in POCs  
Twelve samples were informative for H19. Ten samples showed monoallelic 
expression and two samples showed biallelic expression. Seven samples were maternally 
expressed, paternally imprinted (Fig. 3-12). The parental origin for three samples could not 
be determined as both parents were heterozygotes at the same SNP. This mixed imprinting 
status of H19 with 17% of samples showing biallelic expression and the remained showing 
monoallelic expression from the maternal allele, was considered to be normal (Yu et al., 
2009).  
 
 H19 
Lab ID A) Genomic DNA - rs2067051 C) cDNA - rs2067051 
102 Mother 
 
 
102 Father 
 
 
102 POC 
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 H19 
Lab ID B) Genomic DNA - rs2067051 D) cDNA - rs2067051 
215 Mother 
 
 
215 Father 
 
 
215 POC 
  
 
Figure 3-12: Imprinting analysis of H19 in POCs. Representative Sanger sequencing 
chromatograms are shown from two of the twelve informative POC samples for the H19 A/G 
polymorphism (rs2067051) (A, B). Biallelic expression was observed in two out of the 
twelve samples tested (C). Monoallelic expression was observed in all the remaining ten 
samples. Seven samples expressed the maternal allele (D). The parental origin for three 
samples could not be determined as both parents were heterozygotes at the same SNP. 
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3.6.2.5 Imprinting status of PEG3 in POCs  
Seven samples were informative for PEG3. However, for two of these samples a clear 
cDNA chromatogram could not be obtained. The remaining five informative samples were 
monoallelically expressed (Fig. 3-13). Expression from the paternal allele indicated that the 
imprinting status of PEG3 in POCs was as expected. 
 
 PEG3 
Lab ID A) Genomic DNA – rs1055359 B) cDNA from POC – rs1055359 
220 Mother 
 
 
220 Father 
 
 
220 POC 
  
 
Figure 3-13: Imprinting analysis of PEG3 in POCs. Representative Sanger sequencing 
chromatograms are shown from one of the five informative POC samples for the PEG3 A/G 
polymorphism (rs1055359) (A). Monoallelic expression was observed in all of the five 
samples. Two samples expressed the paternal allele (B). The parental origin for three POC 
samples could not be determined as both parents were heterozygotes at the same SNP. 
 
 
 
  
120 
 
3.6.2.6 Imprinting status of DLK1 in POCs  
Nine samples were informative for DLK1. However, only one generated a clear 
cDNA chromatogram (Fig. 3-14). This is most likely because DLK1 is not highly expressed 
early in pregnancy. This sample was monoallelically paternally expressed as expected. 
 
 DLK1 
Lab ID A) Genomic DNA – rs1802710 B) cDNA from POC – rs1802710 
219 Mother 
 
 
219 Father 
 
 
219 POC 
  
 
Figure 3-14: Imprinting analysis of DLK1 in POCs. Sanger sequencing chromatograms are 
shown from the one POC sample for the DLK1 C/T polymorphism (rs1802710) (A). 
Monoallelic expression from the paternal allele was observed in this sample (B). 
 
Table 2-6 summarizes the imprinting status of the maternally expressed HLA-C, 
PHLDA2 and H19 and the paternally expressed IGF2, PEG3 and DLK1 in the 22 POCs 
tested. In summary, two of the genes tested showed abnormal expression in POCs, as 38% of 
samples showed paternal expression of HLA-C and 29% showed maternal expression of 
IGF2, whereas the rest of the genes were expressed as normal. Combining all the data 
together, 11 of the 22 POCs (50%) showed abnormal expression for at least one imprinted 
gene tested. 
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Table 3-6: A summary of the imprinting status of the genes HLA-C, IGF2, PHLDA2, H19, PEG3 and DLK1 in the 22 POC samples tested. 
POC no Sex Cont. in DNA Cont. in RNA HLA-C  
(mat) 
IGF2  
(pat) 
PHLDA2 
(mat) 
H19 
 (mat) 
PEG3 
 (pat) 
DLK1  
(pat) 
5 Female NO cont NO cont PAT PAT  BIALLELIC   
36 BBB Male NO cont NO cont PAT MAT  MONO   
43 Female NO cont NO cont MAT MAT MAT    
45 Male 65% 32% MAT MONO MAT    
67 Male 41% 70% MAT     ? 
72 Female 67% 71% MAT      
84 Male 38% 40% MONO MAT   PAT ? 
102 Female NO cont NO cont MAT MAT  BIALLELIC   
119 BBB Male 29% 36% MAT MONO  MONO MONO  
120 Male 70% 43% MAT PAT    MONO ? 
129 Female 28% 11% MAT   MAT   
131 Female 53% 63% PAT PAT MONO  ? ? 
138 Male NO cont NO cont    MAT ? ? 
145 Female 31% 70% PAT      
151 Female 32% 52% MAT      
158 Male 23% 66% PAT  MAT MONO   
163 Male 45% 15% PAT   MAT  ? 
201 Male NO cont 13% PAT PAT  MAT MONO ? 
215 Male NO cont 20% MONO MONO  MAT   
217 Male 40% 40% MAT PAT  MAT   
219 Female 67% 56% MONO PAT MONO MAT  PAT 
220 Female 69% 65% PAT PAT   PAT ? 
KEY 
MAT Maternally expressed 
PAT Paternally expressed 
MONO Monoallelic expression 
BIALLELIC Biallelic expression  
? No amplification of cDNA 
POC no POC has at least one abnormal expression of one imprinted gene 
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3.7 DISCUSSION 
For this study, POCs were collected from pregnancies that had miscarried. The 
samples used here had no chromosomal abnormalities detected. However, one can argue that 
as a high percentage of POCs had MCC, this could be in fact reflecting the maternal 
karyotype and not the fetal in some of the cases. Assuming that in those POCs that had no 
contamination or partial contamination, the normal karyotype detected was that of the fetus, 
we hypothesize that something else must have contributed to the failure of these pregnancies. 
We focused our investigation on imprinted genes, as these genes are important for gene 
expression, gene regulation and development. As there is only one functional allele, 
imprinted genes can be susceptible to lethal mutations. Lethality could be either due to 
changes in the DNA sequence of the active allele, or because of epimutations. Epimutations, 
such as altered methylation patterns in imprinted genes, lead to heritable changes in the gene 
without changing its DNA sequence, and can cause an inactive gene to become active or vice 
versa (Ubeda and Wilkins, 2008).  
In this study, we investigated the imprinting status of three maternally (HLA-C, 
PHLDA2, H19) and three paternally (IGF2, PEG3, DLK1) imprinted genes. We suggest that 
in some of these failed pregnancies, abnormal imprinting could be the cause of the 
miscarriage, as aberrant imprinting disturbs development and possibly HLA-C allorecognition 
of the new organism.  
The fact that only 8% of the POCs tested were free of MCC highlights the importance 
of checking for maternal contamination in POCs before conducting any experiments. It is not 
adequate to simply choose male POCs as we can see that even in males, different levels of 
MCC were detected (Fig. 3-5).  
In summary, 38% of POCs tested showed an abnormal imprinting for HLA-C, as eight 
samples showed monoallelic expression from the paternal allele and ten showed the normal 
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maternal monoallelic expression. As 16 samples used in this study had some levels of MCC, 
one could argue that the imprinting status of HLA-C observed in some of these POCs is 
actually the imprinting status of the mother. However, by showing that HLA-C in maternal 
decidua is not imprinted and that it is in fact biallelically expressed (Fig. 3-6), rules out that 
assumption. 
In addition, 29% of samples showed abnormal imprinting of IGF2, as four samples 
showed monoallelic expression from the maternal allele and seven showed the normal 
monoallelic paternal expression. This data is unequivocal since three of these samples with 
maternal expression of IGF2 were found to be completely free of contamination and IGF2 is 
a known paternally expressed gene (Giannoukakis et al., 1993). Although, biallelic 
expression of IGF2 is seen in adult liver (Davies, 1994), to our knowledge, this is the first 
time maternal expression of IGF2 has been observed in humans. Whether maternal 
expression levels of IGF2 would be any different from the paternal expression is not known, 
as in both cases only one allele is expressed. Further work, such as real-time PCR, needs to 
be performed to investigate whether there are any differences in IGF2 expression levels 
between maternal and the normal paternally expressed samples.  
Imprinting status of the remaining genes tested (H19, PHLDA2 and PEG3) was 
normal. Definitive conclusions about DLK1 could not be made as only one sample was 
successfully amplified, which showed normal paternal expression. Overall, out of the 22 
POCs used in this study, eleven (50%) had an abnormal imprinting expression of either HLA-
C or IGF2 (Table 2-6). In conclusion, the disruption of imprinting in particular the expression 
of HLA-C from the paternal allele and the expression of IGF2 from the maternal allele may 
have been involved in the pathology of these miscarriages. Expression of IGF2 has been 
shown to be involved in fetal growth early in pregnancy (Demetriou et al., 2014), hence any 
deviations from the normal expression and expression of the maternal allele could impair 
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normal fetal development. HLA-C is implicated in allorecognition during human pregnancy 
and recently has been shown to be maternally expressed in the fetus (Fogarty et al., 
unpublished data, manuscript in preparation), which can explain why the mother does not 
reject the allogeneic fetus. However, as we have shown in our study, if the paternal allogeneic 
allele is no longer repressed, it means that the conceptus could be detected by the maternal 
immune system as a foreign entity, and hence rejected. However, since a woman is 
considered to be pregnant only after implantation has occurred, this suggests that 
allosuppression must have taken place after implantation. 
Regulation of MHC expression in the conceptus is observed in other species too, as in 
the mouse, only one polymorphic MHC class I gene is expressed in the trophoblast, although 
both parental alleles are expressed (Madeja et al., 2011). In the rat however, experiments 
have shown that MHC class I is imprinted and paternally expressed in the placenta (Kanbour-
Shakir et al., 1993). These differences between species reflect the differences in placentation 
and reproductive strategies. Humans reproduce less frequently than rodents and have longer 
gestational periods hence prolonged exposure of alloantigens to maternal cells in human 
pregnancy. The fact that HLA-C is biallelically expressed in the latter stages of pregnancy, 
when the pregnancy is well established, suggests that the process of implantation and early 
placental development are at the highest risk of allorecognition and this risk is decreased by 
silencing the foreign paternal allele. 
It is possible that a high proportion of miscarriages can be explained by gene 
deregulation at imprinted loci leading to early embryonic lethality. The early stage of 
development is a time of genome-wide epigenetic remodelling and if incomplete, can lead to 
aberrant expression of genes and possibly failure to maintain normal expression. In 
conclusion, embryonic lethality in these cases could be due to the failure to maintain normal 
expression of imprinted genes, especially that of HLA-C. 
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3.8 FUTURE WORK 
As previously described, erasure, establishment and maintenance of methylation 
imprints at imprinting centres take place during germ cell and embryonic development. The 
pre-implantation embryonic genome losses its DNA-methylation through demethylation 
beginning in the zygote, followed by de novo DNA-methylation around implantation time 
(Reik and Walter, 2001). It is likely that embryonic fatality is due to faulty demethylation and 
de novo acquisition of DNA-methylation after fertilisation, hence due to reprogramming 
errors in the life cycle of imprints.  
It would therefore be of considerable interest to investigate methylation patterns in 
these POCs by bisulphite sequencing, a method used to detect and quantify DNA 
methylation. We can investigate for example the IGF2/H19 DMR and see whether POCs that 
show maternal expression of IGF2, have abnormal methylation on the maternal inherited 
allele. In addition, we can use bisulphite sequencing to identify the DMR of HLA-C and 
investigate methylation patterns in the available POCs. In addition, real-time quantitative 
PCR could be carried out in the POCs whose expression of either HLA-C or IGF2 is 
expressed from the opposite parental allele. These can be compared to the POCs whose 
expression of these two genes was normal, to see if any differences in expression levels are 
observed. Finally, a larger collection of POCs should also be established and analysed to 
confirm the reproducibility of these findings. 
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CHAPTER 4 – ROLE OF ANNEXIN A5 (ANXA5) IN      
RECURRENT MISCARRIAGE  
 
4 INTRODUCTION 
As described in more detail in the Introduction in Chapter 1, RM is defined as having 
three or more consecutive pregnancy losses and it affects about 1% of couples trying to 
conceive (Stirrat, 1990). RM is not only associated with higher rates of morbidity but is also 
associated with complications later in pregnancy including fetal growth restriction, 
prematurity and pre-eclampsia (Rai and Regan, 2006). A number of these miscarriages occur 
due to chromosomal abnormalities in the fetus and the chance of this taking place increases 
as the maternal age rises (Nybo et al., 2000). 
In addition to the risk factors detailed in Chapter 1, such as APLS and FVL, ANXA5 
has been implicated in this disorder. This chapter deals with investigating this gene and its 
relevance to RM.  
 
4.1 Annexins and ANXA5 
 Annexins were discovered approximately 35 years ago and have a unique core 
domain that is made up of four similar repeats, each about 70 aa long. These repeats usually 
contain a characteristic ‘type 2’ motif for binding calcium ions, hence annexins are 
traditionally thought of as calcium-dependent phospholipid-binding proteins. However more 
recent work suggests more complex functions, as annexins interact with various cell-
membrane components that are involved in the structural organisation of the cell, adhesion 
mechanisms, intracellular signalling and ion fluxes (Moss and Morgan, 2004). 
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The twelve human annexin genes range in size from 15 to 96 kb and are dispersed 
throughout the genome on chromosomes 1, 2, 4, 5, 8, 9, 10 and 15 (Fernandez and Morgan, 
2003). The ANXA5 gene is found on human chromosome 4q27 and consists of 13 exons and 
12 introns. The gene spans 29 kb and encodes a single transcript of approximately 1.6 kb and 
a protein product of 320 aa with a molecular weight of about 35 kDa. The region genomic 
locus encompassing the promoter is very GC rich (73% GC) (Cookson et al., 1994).  
ANXA5 is an anti-coagulant protein that occurs on normal placental villi. Due to its 
ability to bind to anionic phospholipids that are found on platelets, it impedes aggregation 
and hence it is thought to function as an inhibitor of coagulation (Thiagarajan and Tait, 
1990). Moreover, due to its affinity to phosphatidylserine (PS) and phosphatidylethanolamine 
(PE), ANXA5 is used as a probe to detect cells that are undergoing apoptosis, as these cells 
express PS and PE on their cell surface (Koopman et al., 1994). ANXA5 is a ubiquitous, but 
not abundantly expressed protein, manifesting highest levels in liver, kidney and placenta 
(Morgan et al., 1998). ANXA5 abundance appears to be reduced in the placental trophoblast 
in the presence of aPL (Rand et al., 1994). However, the ANXA5 knockout mouse lacks any 
clear phenotype, perplexing theories about its function in anticoagulation (Brachvogel et al., 
2003). 
Bogdanova et al., 2007 reported the presence of two variant ANXA5 promoter 
haplotypes in addition to the WT; the M1 and M2 haplotypes, which are common in the 
normal population. The M1 haplotype comprises of two nucleotide substitutions (1AC and 
27TC) and the M2 haplotype comprises of four substitutions (-19GA, 1AC, 27TC 
and 76GA) that are in linkage disequilibrium (LD) with each other.  
The frequency of the M2 haplotype was found to be significantly higher in RM 
patients than among controls (Bogdanova et al., 2007). In fact, subsequent studies have 
shown that the M2 haplotype is present in 11% of the Japanese population (Miyamura et al., 
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2011), 15% of the Caucasian population and 30% in RM patients (Tüttelmann et al., 2013; 
Tiscia et al., 2009). No significant association of the M1 haplotype was found with RM. 
Other studies have also shown an association between the M2 haplotype and pre-eclampsia or 
gestational hypertension (Tiscia et al., 2009), as well as being a risk factor for fetal growth 
restriction (Chinni et al., 2009) and small for gestational age  babies (Tiscia et al., 2012). 
Reporter gene assays demonstrated a 60% reduction in the ANXA5 promoter activity 
when the M2 haplotype was present in comparison to the WT promoter (Bogdanova et al. 
2007). Therefore, in patients carrying the M2 haplotype, the anti-coagulant properties of 
ANXA5 are reduced and may lead to a hypercoagulable state in the intervillous space, 
potentially explaining an increased risk of RM. In addition, a study on ANXA5 expression in 
RM placentas demonstrated that mRNA levels are reduced regardless of the parental origin of 
the M2 haplotype (Markoff et al., 2010). 
 
4.2 Aim and Hypothesis 
The aim of this study was to replicate and further elucidate the role of the M2 ANXA5 
haplotype and its association with RM. In order to do that we genotyped a large cohort of 
white European couples with RM (n=500) and a control cohort where the couple had a 
normal pregnancy and no history of miscarriage (n=241).  
Our primary hypothesis was that the M2 haplotype would be associated with a higher 
risk of RM as shown in previous studies.  However, by using a larger cohort we could also 
investigate the influence of the ANXA5 M2 haplotype on the timing of miscarriages, to assess 
the male risk and to investigate interactions with known risk factors, such as APLS and FVL. 
 
 
 
129 
 
4.3 MATERIALS AND METHODS 
4.3.1 Subjects  
DNA samples and medical records for this study were obtained from two independent 
cohorts described below. The Recurrent Miscarriage Clinic at St Mary’s Hospital, part of 
Imperial College Healthcare NHS Trust, contains blood samples from over seven thousand 
women and their partners who agreed to participate in research with signed, informed 
consent. A total of 996 white European samples (501 female patients and 495 male partners) 
were used in this study. Patients with uterine anomalies, polycystic ovaries (Rotterdam, 2004) 
and fetal and parental chromosomal abnormalities were excluded. APLS was confirmed by 
the presence of LA antibodies and/or aCL antibodies and b2-glycoprotein IgG and IgM 
autoantibodies (Wilson et al., 2001). Patients were broadly divided into different classes 
according to the gestational period in which the miscarriage occurred. A total of 310 females 
and 309 male partners that had 3 or more early miscarriages (before 12
th
 week of gestation) 
and no late miscarriages were classified as “early miscarriage patients”. A total of 191 
females and 186 males that had at least 1 late miscarriage (after 12
th
 week of gestation) were 
classified as “late miscarriage patients”. The study was approved by the Imperial College 
Hospital Ethics Committee (REC ref EC0081). 
A total of 241 control trio (mother, father and placenta) samples were used in this 
study who were recruited from the Moore cohort. The Moore cohort consists of 306 white 
European trios recruited at Queen Charlotte and Chelsea Hospital, London between 2003 and 
2004 (Apostolodou et al., 2007). Inclusion criteria for control couples required at least one 
successful pregnancy and no previous history of miscarriage. All placental samples were 
collected from singleton pregnancies that resulted in live-birth term deliveries. From each 
placenta, four pieces of tissue were dissected near the umbilical cord insertion point, washed 
three times in phosphate buffered saline (PBS) to eliminate traces of maternal blood, snap 
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frozen in liquid nitrogen and stored at -80 °C until use. The study was approved by the 
Hammersmith and Queen Charlotte’s and Chelsea Hospital Trust ethics committee 
(Registration number: 2001/6029). 
The PopGen control group of 533 randomly selected German individuals (UKSH, 
Kiel) was also used as a control population. These samples were previously genotyped by 
Professor Arseni Markoff’s research group in Germany (Bogdanova et al., 2007)   and were 
used as an additional control group for our study.  
 
4.3.2 DNA extraction from blood and placenta 
DNA samples from the Moore cohort (parental blood and placenta) were available as 
previously described (Apostolidou et al., 2007). DNA from patients from the RMC was 
extracted from blood using the iPrep™ PureLink™ gDNA Blood Kit using the iPrep 
Purification Instrument based on the manufacturer’s instructions (Invitrogen, UK). 
 
4.3.3 Polymerase Chain Reaction 
Genomic DNA from patients was amplified by PCR before sequencing. Primers used 
to amplify the promoter region of ANXA5 are shown in table 4-1 below. 
 
Table 4-1: Primers designed for sequencing the promoter region of ANXA5.  
Gene Primer sequence 5’ to 3’ Tm 
(°C)   
Product  
size (bp) 
Accession  
number  
Notes 
ANXA5 F: ccgagccctggacagctccc 
R: gccccgcgaccacgctctcctc 
60 496 NM_001154 for DNA 
 
 
The first 50 female patients were sequenced after PCR was carried out using a 
standard Taq polymerase (BIOLINE). It was a concern that all 50 patients appeared to be 
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wildtype since it had previously been reported that about 30% of RM patients carry the M2 
haplotype (Bogdanova et al., 2007). The region encompassing the promoter of ANXA5 is very 
GC rich (Cookson et al., 1994), so it was decided to replicate the experiment using 
HotStarTaq DNA polymerase (Qiagen) (Table 4-2). The same patients were amplified and 
sequenced and this time, different alleles were readily detected, with 12 patients found to 
carry the M2 haplotype. This result was found to be reproducible and we concluded that 
HotStar Taq was capable of more robust amplification and reduced allelic dropout in this 
difficult, GC rich region (Fig. 4-1). 
 
 
A) Three patients samples sequenced following PCR carried out with Bioline Taq DNA polymerase 
Sample 5948 female – Wildtype (GATG) 
Sample 5949 female – Wildtype (GATG) 
Sample 5950 female – Wildtype (GATG) 
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B) The same three patients samples sequenced following PCR carried out with HotStar Taq DNA polymerase 
 
Sample 5948 female  – Wildtype (GATG) 
Sample 5949 female – M2 heterozygote (ACCA) 
Sample 5950 female – M1 heterozygote (GCCG) 
 
Figure 4-1: Sanger sequencing chromatographs of the ANXA5 promoter region. 
Chromatographs are shown for 3 patients, all of who were sequenced after PCR was carried 
out using the regular Taq DNA polymerase (BIOLINE) (A) and the high fidelity HotStar 
DNA polymerase (Qiagen) (B). 
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Table 4-2: A standard HotStar PCR reaction mix. 
Reagent Volume (μl) per reaction 
10 x PCR buffer 2 
dNTPs (2.5 mM)  1.8 
Forward primer (50 ng/μl) 1 
Reverse primer (50 ng/μl) 1 
HotStar Taq DNA polymerase 0.5 
Q-solution (5 M) 6 
DEPC-treated water 6.7 
DNA or cDNA template (50-100 ng)  1 
 
All reactions were carried out in a Veriti® 96-Well Thermal Cycler (ABI) with a 
heated lid set at 100 °C to prevent evaporation. A standard PCR cycle consisted of an initial 
denaturation at 96 °C for 15 minutes, and 35 cycles of: denaturation at 96 °C for 30 seconds, 
annealing at 60 °C for 30 seconds and extension at 72 °C for 30 seconds, and a final 
extension at 72 °C for 2 minutes. 5 μl of PCR products were used to confirm product size and 
quality on an agarose gel. 
 
4.3.4 Agarose gel electrophoresis   
For protocol see section 2.6.6 in Chapter 2. 
 
4.3.5 Sequencing   
For protocol see section 2.6.10 in Chapter 2.   
Sequencing/genotyping results of patients and controls are shown in Appendix C. 
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4.3.6 Statistical analysis 
When two groups are under observation, two measures can be used to describe the 
comparative likelihood of an event happening. These are the odds ratio (OR) and the relative 
risk (RR). Both are two different statistical concepts, although they are closely related to each 
other. OR is defined as the ratio of the odds of an event occurring in one group to the odds of 
it occurring in another group. RR is the risk of an event (or of developing a disease) relative 
to exposure. 
OR and RR with 95% confidence intervals (CI) were calculated using an online 
software package (http://www.hutchon.net/ConfidOR.htm). Departure from Hardy-Weinberg 
equilibrium (HWE) was assessed using a Monte-Carlo Markov Chain (MCMC) 
implementation of an exact test, part of the Genepop package (http://genepop.curtin.edu.au/). 
Deviations from HWE were investigated by Professor Arseni Markoff. 
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4.4 RESULTS 
A possible association between RM and the M2 haplotype was investigated by 
genotyping RM patient and control cohorts (Table 4-3). Similar to the Muenster control 
group (Bodganova et al., 2007), female controls in the Moore cohort were shown to deviate 
from HWE (MCMC P=0.03). This was due to an excess of M2 homozygotes (lack of 
heterozygotes), possibly because of positive ascertainment bias as miscarriage occurs in 
about 10% of women worldwide. In contrast, male controls were in HWE (MCMC P=0.79). 
Since the prevalence of the M2 haplotype was similar between female and male controls, 
frequencies were combined (Table 4-4). The association between the M2 haplotype and RM 
was also tested by comparison to an independent White-European patient cohort comprising 
of PopGen controls (Bodganova et al., 2007) (Table 4-3).  
The analysis showed a similar prevalence of the M2 haplotype between female and 
male partners of the RM group. The allele frequency (AF) of female and male partners of the 
early RM group was 0.134 and 0.141, respectively and that of the late RM group was 0.094 
and 0.108 for females and males, respectively (Table 4-4).  
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Table 4-3: Genotype frequencies of ANXA5 gene promoter haplotypes in White European RM patients and two control groups. 
 
 All miscarriage patients Early miscarriage patients Late miscarriage patients Moore Controls PopGen Controls 
Genotype Observed Expected Observed Expected Observed Expected Observed Expected Observed Expected 
WT/WT 622 (62.4%) 617.8 385 (62.2%) 377.6 237 (62.9%) 240.2 320 (66.4%) 320.4 415 (77.9%) 411.8 
WT/M1 136 (13.7%) 139.5 71 (11.5%) 78.9 65 (17.2%) 60.7 71 (14.7%) 71.8 35 (6.6%) 37 
M1/M1 10 (1.0%) 7.8 6 (0.9%) 4.1 4 (1.1%) 3.8 7 (1.5%) 4 1 (0.2%) 0.8 
WT/M2 189 (19.0%) 193.9 126 (20.4%) 132.9 63 (16.7%) 60.8 75 (15.6%) 73.5 72 (13.5%) 76.5 
M2/M2 18 (1.8%) 15.1 13 (2.1%) 11.6 5 (1.3%) 3.8 6 (1.2%) 4.1 5 (0.9%) 3.5 
M1/M2 21 (2.1%) 21.9 18 (2.9%) 13.9 3 (0.8%) 7.7 3 (0.6%) 8.2 5 (0.9%) 3.4 
Total 996 996 619 619 377 377 482 482 533 533 
 
Expected: genotype frequency expected at Hardy-Weinberg equilibrium  
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Table 4-4: Genotype distributions of female/male partners in the RM cohort and Moore controls. 
 
 All RM patient couples Early RM patient couples Late RM patient couples Moore control couples 
Genotype Females Males Females Males Females Males Females Males 
WT/WT 305 (60.9%) 317 (64.1%)  186 (60.0%) 199 (64.4%) 119 (62.3%) 118 (63.4%) 159 (66.0%) 161 (66.8%) 
WT/M1 79 (15.8%) 57 (11.5%) 44 (14.2%) 27 (8.7%) 35 (18.3%) 30 (16.1%) 34 (14.1%) 37 (15.4%) 
M1/M1 6 (1.2%) 4 (0.8%) 3 (1.0%) 3 (1.0%) 3 (1.6%) 1 (0.6%) 5 (2.1%) 2 (0.8%) 
WT/M2 95 (18.9%) 94 (19.0%) 65 (21.0%) 61 (19.7%) 30 (15.7%) 33 (17.7%) 38 (15.8%) 37 (15.4%) 
M2/M2 8 (1.6%) 10 (2.0%) 6 (1.9%) 7 (2.3%) 2 (1.05%) 3 (1.6%) 4 (1.6%) 2 (0.8%) 
M1/M2 8 (1.6%) 13 (2.6%) 6 (1.9%) 12 (3.9%) 2 (1.05%) 1 (0.6%) 1 (0.4%) 2 (0.8%) 
Total 501 495 310 309 191 186 241 241 
M2 AF 0.119 0.128 0.134 0.141 0.094 0.108 0.098 0.089 
Combined M2 AF 0.123 0.137 0.101 0.093 
 
 
 
 
 
 
138 
 
The AF of the M2 haplotype was found to be higher among all patients (0.123) than 
among Moore controls (0.093) or PopGen controls (0.082). Consequently, carriers of M2 face 
a 1.3 times higher risk of RM than non-carriers (OR 1.41, 95% CI 1.07 - 1.86) compared to 
the Moore controls and a 1.5 higher risk (OR 1.63, 95% CI 1.24 - 2.16) in comparison to the 
PopGen controls (Table 4-5A). As shown in previous studies, the M1 haplotype was not 
associated with a higher RM risk. 
Because of the noted similar M2 frequency in RM couples, female and male subjects 
were pooled together and divided into two different groups according to the timing of 
miscarriage; early miscarriage patients (n=619) and late miscarriage patients (n=377). In 
early miscarriage patients, the AF of M2 was 0.137 that contributes a RR of 1.4 (OR 1.61, 
95% CI 1.21 - 2.17) as compared to Moore controls and a RR of 1.6 (OR 1.87, 95% CI 1.39 - 
2.51) when compared to PopGen controls (Table 4-5B). In late miscarriage patients, the AF 
of M2 was 0.101 and no significant difference was observed between late miscarriage M2 
carriers in either Moore (P=0.60) or PopGen (P=0.17) controls (Table 4-5C). 
Patients were stratified according to those that had no live births (n=495) and those 
that had at least 1 live birth (n=352). Relative risks for M2 carriers that either had or did not 
have a live birth compared to the Moore controls were 1.5 (OR 1.60, 95% CI 1.15 - 2.24) and 
1.4 (OR 1.53, 95% CI 1.12 - 2.09), respectively and 1.6 (OR 1.86, 95% CI 1.33 - 2.61) and 
1.6 (OR 1.8, 95% CI 1.25 - 2.59) when compared to the PopGen controls (Table 4-5A). The 
same relative risks were observed for early RM M2 carriers when compared to Moore 
controls (Table 4-5B), but no significant difference was observed between late RM M2 
carriers and Moore controls (Table 4-5C). More importantly, no significant differences were 
observed between early RM patients who are M2 carriers whether they had a live birth or not.  
In order to investigate whether ANXA5 promoter mutations interact with other general 
thrombophilic factors in terms of RM risk, patients were divided into those patients who were 
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positive for known risk factors (APLS, FVL or LA) (n=265) and those who were negative 
(n=466). The relative risks compared to the Moore cohort for M2 carriers who were positive 
for known risk factors was 1.4 (OR 1.57, 95% CI 1.10 - 2.26) and for those who were 
negative was 1.3 (OR 1.45, 95% CI 1.05 – 1.99), while compared to the PopGen controls was 
1.6 (OR 1.80, 95% CI 1.25 - 2.59) and 1.5 (OR 1.68, 95% CI 1.22 - 2.30), respectively (Table 
4-5A). Slightly higher relative risks were observed for early RM M2 carriers when compared 
to both control groups (Table 4-5B), while no significant difference was observed between 
late RM M2 carriers and controls (Table 4-5C). The relative risks became even higher when 
patients that were positive only for APLS were compared to controls, as the AF of M2 
increased to 0.142 for all patients and to 0.163 for early RM, with an M2 carriage of 30.4%. 
However, no significant differences were observed between M2 carriers of RM patients that 
were positive for known risk factors and those that were negative.  
The highest RR for M2 haplotype (1.7) carriage was observed in patients who had 
early fetal losses before the 12
th
 week of gestation and who were also positive for APLS (OR 
2.07, 95% CI 1.35 - 3.20) when compared to the Moore controls and increased to 2.0 (OR 
2.41, 95% CI 1.56 - 3.71) when compared to PopGen controls. This is generally in agreement 
with Tüttelmann et al., 2013, where the highest relative risk of the M2 haplotype was 
observed in women that had early fetal losses. 
Interestingly, in our study, out of 29 couples where both parents were M2 carriers, 23 
couples had only early miscarriages (average 4.3 miscarriages), 3 couples had both early and 
late miscarriages and 3 couples had only late miscarriages.  
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Table 4-5: Relative risks and odds ratios for the M2 haplotype between A) all RM patients and controls, B) early RM patients and controls and 
C) late miscarriage patients and controls, stratified into different sub-groups.  
 Recurrent miscarriage patients against Moore Controls against PopGen Controls 
  N M2 AF M2 carriage RR OR; 95CI P-value RR OR; 95CI P-value 
A) All RM patients 996 0.123 22.9% 1.3 1.41; (1.07 – 1.86) 0.02 
 
1.5 1.63; (1.24 – 2.16) 0.0005 
 No live births 495 
 
0.130 24.4% 
 
1.4 1.53; (1.12 – 2.09) 
 
0.007 1.6 1.78; (1.30 – 2.43) 
 
0.0003 
At least 1 live birth 352 
 
0.139 25.3% 
 
1.5 1.60; (1.15 – 2.24) 
 
0.006 1.6 1.86; (1.33 – 2.61) 
 
0.0003 
Positive for known risk factors 265 0.136 24.9% 1.4 1.57; (1.10 – 2.26) 
 
0.02 1.6 1.80; (1.25 – 2.59) 
 
0.002 
Positive for APLS  
 
240 0.142 25.8% 1.5 1.65; (1.14 – 2.40) 0.008 1.7 1.92; (1.32 – 2.78) 0.0006 
Negative for known risk factors 466 
 
0.124 23.4% 
 
1.3 1.45; (1.05 – 1.99) 0.02 
 
1.5 1.68; (1.22 – 2.30) 
 
0.001 
 
B) Early RM  patients  
(< 12 weeks of gestation) 
619 0.137 25.4% 
 
1.4 1.61; (1.20 – 2.17) 
 
0.002 
 
1.6 1.87; (1.39 – 2.51) 
 
0.0001 
 
 
 
No live births 
 
382 0.131 24.9% 1.4 1.57; (1.13 – 2.18)  0.008 1.6 1.82; (1.31 – 2.53) 0.0004 
At least 1 live birth 
 
237 0.148 26.2% 1.5 1.68; (1.16 – 2.44) 0.007 1.7 1.95; (1.34 – 2.83) 0.0005 
Positive for known risk factors 148 0.159 
 
29.7% 1.7 2.00; (1.31 – 3.05) 0.001 1.9 2.33; (1.52 – 3.56) 0.0001 
Positive for APLS  
 
138 0.163 30.4% 1.7 2.07; (1.35 – 3.20) 0.0009 2.0 2.41; (1.56 – 3.71) 0.0001 
Negative for known risk factors 
 
316 0.136 25.3% 1.4 1.61; (1.14 – 2.27) 0.007 1.6 1.86 (1.32 – 2.64) 0.0004 
 
C) Late RM  patients  
(> 12 weeks of gestation) 
377 0.101 18.8% 
 
1.1 1.10; (0.78 – 1.56) 
 
0.60 
 
1.2 1.27; (0.90 – 1.81) 
 
0.17 
 No live births 
 
113 0.128 23.0% 1.3 1.42; (0.86 – 2.33) 0.17 1.5 1.64; (1.00 – 2.70) 0.05 
At least 1 live birth 
 
115 0.122 23.5% 1.3 1.45; (0.89 – 2.38) 0.14 1.5 1.69; (1.03 – 2.76) 0.04 
Positive for known risk factors 
 
117 0.107 18.8% 1.1 1.10; (0.65 – 1.85) 0.73 1.2 1.27; (0.76 – 2.14) 0.36 
Positive for APLS  
 
102 0.113 19.6% 1.1   1.16; (0.67 – 1.99) 0.60 1.3 1.34; (0.78 – 2.31) 0.29 
Negative for known risk factors 
 
150 0.100 19.3% 1.1 1.14; (0.71 – 1.81) 0.59 1.3 1.32; (0.82 – 2.11) 0.25 
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      Table 4-6: Genotype distributions of Moore control trios. 
 
Genotype All controls Female controls Male controls All Placentas Female Placentas Male Placentas 
WT/WT 320 (66.4%) 159 (66.0%) 161 (66.8%) 146 (60.6%) 72 (61.5%) 74 (59.8%) 
WT/M1 71 (14.7%) 34 (14.1%) 37 (15.4% 44 (18.3%) 22 (18.8%) 22 (17.7%) 
M1/M1 7 (1.5%) 5 (2.1%) 2 (0.8%) 1 (0.4%) 0 (0%) 1 (0.8%) 
WT/M2 75 (15.6%) 38 (15.8%) 37 (15.4%) 43 (17.8%) 21 (18.0%) 22 (17.7%) 
M2/M2 6 (1.2%) 4 (1.6%) 2 (0.8%) 5 (2.1%) 2 (1.7%) 3 (2.4%) 
M1/M2 3 (0.6%) 1 (0.4%) 2 (0.8%) 2 (0.8%) 0 (0%) 2 (1.6%) 
Total 482 241 241 241 117 124 
AF M2 0.093 0.098 0.089 0.114 0.107 0.121 
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4.5 DISCUSSION 
Previous studies have shown that polymorphisms in the promoter region of the 
ANXA5 gene are significantly associated with RM. Women with the M2 haplotype have a 
higher risk of fetal loss than non-carriers. This was shown initially in a population of 70 
German women with RM (Bogdanova et al., 2007), and reproduced in cohorts of 103 Italian 
(Tiscia et al., 2009), and 243 Japanese women (Miyamura et al., 2011). Recently these 
findings have been confirmed in populations of 243 German and 236 Bulgarian patients with 
RM (Tüttelmann et al., 2013).  
Findings from our study on 501 White-European females and 495 male partners are in 
agreement with previous studies, as we have shown that carriers of M2 exhibit a higher RM 
risk than non-carriers. In this study we show that the haplotype confers about the same 
relative risk to carriers of both sexes, suggesting that paternal M2 carriage confers an equal 
risk for RM as M2 carriage in mothers and that both maternal and paternal promoter alleles of 
the ANXA5 gene contribute equally to the lower expression levels seen in the M2 carriers. 
This confirms a pilot study that showed that the M2 haplotype confers the same relative risk 
to carriers of both sexes, based on 30 couples (Rogenhofer et al., 2012), and a more recent 
study based on 109 couples (Tüttelmann et al., 2013). Collectively, this finding provides 
strong evidence that both partners in RM couples should be screened for carriage of the M2 
haplotype.  
Most importantly, our data demonstrate that M2 is associated with ‘early’ RM and not 
with ‘late’ RM. In addition the M2 haplotype appears to be enriched in the subgroup of early 
RM patients that are positive for known risk factors (FVL and APLS) in comparison to those 
that are negative, although the observed difference is not statistically significant. Filtering out 
the FVL positive individuals from this group results in M2 carriage rate of almost 31% for 
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APLS patients. This is in general agreement with the proposed function of the M2/ANXA5 as 
genetic predisposition for the development of obstetric APLS (Bogdanova et al., 2012).  
Reduced levels of ANXA5 have been observed in women with APLS, who suffered 
RM and these may contribute to the placental thrombosis observed in these patients (Rand et 
al., 1994). However, even in the absence of aPL, reduced ANXA5 expression would probably 
lead to a hypercoagulable state in the intervillous placental space. The fact that no association 
was seen between the M2 haplotype and late miscarriages implies that reduced levels of 
ANXA5 may be used as a marker only for early miscarriages. It also suggests that the effect 
of coagulation of this specific gene on late pregnancy miscarriage is not the main cause for 
the loss. 
ANXA5 is most abundantly enriched at the syncytiotrophoblast surface covering the 
placenta villi (Krikun et al., 1994). This is consistent with its role as an anticoagulant, playing 
an important role in the maintenance of a hemodynamic balance during pregnancy. Since 
reduced ANXA5 expression is seen in M2 carriers, the onset of this pathology during the 
course of pregnancy is an important question. The classic inherited thrombophilia conditions 
associated with pregnancy loss generally lead to late events that are rare in comparison with 
early miscarriages. However, the M2 haplotype of ANXA5 emerged as a marker for patient 
groups with early recurrent miscarriages. When binding to phosphatidylserine surfaces, 
ANXA5 forms unique two-dimensional crystals which are essential for the dynamics of 
membrane repair in living cells (Bouter et al., 2011). Repair of syncytiotrophoblast 
membranes should progressively activate upon enhanced mechanical stimuli, parallel to the 
dramatic increase of the uteroplacental and intervillous blood flow after the 10
th
 week of 
gestation (Burton et al., 1999). This occurs when the growing fetus and placenta are exposed 
to a more normal oxygen concentration environment. Therefore, the finding of a significant 
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association of the ANXA5 M2 haplotype with fetal losses early in pregnancy correlates well 
with this biological hypothesis.   
In Bogdanova et al., (2007) reporter gene assays have shown that the M2 haplotype 
decreases the activity of the promoter of this anti-coagulant gene, potentially leading to fetal 
loss. However, data in our study from the control placentas is suggestive that this M2 
haplotype may be advantageous at some point in pregnancy. Although not statistically 
significant, the AF of M2 was found to be higher in control placentas (0.114) as compared to 
the parents (0.093). This was true for placentas of both female (0.107) and male fetuses 
(0.121) (Table 4-6). In fact, out of 47 control couples where one parent was WT and the other 
was an M2 carrier, M2 was inherited by 30 offspring. If the M2 haplotype was completely 
disadvantageous, one might have expected it to disappear or at least diminish in frequency 
over generations due to natural selection.  
Another example of a possible survival advantage of a prothrombotic phenotype is the 
FVL mutation. The high population frequency of FVL mutation despite the disadvantages 
associated with it such as APC resistance, increased risk of venous thrombosis and 
miscarriage (Bertina et al., 1994; Dahlbäck, 1995), suggests some sort of evolutionary 
advantage for carriers, such as aversion of sepsis (Kerlin et al., 2003). In addition there may 
be protection from bleeding, as APC-resistant women were characterized by less intrapartum 
blood loss than non APC-resistant women (Lindqvist et al., 1998). Findings from a more 
recent study also suggest that FVL as well as prothrombin G20210A might have conveyed a 
survival advantage (Lussana et al., 2012). It has been also shown that men carrying the FVL 
mutation display an increased sperm count (Cohn et al., 2010) and a higher fecundity rate 
(van Dunne et al., 2006). 
The high prevalence of the ANXA5 M2 haplotype in the population raises the question 
whether carriers may also have a survival advantage. It is possible that the hypercoagulable 
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state might have an evolutionary benefit, for example to avoid excessive bleeding in the 
mother and hence reduce the risk of intrapartum bleeding complications. 
In conclusion, this study strongly suggests that the M2/ANXA5 haplotype is a risk 
factor for early miscarriages that occur before the 12
th
 week of gestation. The M2 haplotype 
confers about the same relative risk to carriers of both sexes, suggesting a role of ANXA5 
expression levels in the fetus and/or the extraembryonic membranes. It appears that the M2 
haplotype is not associated with the presence of other known risk factors and that M2 carriers 
may have a survival advantage. 
As a final comment on the methodology employed here, although Sanger sequencing 
using Taq DNA polymerase is known to be a very robust technique, in this study, the regular 
Taq polymerase failed to amplify both alleles in the ANXA5 promoter region. This resulted in 
M2 carriers wrongly being classified as wildtype. The lack of heterozygotes was suspicious 
and it was only when Hotstar Taq DNA polymerase was tested on the same samples that it 
was possible to conclude that allelic dropout was taking place. Hotstar Taq is a higher fidelity 
enzyme and uses a modified protocol, involving heating at 96°C for a longer period to ensure 
complete denaturation of the dsDNA. In addition, the protocol contains Q-solution that 
enables more efficient amplification of difficult templates including templates that have a 
high degree of secondary structure or are GC rich. Therefore, when sequencing targets that 
are hard to amplify, testing an alternative DNA polymerase should be considered. 
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4.6 FUTURE WORK 
As described in Chapter 1, a meta-analysis has shown that the best treatment for 
women with RM and APLS included a combination of heparin and aspirin, as this 
combination reduced pregnancy loss by 54% (Empson et al., 2002), as aspirin and heparin 
helped to reduce the risk of thrombosis. ANXA5 is an anti-coagulant protein and the M2 
haplotype has been shown to reduce the ANXA5 promoter activity by 60% in comparison to 
WT (Bogdanova et al. 2007). This suggests that the anti-coagulant properties of ANXA5 are 
reduced, leading to a hypercoagulable state in the intervillous space. 
Future work would therefore include a prospective survey of our female RM patients 
to see if any had undergone heparin or aspirin treatment throughout any of their pregnancies 
and whether that had resulted in a successful pregnancy leading to birth. Ideally, we could 
investigate whether M2 carriers were more successful if they were treated with heparin or 
aspirin compared to those M2 carriers that were not treated.  
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CHAPTER 5 - WHOLE-EXOME SEQUENCING IN A 
RECURRENT MISCARRIAGE FAMILY 
5 INTRODUCTION 
As previously described in Chapter 1, miscarriage is the commonest complication of 
pregnancy and it is the spontaneous loss of a fetus before it has reached viability (Stirrat, 
1990). Studies have shown that the risk of miscarriage increases after each successive 
pregnancy loss and can reach as high as 45% after three consecutive losses (Regan et al., 
1989). RM has been attributed to genetic causes, anatomical disorders, infection, endocrine, 
immune and thrombophilic disorders. However, in the majority of patients, the cause of RM 
remains a clinical dilemma, since even after detailed investigation most miscarriages remain 
unexplained.   
Chapter 5 describes a genomics approach to identify a new candidate gene for RM. 
This study focuses on a single family where the patient suffered a total of 29 early RMs, all 
of which were unexplained. 
 
5.1 The family pedigree 
The patient (II-3) and her family (Fig. 5-1) originate from Bangladesh but live in 
London, and she is under the care of the Recurrent Miscarriage team at St Mary’s Hospital, 
Imperial College London. This patient, who is now 46 years old, had a total of 29 
miscarriages all of which were early, between 9-11 weeks of gestation, and had no live births. 
She had 17 miscarriages with her first husband (II-1), five miscarriages with her second 
husband (II-2) and seven miscarriages with her third husband (II-4). All of these pregnancies 
were naturally conceived and the miscarriages were unexplained as the patient tested normal 
for APLS and LA and negative for the FVL mutation. The patient’s mother had three 
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successful pregnancies and three late miscarriages all of which were in the second or third 
trimester. The patient’s brothers (II-5 and II-6), each had two successful pregnancies. 
 
Figure 5-1: Family pedigree.  
The affected patient (II-3) had a total of 29 early miscarriages: 17 with her first husband (II-
1), five with her second husband (II-2) and seven with her third husband (II-4). Her two 
brothers (II-5 and II-7) had each two successful pregnancies. Her mother (I-2) had suffered 
three late miscarriages. Blood was collected from individuals marked with a “b”, buccal swab 
was collected from individuals marked with an “s” and POC tissue was available from one of 
the miscarriages, marked with a “t”.  
 
 
5.2 Whole Exome Sequencing  
Striking revolutions in gene identification strategies have been derived from the 
development of next-generation sequencing (NGS) technologies at both the exome and 
genome level. These technologies rely on a combination of template preparation and 
sequencing, along with genome alignment and assembly methods. The main advantage of 
NGS is the massive amount and coverage of sequence data generated. Although NGS is 
much cheaper than Sanger sequencing per base, it is still expensive on a genome scale, 
although the cost has dramatically reduced as the methodologies improve and become more 
widely available. Several reviews have focused on the technical details of these new 
technologies (Mardis, 2008; Metzker, 2010; Coonrod et al., 2013). 
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As the majority of all single base mutations causing monogenic disorders are located 
in exons or in splice sites, sequencing of an exon enriched fraction of the genome, the exome, 
would detect most mutations causing monogenic diseases, whilst significantly reducing the 
amount of DNA to be covered (Rabbani et al., 2014). Whole exome sequencing (WES), 
which is still much cheaper than whole genome sequencing (WGS), is currently the main 
approach used, as researchers tend to look at the exome fraction of the genome first. 
Obviously, WES will miss those mutations located in non-coding regions, but it will probably 
take some time before WGS is performed cheaply and routinely. With this will come larger 
capacity computer storage as well as the appropriate tools to better evaluate the importance 
and frequency of these types of mutations than are currently available. 
The starting material used for NGS is usually whole genomic DNA and the initial 
preparatory step is the same for exome and genome libraries, which is to generate a “library” 
of DNA fragments. Different methodologies may be used for library preparation, as some 
platforms require fragment amplification and others are capable of reading single DNA-
molecules. Exon enrichment is performed prior to sequencing, using a number of methods 
involving fragment capture, which are also frequently updated. Commercial in-solution 
exome capture kits are currently the most commonly used methods and kits differ in targeted 
capture areas (part of the exome covered), type of capture probes and their sequence 
composition, according to the company (Coonrod et al., 2013). The sequencing reaction is 
then performed; different platforms such as the Illumina Genome Analyzer and Life 
Technologies SOLiD instruments are commercially available and use significantly different 
sequencing concepts and chemistries (Metzker, 2010). 
Analysing reads from NGS in order to develop a list of variants in relationship to the 
reference sequence involves multiple steps. After sequence base call files are generated, they 
are converted to a common file format, usually a FASTQ file format, for storage and 
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subsequent analyses. Multiple alignment-to-reference software such as the Burrows-Wheeler 
Aligner (BWA) is then used to map reads to a best-fit location on the reference sequence (Li 
and Durbin, 2010). Mapped reads for the entire data set are stored in a binary alignment file 
format called BAM and these reads can then be visualised in the Integrative Genomics 
Viewer (Robinson et al., 2011). 
Nucleotides in aligned sequenced reads are then used to infer the presence and 
zygosity of variants in a process known as variant calling. The Genome Analysis Toolkit 
(GATK) is a program commonly used to call variants and this task produces SNPs and 
insertions and deletions (indels) (McKenna et al., 2010). To call variants, different 
parameters are considered, which include the ratio of reference to alternate allele bases in the 
reads, read coverage, base quality and read mapping scores. After alignment is complete, 
variants are annotated for further analysis, usually using the variant annotation tool 
ANNOVAR (Wang et al., 2010). ANNOVAR annotates single nucleotide variants (SNVs) 
and indels, such as examining their functional consequence on genes, finding variants in 
conserved regions, or identifying variants reported in SNP databases such as dbSNP or 1000 
Genomes Project.  
Once a list of variants has been generated and annotated, the process of candidate 
gene identification can begin. With WES, approximately 15 to 20 thousand changes from the 
reference will be observed in coding regions. Bioinformatics tools are then required to narrow 
down variant lists to a small subset of variants in candidate genes. The major challenge is the 
interpretation of the results where a complex network of different combinations of filtering 
steps is possible and requires optimisation for each project. An increasing number of user-
friendly software designed to help in this filtering task and customise analyses parameters for 
each study have been developed and commercialised, such as the Ingenuity Variant Analysis 
software (www.ingenuity.com).  
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5.3 Literature assessment of candidate genes  
5.3.1 FK506 binding protein 4 (FKBP4) 
FKBP4 maps to chromosome 12 (12p13.33) and consists of ten exons that spans 
approximately 9 kb of genomic DNA (Scammell et al., 2003).  FKBP4 encodes FKBP52, 
which is a member of the immunophilin protein family FK506-binding proteins (FKBPs) that 
can bind to the immunosuppressive drug FK506. Immunophilins play a role in 
immunoregulation and basic cellular processes involving protein folding and protein 
trafficking. FKBPs range in size from 12 to 135kDa (Galat, 2004) but all share a common 
domain for immunosuppressant ligand binding. However, they differ in their FK506 affinity, 
in other domain structures and their subcellular localization, suggesting that each FKBP may 
have a distinct function.  
FKBP52 is common to several vertebrate species and the respective mRNA 
transcripts are expressed in a variety of human tissues such as brain, heart and placenta 
(Peattie et al., 1992). Human FKBP52 contains 458 aa and is composed of 4 distinct domains 
(see Fig. 5-11) (Callebaut et al., 1992; Lebeau et al., 1992).  
Domain I: aa 1 to 149 includes the N-terminal portion of FKBP52 and consists of the FK506-
binding site, which contains peptidyl-prolyl cis-trans isomerase (PPIase) activity (Chambraud 
et al., 1993). PPIase catalyses the conversion of prolyl-peptide bonds from trans- to cis-
proline, often a rate-limiting step in protein folding (Schiene and Fischer, 2000). The PPIase 
activity of FKBP52 is inhibited by FK506 and rapamycin, whose immunosuppressant drug 
action is mediated partly by binding to immunophilins (Schreiber, 1991; Peattie et al., 1992).  
Domain II: aa 149 to 267 contains the PPIase-like domain, which shares 32% sequence 
homology to domain I, but exhibits no PPIase activity (Callebaut et al., 1992; Chambraud et 
al., 1993). Domain II contains an ATP/GTP binding sequence (Le Bihan et al., 1993).  
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Domain III: aa 273 to 379 possesses three tetratricopeptide repeat (TPR) domains, that serve 
as binding sites for 90-kDa heat shock protein (Hsp90), which is also a component of the 
steroid receptor complexes (Radanyi et al., 1994).  
Domain IV: The C-terminal domain of FKBP52 is a short helix that contains a putative 
binding site for calmodulin (Massol et al., 1992). 
A more recent study has shown that FKBP52 interacts directly with tubulin. More 
specifically, the region of FKBP52 located between aa 267 and 400 is required for tubulin 
binding. Evidence is provided that FKBP52 prevents tubulin polymerization and that aas 375 
to 458 are necessary for its microtubule depolymerization activity. The property of FKBP52 
as a novel regulator of microtubule dynamics suggests that it could contribute to neuronal 
differentiation (Chambraud et al., 2007). 
The fact that FKBP52 associates with hsp90 in steroid receptor complexes, suggested 
a role in the nuclear translocation of steroid hormone receptors such as the glucocorticoid 
receptor (GR). The hormone-free GR is localized in the cytoplasm and it translocates to the 
nucleus after steroid binding (Picard and Yamamoto, 1987). Studies suggest that the hsp90-
based chaperone system and the hsp90-binidng FKBP52 are involved in the movement of the 
GR to the nucleus (Davies et al., 2002). In fact, in vivo studies have shown that FKBP52 is 
incorporated into steroid receptor complexes by binding to hsp90 via the TPR domain and it 
then facilitates translocation of the activated receptor to the nucleus via PPIase domain 
binding to dynein (Galigniana et al., 2001). 
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5.3.3.1 FKBP4 and implantation 
One of the requirements for implantation and pregnancy maintenance in Eutherian 
animals (animals that have a placenta) is progesterone signaling, which acts through the 
nuclear P4 receptor (PR) to activate transcription of genes that are involved in ovulation, 
implantation and pregnancy maintenance (Dey et al., 2004). FKBP52 is also a cochaperone 
that binds to the PR to optimise progesterone P4-PR signaling (Davies and Sanchez, 2005). 
A critical role for FKBP4 in mouse implantation was shown by Tranguch et al., 
(2005), where knockout mice (Fkbp4
-/-
) were created. Both male and female mice lacking 
Fkbp4 were infertile. Further experiments showed that infertility in the female mice was not 
due to a failure in ovulation or fertilization, but as a result of implantation failure or 
pregnancy failure following implantation. While this implantation failure phenotype was 
observed in both CD1 and C57BL6/129 knockout mice, daily P4 supplementation rescued 
implantation with subsequent decidualization in CD1 Fkbp4
-/-
 females but was ineffective in 
rescuing implantation in C57BL6/129 Fkbp4
-/-
 females (Tranguch et al., 2007). Further 
experiments by the same group found that uterine levels of an antioxidant, peroxiredoxin-6 
(PRDX6) were significantly lower in Fkbp4
-/-
 mice and that these mice having reduced 
uterine PRDX6 levels were susceptible to oxidative stress leading to implantation failure 
even with P4 supplementation (Hirota et al., 2010).  
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5.3.2 Serpin peptidase inhibitor, clade B member 2 (SERPINB2) 
SERPINB2, also known as placental plasminogen activator inhibitor 2 (PAI-2), is 
located on chromosome 18q21.3 and it is a member of the serine protease inhibitor 
superfamily. PAI-2 is a coagulation factor that inactivates tissue plasminogen activator and 
urokinase plasminogen activator (Kawano et al., 1970)  
PAI-2 is only detectable during pregnancy (Kruithof et al., 1984) and the main 
physiological producers of PAI-2 are activated monocytes and macrophages (Wohlwend et 
al., 1987). Secreted or released PAI-2 has been detected in biological fluids such as umbilical 
cord blood, pregnancy plasma and amniotic fluid (Lecander and Astedt, 1987; Booth et al., 
1988). During pregnancy fibrinolytic activity declines, but following delivery, it quickly 
returns to normal levels (Kruithof et al., 1995; Astedt et al., 1998). This is due to increases in 
PAI-2. Although PAI-2 antigen is undetectable in human plasma, it increases during late 
pregnancy (Kruithof et al., 1987; Hunt et al., 2009) and this increase is largely due to PAI-2 
secretion by the placental trophoblast cells (Kruithof et al., 1995; Brenner, 2004).  
Two forms of PAI-2 have been described with variations in three aa at positions 
Asn120, Asn404 and Ser413 in form A and Asp120, Lys404 and Cys413 in form B. 
Although the functional consequences of these aa residue changes are unknown, form A has 
been associated with APLS (Vázquez-Del et al., 2007), whereas form B is linked to preterm 
birth (Gibson, et al., 2007).  
It has been suggested that during pregnancy, the physiological role of PAI-2 is to 
protect against premature placental separation and secure homeostasis at birth, as reduced 
plasma levels of PAI-2 correlate with FGR and pre-eclampsia (Reith et al., 1993; Astedt et 
al., 1998; Brenner, 2004). In general, SERPINB2 has been linked to pregnancy as there are 
some studies supporting a role for PAI-2 in fibrinolysis and proteolysis, but its role was not 
fully characterized (Lee et al., 2011).  An impaired plasmin-dependent proteolysis in women 
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may favour recurrent abortion by promoting fibrin deposition in early placental circulation 
and/or by limiting trophoblast development (Gris et al., 1993). 
 
5.3.3 Cluster of differentiation 46 (CD46) 
CD46 complement regulatory protein, also known as membrane cofactor protein 
(MCP), is a type I membrane protein which in humans is encoded by the CD46 gene. This 
gene is found in a cluster on chromosome 1q32 with other genes encoding structural 
components of the complement system. Alterations in complement regulation have been 
associated with pregnancy complications including pregnancy loss (Girardi et al., 2006). 
Activation of the complement cascade early in pregnancy has been associated with pre-term 
birth and pre-eclampsia (Lynch et al., 2008; Lynch et al., 2011). Mutations in the 
complement regulatory proteins that regulate the complement cascade have been indicated as 
risk factors for various pregnancy outcomes, including pre-eclampsia. CD46 has been 
implicated in pregnancy complications with over 20 mutations identified in the gene (Fang et 
al., 2008). The data however, is controversial, with polymorphisms of the human CD46 gene 
were associated with RMs in some studies (Wang et al., 2006) but not in others (Heuser et 
al., 2011). 
 
5.3.4 Micro RNA lethal 7d (MIRLET7D) 
MicroRNas (miRNAs) are short (21-24 nucleotide) non-coding RNAs found in many 
organisms, but only a few have been functionally characterized. MiRNAs are involved in 
post-transcriptional regulation of gene expression in multicellular organisms by affecting 
both the stability and translation of mRNAs. It is estimated that miRNAs account for about 
1% of genes in higher eukaryotic genomes and that miRNAs regulate about 30% of genes 
(Griffiths-Jones, 2004; Brown and Sanseau, 2005). 
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Analysis of mRNA expression by microarray has shown that many genes are 
significantly changed in mouse uterus between implantation sites and inter-implantation sites 
(Reese et al., 2001). A miRNA microarray in the mouse uterus has revealed that 8 miRNAs 
were up-regulated at implantation sites, half of which belonged to the let-7 family (Hu et al., 
2008).  One of these was miRNA let-7d. MIRLET-7D is highly expressed in human 
endometrium and represents one of the exceptional cases of a miRNA with perfect sequence 
conservation over distant species (Pasquinelli et al., 2000). A known role of let-7 is the 
repression of genes that promote cell division and proliferation, as it has been shown to 
reduce tumour growth in mouse models of lung cancer (Esquela-Kerscher et al., 2008). 
 
5.4 Aim and hypothesis 
Our hypothesis is that the cause of miscarriages in this family is genetic. We also 
hypothesise that the unsuccessful mother is the affected proband (rather than the POCs or 
involvement of the male partner) since she has had no successful pregnancies so far, with 
three different partners. The aim of this study was therefore to carry out next generation 
exome sequencing on available samples from this family pedigree with a view to identifying 
a rare genetic variant causal of the RM phenotype. Two genes, FKBP4 and SERPINB2, with 
potential damaging mutations were identified and investigated in more depth. This included 
sequencing them in 100 Asian RM patients, 120 White European RM patients and 100 
Bangladeshi controls. Three novel variants and one very rare SNP in FKBP4 were identified 
in a total of 4 Asian RM patients, which were all predicted to be damaging by different 
prediction programs.  
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5.5 MATERIALS AND METHODS 
 
5.5.1 Subjects 
Blood samples were available from the RM patient with the 29 miscarriages, her third 
husband and her two brothers. POC tissue was also available from her most recent 
miscarriage. Buccal swabs were collected from the patient’s parents. 
100 Asian female patients from the same RM cohort at St Mary’s Hospital and 120 
White-European female patients that were used in chapter 3 were also used in this study. 
Inclusion criteria were that the patients had three or more RMs and no live births. 100 
Bangladeshi controls with at least one live birth were also used in this study. These samples 
were provided by Prof Maria Bitner-Glindzicz (Institute of Child Health – UCL).  
 
 
5.5.2 Preparation of DNA from samples  
For extraction of DNA from blood and POC tissue see section 3.5.2 in Chapter 3. 
DNA from buccal swabs was extracted using the Isohelix Buccal DNA isolation kit (Cell 
Projects) according to the manufacturer’s instructions.  
 The 100 Bangladeshi DNA samples were whole genome amplified before being used 
as controls by using the Genomiphi V2 DNA Amplification Kit (GE Healthcare) according to 
manufacturer’s instructions. 
 
5.5.3 Whole exome sequencing 
Five samples from the family (Figure 5-1) were sent for WES (samples marked with b 
and t). This was done in collaboration with GOSgene (UCL genomic partner 
http://www.ucl.ac.uk/ich/services/lab-services/gosgene). Genomic DNA was subjected to 
array capture with the SureSelect Human Exon Kit v.4 (Agilent Technologies) according to 
the manufacturer’s instructions. Adapters were ligated, and paired-end sequencing was 
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performed on an Illumina HiSeq 2000, which generated 2 x 50 bp reads. The mean exome 
coverage was 81 to 91-fold, and 98% and 86% of the target sequence was covered at least 10 
and 30 times, respectively. Sequencing reads were aligned to the reference human genome 
(GRCh37/hg19, UCSC Genome Browser) with the BWA consensus, variant bases were 
called with GATK and variants were annotated with ANNOVAR.  
 
5.5.4 Ingenuity Analysis Variant Server 
Ingenuity Analysis Variant Server is a web-based functional analysis tool for 
comprehensive omic data. Analysis using Ingenuity was performed by me, Dr William 
Hywel and Dr Estelle Chanudet (Gosgene). The model we used was a dominant model that 
considered the RM patient as an affected individual and her two brothers and husband as 
unaffected.  Four Asian females provided by Gosgene were used as additional unaffected 
controls. 
Filters used using Ingenuity were: 
1) Confidence filter: kept variants that have a call quality of at least 20 in any case 
or in any control and a read depth of at least 10 in any sample. 
2) Common variants filter: excluded variants that are observed in a population with 
an allele frequency of at least 3% in the 1000 Genomes Project, 3% in the public 
Complete Genomics genomes and are present in dbSNP. 
3) Predicted deleterious filter: kept variants that are experimentally observed to be 
pathogenic, likely pathogenic or uncertain significance. Kept variants that are 
associated with a gain of function or loss of function (frameshift, in-frame indel, 
missense, stop-codon) and not predicted tolerated by PolyPhen-2 or SIFT. 
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4) Genetic Analysis filter: kept variants that are homozygous, heterozygous 
compound heterozygous, haploinsufficient and occur in the case sample and 
exclude variants that occur in at least 1 of the control samples. 
5) Biological context filter: kept only variants that are known or predicted to affect 
genes implicated in the following diseases, processes, pathways or phenotypes: 
implantation, thrombosis or miscarriage. 
 
Therefore, based on variant changes that were present in the patient but not present in 
the remaining samples, and based on genes that were linked to miscarriage, thrombosis or 
implantation, a list of genes was prioritized using the software program Ingenuity.  A 
complete list of the variants and genes prioritized can be found in Appendix D. 
 
 
5.5.5 Sequencing candidate genes 
 For protocol see section 2.6.10 in Chapter 2. Primers used for sequencing variants in 
candidate genes CD46 and MIRLET7D, as well as the whole FKBP4 and SERPINB2 genes 
are shown in Table 5-1. 
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Table 5-1: Primers designed for sequencing candidate genes in RM patients. 
Gene Primer sequence 5’ to 3’ Tm 
(°C)  
Product  
size (bp) 
Accession  
number  
Notes 
CD46 F: tcgtttctttttggtttgaagtc 
R: gccaatatctctttgctcagg 
60 250 NM_002389  for gDNA 
MIRLET7D F: gaaacaaaactcaaagaacatgacc 
R: caccaaagcaaagtagcaagg 
56 227 NR_029481 for gDNA 
FKBP4 
exon 1 
F: cccgccgtctctagaaagtt 
R: cctcggtgccttaaacgac 
60 575  NM_002014 
 
for gDNA 
FKBP4 
exon 2 
F: gtgctggtgcccctttc 
R: gcttgtgacagcttgtgtcc 
56 265  NM_002014 
 
for gDNA 
FKBP4 
exon 3 
F: ttcaggagcactgtttgagc 
R: gtctccaagaagcaggaagg 
56 307  NM_002014 
 
for gDNA 
FKBP4 
exon 4 
F: tgtttcactgcccatgagttag 
R: gagaacggaagtgtcttgcc 
60 260  NM_002014 
 
for gDNA 
FKBP4 
exon 5 
F: tcctcagtcacctgccctc 
R: acaaacagctggttctacaattc 
56 296  NM_002014 
 
for gDNA 
FKBP4 
exons 6-7 
F: agcctggagcaggttaagtg 
R: tctcagtcaccaagggaagg 
60 407  NM_002014 
 
for gDNA 
FKBP4 
exon 8 
F: tgtctgcagggtataagagcc 
R: agacatgctggcagctcac 
62 324 NM_002014 
 
for gDNA 
FKBP4 
exon 9 
F: ggtacctttggaacccagtc 
R: tagccaggttaagtggaggg 
60 377  NM_002014 
 
for gDNA 
FKBP4 
exon 10 
F: gacagatgtaggagaatgggtgt 
R: gtgaccccttgattgtgcta 
62 985 NM_002014 
 
for gDNA 
SERPINB2 
exon 1 
F: aaaatgccatgtgggagg 
R: aataccagcatgagggaagag 
60 197  NM_002575 for gDNA 
SERPINB2 
exon 2 
F: gacctcacccaaaatgttacc 
R: gcataaaacaagagcagttctcc 
60 317  NM_002575 for gDNA 
SERPINB2 
exon 3 
F: ttaaaagttcagtaaatccgtgg 
R: ggctttaagacaggaagattgc 
62 243  NM_002575 for gDNA 
SERPINB2 
exon 4 
F: ccatggcttaagaactatcttgtt 
R: gtttgggatccagccattt 
60 238 NM_002575 for gDNA 
SERPINB2 
exon 5 
F: ccatggcttgtttggtatg 
R: ggctaactaagttcatggatgg 
60 258  NM_002575 for gDNA 
SERPINB2 
exon 6 
F: cagaagattcagtaagtaatttcacag 
R: tctgtctatatcttgtcaaaagccc 
60 277  NM_002575 for gDNA 
SERPINB2 
exon 7 
F: ccaatcctcctttatgtctaattg 
R: catctcatctcacgaaaggtagg 
60 304  NM_002575 for gDNA 
SERPINB2 
exon 8 
F: tttccttctttctaatacttgctgt 
R: tgggtagcagaagttgttcag 
62 600  NM_002575 for gDNA 
SERPINB2 
exon 9 
F: tttcggcagattttcctcac 
R: cttggctccttcatcctgtc 
60 723  NM_002575 for gDNA 
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5.5.6 Real-time quantitative PCR 
The quantitative expression analysis of gene FKBP4 (primers shown in Table 5-2) in 
different tissues was determined by RTqPCR. For protocol see section 2.6.8 in Chapter 2. 
Tissues tested included maternal decidua from the exome patient that carried the A16E 
variant, maternal decidua from miscarried pregnancies and from termination of pregnancies. 
We also used chorion tissue (CVS pool – Chapter 2) and tissue from products of conception 
(POC pool – Chapter 3).  
 
Table 5-2: Primers designed for RTqPCR of gene FKBP4 in different human tissues. 
Gene Primer sequence 5’ to 3’ Tm 
(°C) 
Product 
size (bp) 
Accession 
number 
Notes 
FKBP4 
Real-time 
F: accagctcccggataaacg 
R: tgatgtccactccctccatg 
60 110 NM_002014 
 
for cDNA 
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5.6 RESULTS 
5.6.1 Ingenuity analysis Variant Server  
 Although five samples were sent for exome sequencing, the POC was found not to be 
useful as the sequence data showed it to be identical to the mothers DNA and therefore that it 
was maternal decidua, not of fetal origin. DNA sequences were uploaded into the Ingenuity 
programme and filters were applied, revealing the best candidate gene as FKBP4 (Fig. 5-2). 
This gene was the only one selected at the “Biological Context” filter. This was because it 
has been reported in the literature to be associated with infertility in mice (Tranguch et al., 
2005; Tranguch et al., 2007; Hirota et al., 2010).  
Nevertheless, we also chose to investigate three other genes (SERPINB2, MIRLET7D 
and CD46) out of the 34 genes that passed the “Genetic analysis” filter, as we cannot truly 
exclude any of the genes in this list just because there are no reports directly associating these 
genes with implantation, thrombosis or miscarriage. These three genes were chosen because 
there are some studies suggesting a role in processes involved in pregnancy and the variants 
identified in these genes were novel as they haven’t been reported before in SNP databases 
such as dbSNP, Exome Variant Server (EVS), UK10K or 1000 Genomes. Sanger sequencing 
was then applied on the original DNAs to confirm the validity of the variant changes detected 
in these genes. 
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Figure 5-2: Ingenuity analysis Variant Server filters.  
Filters applied to this study using software program Ingenuity revealed one variant in one 
candidate gene, FKBP4 and 37 variants in 34 candidate genes. 
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5.6.2 Candidate genes 
 
5.6.2.1 FKBP4 
 
The female patient had a novel missense heterozygous change (c.47C>A) in FKBP4 
at position chr12:2904352 that causes an alanine at position 16 to change to glutamic acid 
(p.A16E). This change was confirmed by Sanger sequencing and was not present in the other 
family members checked (Fig. 5-3). 
 
 FKBP4 
Husband & 
2 brothers 
 
Wildtype 
 
 
Patient 
 
c.47C>A 
 
 
 
 
Figure 5-3: Sanger sequencing chromatogram showing the C/A change at position 
chr12:2904352 in gene FKBP4, present only in the RM patient. 
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5.6.2.2 SERPINB2  
 
The female patient had a novel missense heterozygous change (c.328C>G) in 
SERPINB2 at position chr18:61564364 that causes leucine at position 110 to change to valine 
(p.L110V). This change was confirmed by Sanger sequencing and was not present in the 
other family members checked (Fig. 5-4). 
 
 SERPINB2 
 
Husband & 
2 brothers 
 
Wildtype 
 
 
 
Patient 
 
c.328C>G 
 
 
 
 
Figure 5-4: Sanger sequencing chromatogram showing the C/G change at position 
chr18:61564364 in gene SERPINB2, present only in the RM patient. 
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5.6.2.3 CD46 
 
The female patient had a novel 16 bp deletion (ACTTCTCTCTGAGAAG) in CD46 
at position chr1:207963638. This change was confirmed by Sanger sequencing and was not 
present in the other family members checked (Fig. 5-5). The deletion (c.1168_1183del) 
spanned the stop codon TGA at the 3’ end of the coding region. This would result in loss of 
three aas (threonine, serine, leucine), but would result in the incorporation of glutamic acid 
and arginine before the next stop codon TGA. 
 
 CD46 
Husband & 
2 brothers 
 
Wildtype 
 
 
 
Patient 
 
 
c.1168_1183del 
 
 
 
 
Figure 5-5: Sanger sequencing chromatogram showing a 16 bp deletion at position 
chr1:207963638 in gene CD46, present only in the RM patient. 
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5.6.2.4 MIRLET7D 
 
The female patient had a novel AC insertion in the microRNA LET-7D at position 
chr9:96941126. This change was confirmed by Sanger sequencing and was not present in the 
other family members checked (Fig. 5-6). 
 
 MIRLET7D 
Husband & 
2 brothers 
 
Wildtype 
 
 
Patient 
 
 AC insertion 
 
 
 
 
Figure 5-6: Sanger sequencing chromatogram showing the AC insertion at position 
chr9:96941126 in microRNA LET-7D, present only in the RM patient. 
 
 
 
 
 
 
 
 
 
 
 
168 
 
5.6.3 Sequencing variants in candidate genes in RM and control cohorts 
After confirmation of these four novel changes in the RM patient, we sequenced the 
regions of these genes in 100 Bangladeshi controls (parents that had successful pregnancies) 
as we wanted to check whether these variants were polymorphisms found specifically in the 
Bangladeshi population. However, no controls had these novel changes therefore none of 
these variants could be excluded.  
We then decided to check the presence of these variants in RM patients, including 100 
patients from Asia and 120 White European patients, all of whom had no successful 
pregnancies. However no patients were found to carry these novel variants. The results are 
summarized in Table 5-3 below. 
 
Table 5-3: Sequencing results of the four variants in the four candidate genes.  
These novel variants are only present in the RM patient and not present in other family 
members, or in the two RM cohorts (100 Asians and 120 White-European RM patients) and 
Bangladeshi controls.  
 
Gene/novel 
variant 
RM patient 
 
 
Family 
members 
 
100 Asian 
patients 
 
120 White-
Europ. patients 
 
100 
Bangladeshi 
controls 
 
 
FKBP4/ 
c.47C>A 
  
 
 
 
 
 
 
 
 
 
SERPINB2/ 
c.328C>G 
  
 
 
 
 
 
 
 
 
CD46/ 
c.1168_1183del 
 
 
 
 
 
 
 
 
 
MIRLET7D/ 
AC insertion 
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5.6.4 Grandparental DNA 
The four variants in the four candidate genes were then sequenced in the grandparents 
since we were able to obtain DNA from the patient’s parents (individuals I-1 and I-2) using 
buccal swabs. The grandmother had the wildtype allele for all four variants, whereas the 
grandfather had the same alleles as his daughter for all four variants (Table 5-4). 
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Table 5-4: Grandparental DNA 
Sanger sequencing results of the four variants in the four candidate gene indicate that these variants present in the RM patient were all inherited 
from her father, as her father was heterozygote for all four variants, whereas the patient’s mother was wildtype. 
 
 Grandfather Grandmother 
FKBP4 
 
  
SERPINB2 
 
  
CD46 
 
 
 
MIRLET7D 
 
 
 
 
Based on these results, we cannot exclude any of the four candidate genes, as all the variants present in the RM patient were inherited from 
her father and it is possible that the variants do not manifest when present in a male.
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5.6.5 Sequencing SERPINB2 and FKBP4 genes in RM patients 
 
Next, SERPINB2 and FKBP4 were investigated in more depth by sequencing the 
coding regions of each gene in the RM Asian cohort, the RM White European cohort and the 
Bangladeshi controls to check if any novel missense variants are identified in these patients. 
A number of different prediction methods were used to predict pathogenicity of any novel 
missense changes found in SERPINB2 and FKBP4 (Thusberg et al., 2011). 
 
5.6.5.1 Sequencing gene SERPINB2 
SERPINB2 (chr18:61538926-61571124) has nine coding exons and Table 5-5 below 
summarizes the variants found in the patients and controls sequenced. A more detailed table 
showing chromatograms, protein changes and prediction scores is presented in Appendix E.  
 
Table 5-5: Table summarizing the variants found in RM patients and controls in gene 
SERPINB2. 
 
Exon SNP database SNP type 
Asian 
RM patients 
White European 
RM patients 
Bangladeshi 
controls 
5’UTR rs2288288  13 het, 2 homo 2 het 11 het 
Exon 4 NOVEL missense Exome patient none none 
Exon 5 rs6106 synonymous 2 het 1 het none 
Exon 5 rs6105 synonymous 17 het, 3 homo 14 het 15 het, 2 homo 
Exon 6 rs143202684 missense 1 het none 2 het 
Exon 7 rs138446596 missense 1 het none 2 het 
Exon 8 rs6102 synonymous 22 het, 4 homo 30 het, 6 homo 37 het, 3 homo 
Exon 8 NOVEL synonymous 1 het none none 
Exon 8 rs6103 missense 31 het, 8 homo 30 het, 6 homo 35 het, 15 homo 
Exon 8 rs6104 missense 31 het, 8 homo 32 het, 6 homo 35 het, 10 homo 
3’UTR NOVEL  3 het none 1 het 
3’UTR rs12102  4 homo 1 het, 5 homo 1 het, 13 homo 
het: heterozygotes, homo: homozygotes 
 
No novel missense variants in SERPINB2 were identified in patients, other than the 
one identified in the exome patient (highlighted in yellow), as most of them were known 
SNPs. 
 
172 
 
5.6.5.2 Sequencing gene FKBP4 
FKBP4 (chr12:2904119-2914576) has ten coding exons and Table 5-6 below 
summarizes the variants found in the patients and controls sequenced. A more detailed table 
showing chromatograms, protein changes and prediction scores is presented in Appendix E. 
 
 
Table 5-6: Table summarizing the variants found in RM patients and controls in gene 
FKBP4. 
 
Exon SNP database SNP type 
Asian 
RM patients 
White European 
RM patients 
Bangladeshi 
controls 
Exon 1 NOVEL missense Exome patient none none 
Exon 3 NOVEL synonymous 1 het none 1 het 
Exon 3 
rs145385559 
(very rare) 
missense 1 het none none 
Exon 5 
reported but rs 
number unknown 
missense 3 het 1 het 1 het 
Exon 5 rs56196860 missense 1 het 8 het none 
Exon 9 
reported but rs 
number unknown 
synonymous 1 het none none 
Exon 9 NOVEL missense 1 het none none 
Exon 9 NOVEL missense 1 het none none 
3’UTR rs1803818  1 het none none 
3’UTR NOVEL  2 het none none 
3’UTR rs116573718  1 het none none 
het: heterozygotes, homo: homozygotes 
 
In addition to the novel missense variant in FKBP4 identified in exon 1 of the original 
patient, two more novel missense variants were identified in two Asian patients in exon 9, as 
well as one more very rare missense variant in exon 3 (reported in only two out of 13006 
alleles) (Table 5-6). Each of the variants identified in these patients appear to be unique, as 
they are not present in the 1000 Genomes, dbSNP, EVS and UK10K datasets.  
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5.6.6 Variants identified in FKBP4 
 
5.6.6.1 c.374A>G / p.N125S 
 
A very rare SNP in gene FKBP4, reported in only two out of 13006 alleles, was 
detected in an Asian patient (5510) who had three early miscarriages. The female patient had 
a missense heterozygous change (c.374A>G) at position chr12:29047018 that causes 
asparagine at position 125 to change to serine (p.N125S) (Fig. 5-7). 
 
 
 FKBP4 
  
 
 
Wildtype 
 
 
 
 
Patient 5510 
 
c.374A>G  
 
 
 
 
Figure 5-7: Sanger sequencing chromatogram showing the A/G change at position 
chr12:2907018 in gene FKBP4, present in patient 5510. 
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5.6.6.2 c.1142A>T / p.Q381L 
 
A novel variant in gene FKBP4, not reported before, was detected in an Asian patient 
(5644) who had six early miscarriages. The female patient had a missense heterozygous 
change (c.1142A>T) at position chr12:2910392 that causes glutamine at position 381 to 
change to leucine (p.Q381L) (Fig. 5-8). 
 
 FKBP4 
  
 
Wildtype 
 
 
 
 
Patient 5644 
 
c.1142A>T  
 
 
 
 
 
Figure 5-8: Sanger sequencing chromatogram showing the novel A/T change at position 
chr12:2910392 in gene FKBP4, present in patient 5644. 
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5.6.6.3 c.1196G>A / p.R399Q 
 
A novel variant in gene FKBP4, not reported before, was detected in an Asian patient 
(6040) who had three early miscarriages. The female patient had a missense heterozygous 
change (c.1196G>A) at position chr12:2910446 that causes arginine at position 399 to 
change to glutamine (p.R399Q) (Fig. 5-9). 
 
 FKBP4 
  
 
Wildtype 
 
 
 
Patient 6040 
 
c.1196G>A  
 
 
 
 
Figure 5-9: Sanger sequencing chromatogram showing the novel G/A change at position 
chr12:2910446 in gene FKBP4, present in patient 6040. 
 
 
 
 
 
5.6.7 Conservation of FKBP4 among species 
 
Amino acid sequence conservation across different species was investigated using 
Clustal W2 (Larkin et al., 2007), a multiple sequence alignment program for DNA or 
proteins. This protein shows a high degree of conservation between species and the four 
variant residues are at highly conserved positions across mammals, although were not 
conserved in the chicken (Fig. 5-10).  
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Fig. 5-10: Clustal W2 alignment of the human FKBP52 protein and its orthologues in 
selected species. The aa residues at each of the identified variants (p.A16E, p.N125S, 
p.Q381L and p.R399Q) are highlighted in yellow. Asparagine (N) at position 125 and 
glutamine (Q) at position 381 are conserved in the selected species. Alanine (A) at position 
16 and Arginine (R) at position 399 are conserved across mammals, but not in chicken.  
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5.6.8 Prediction of pathogenicity 
 
Next, we used in silico tools to predict the effect that these variants might have on 
FKBP52 (Table 5-7). These tools used sequence homology to predict whether a substitution 
affects protein function. Residues that are conserved in the protein family are expected to be 
important for function. 
 
Table 5-7: In silico pathogenicity prediction of the four FKBP4 missense variants 
identified in Asian RM patients. 
 
Position 
Variant 
FKBP4 
Polyphen-2 
(Adzhubei 
et al., 2010) 
PROVEAN 
(Choi et al., 2012) 
SIFT 
(Ng and 
Henikoff, 2001) 
nsSNPAnalyzer 
(Bao et al., 
2005) 
  PROVEAN SIFT   
12:2904352 
c.47C>A 
p.A16E 
Benign Neutral Damaging Tolerated Neutral 
12:2907018 
c.374A>G 
p.N125S 
Benign Deleterious 
Tolerated 
 
Damaging Disease 
12:2910392 
c.1142A>T 
p.Q381L 
Benign Deleterious Damaging Damaging Disease 
12:2910446 
c.1196G>A 
p.R399Q 
Possibly 
damaging 
Neutral Damaging Damaging Neutral 
 
 
Although most in silico tools predicted the p.N125S, the p.Q381L and the p.R399Q 
variants to be damaging, only one predicted that the p.A16E variant identified in the initial 
RM patient to be damaging. The different prediction tools use different algorithms but it is 
not known which, if any, is the most reliable for any given sequence. It is interesting to note 
that SIFT in Provean gives a different result from the original SIFT in several cases. 
Polyphen-2 for example uses multiple sequence alignment of homologous proteins to 
compare the property of the wild-type ancestral allele and the property of the mutant allele 
(Adzhubei et al., 2010). SIFT for example bases its prediction on sequence data alone and 
does not depend on knowledge of protein structure or function (Ng and Henikoff, 2001). 
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nsSNPAnalyzer on the other hand, combines multiple sequence alignment and protein 
structure analysis to identify disease-associated SNPs (Bao et al., 2005). Prediction by 
PROVEAN is not only based on the aa residue at the position of interest, but also on the 
quality of sequence alignment derived from the neighbourhood flanking sequences (Choi et 
al., 2012). 
Based on the fact that mouse knockout models of FKBP4 are infertile and the fact that 
3 novel and one rare missense variants were identified in 4 RM patients that were predicted to 
be damaging by a number of prediction tools, we decided that this gene was worth pursuing 
further in laboratory based functional tests. These tests could include protein-protein 
interaction studies, such as pull-down assays and are described in more depth in section 5.8 
below. 
A schematic representation of the four FKBP52 protein domains as well as an 
illustration on where about in these domains the four potential damaging variants and three 
common polymorphisms are based is shown in Fig. 5-11 below. 
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Figure 5-11: Schematic representation of FKBP52 protein. 
FKBP52 protein has four domains (described in section 5.3.1). A red cross indicates the position of the four potential mutant variants identified 
in the four Asian patients (p.A16E, p.N125S, p.Q381L and p.R399Q). A yellow cross indicates the position of common polymorphisms that 
were used as controls. p.K181Q and p.N197K are two common variants that were detected in our RM cohort. SNP rs143021274 (p.A374G) was 
chosen from the EVS database as an additional control since this polymorphism is close to the two variants identified in RM patients. 
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5.6.9 FKBP4 mRNA expression in human tissues 
 We analysed FKBP4 mRNA expression using RTqPCR in several human tissues (Fig. 
5-12). These included tissue from maternal decidua from the exome patient that carried the 
c.47C>A variant, maternal decidua from miscarried pregnancies and from termination of 
pregnancies. We also used chorion tissue (CVS pool) and tissue from products of conception 
(POC pool). No significant differences were observed in the relative expression levels of 
FKBP4 between the different tissues tested.  
 
Figure 5-12: RT-qPCR mRNA analysis of gene FKBP4 in selected tissues. These were 
maternal decidua from patient, from miscarriages, from termination of pregnancies, from 
chorionic villi and product of conceptions. mRNA levels for FKBP4 were quantified relative 
to the levels of the endogenous gene L19. 
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FKBP4 mRNA expression in human tissues 
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5.7 DISCUSSION 
Infertility and spontaneous pregnancy losses are a persistent problem to women's 
health. The establishment of pregnancy depends on successful implantation, where a complex 
series of interactions occurs between the uterus and blastocyst. Early loss of pregnancy is a 
significant clinical problem for women and their health care providers. 
In this study, a woman with a severe history of miscarriages was investigated. Exome 
sequencing was carried out and Ingenuity analysis variant server was used to analyse the 
data obtained. FKBP4 was predicted as the best candidate gene, containing a novel 
missense variant (c.47C>A; p.A16E) in the female patient but which was not present in the 
other family members tested and neither in the four Asian female controls provided by 
GOSgene. Three more candidate genes (SERPINB2, CD46 and MIRLET-7D) were chosen 
for further investigation. 
Segregation analysis was performed by PCR and Sanger sequencing in the parents. 
This revealed that all four variants were inherited from the patient’s father and none were de 
novo. This could be consistent for an inheritance model that suggests that the RM effect is 
primarily expressed in the mother as an environment that is not compatible with 
implantation rather than in the fetus. A male (i.e. the mother’s father) could carry such an 
allele for this without expressing the phenotype.  
Genes FKBP4 and SERPINB2 were sequenced in our Asian and White-European RM 
cohorts. Although the novel missense variant identified in gene SERPINB2 (c.328C>G; 
p.L110V) in the exome patient was predicted to be damaging by almost all prediction 
programs, no other novel missense variants were identified in this gene in our RM cohorts. 
Two novel missense variants (c.1142A>T; p.Q381L and c.1196G>A; p.R399Q) in FKBP4, 
which are in a domain that interacts with tubulin, were identified in two Asian patients, as 
well as a very rare missense variant (c.374A>G; p.N125S) in a third patient. These novel 
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variants were not present in the Bangladeshi controls tested, were not reported in any of the 
SNP databases, are conserved amongst mammals and are predicted deleterious or damaging 
by most prediction programs used. Functions of FKBP52 include regulation of steroid 
hormone receptor function (Schülke et al., 2010) and protection of pregnancy from oxidative 
stress through regulation of peroxiredoxin-6 levels (Hirota et al, 2010). Therefore, gene 
FKBP4 is currently the leading candidate, as there is good evidence in the literature that 
FKBP4 is linked to pregnancy and potentially pregnancy failure (Tranguch et al., 2005; 
2007).  
The fact that no significant differences in FKBP4 expression were observed when 
real-time quantitative PCR analysis was carried out between the maternal decidua that 
carried the c.47C>A variant and wildtype decidua does not surprise us (Fig. 5-12). As 
patients carry a point variant that leads to a missense change we do not expect the 
expression levels of the mRNA to change. That would be probably the case if a patient 
carried a stop-codon mutation. 
 
 
5.8  FUTURE WORK 
Preliminary data 
Site-directed mutagenesis was carried out in a FLAG_FKBP4_pcDNA3 plasmid, 
provided by Dr Felix Hausch (Max-Planck-Institute of Psychiatry, Germany) (März et al., 
2013) to introduce mutations in the protein. In addition to the four potential damaging 
mutations (p.A16E, p.N125S, p.Q381L, p.R399Q), three common polymorphisms 
(p.K181Q, p.N197K and p.A374G) were also introduced to be used as controls along with 
the wildtype protein. Cell culture experiments were performed with HEK293 cells, derived 
from human embryonic kidney cells, plasmid DNA was transfected in these cells and 
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proteins extracted. Western blot analysis was performed to detect the FKBP52 protein in the 
sample of cell extracts using a FLAG antibody (Fig 5-13). 
 
Figure 5-13: Western blot showing the presence of FKBP52 in HEK 293 cells. Top panel 
is FKBP52 (52 kDa) and bottom panel is the ACTB house keeping gene loading control. 
 
Future work will involve functional studies to investigate whether the four FKBP4 
variants identified in four patients are indeed damaging mutations. A mutation may lead to 
alterations in the structure, folding or stability of the protein therefore preventing or altering 
the normal function of the protein. Therefore, experiments will include protein-protein 
interaction studies, such as pull-down assays or immunoprecipitation to firstly confirm the 
interaction between wildtype FKBP52 protein and proteins such as tubulin or FKBP506 and 
then test whether the potential mutations introduced affect the normal interaction of FKBP52 
with proteins. 
We can also use mass spectrometry to investigate protein-protein interactions, i.e. 
which proteins physically interact with FKBP52. This methodology will also allow us to 
test whether the proteins carrying the potential harmful mutations bind to different proteins 
than the wildtype FKBP52 or those carrying the normal polymorphisms. In order to do this, 
anti-FLAG magnetic beads can be used to pull the FLAG-FKBP52 proteins from the total 
protein mixture, so that we only isolate the FKBP52 protein and whatever proteins are 
bound to it.  
WT               WT A16E           N125S  K181Q            N197K         A374G   Q381L    R399Q
FKBP52
B-actin
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SUMMARY 
This PhD project investigated the role of genetic factors associated with FGR and 
RM, two of the most common complications of pregnancy by studying large cohorts of 
patients using a number of different techniques such as real-time PCR, Sanger sequencing 
and WES. Part of this PhD focused on imprinted genes such as the paternally expressed IGF2 
and the maternally expressed PHLDA2 investigating their role in fetal growth as well as 
potential links between abnormal imprinting and failed pregnancies.  
The role of IGF2 in human fetal growth was investigated in a large cohort of CVS 
samples (early placenta tissue). Transcript levels of IGF2 revealed a significant positive 
correlation with birth weight (P=0.009), providing evidence for the role of this gene as an in 
utero growth enhancer early in human pregnancy. In addition, SGA neonates had 
significantly lower IGF2 levels than AGA neonates (P=3.6x10
-7
). The fact that no 
association was observed between the PHLDA2 levels in CVS and birth weight, although 
PHLDA2 is a known negative regulator of birth weight in term tissue, suggests that this 
maternally expressed gene is suppressing the baby’s growth later in pregnancy rather than 
early on. Therefore, the two parental genomes appear to be acting at different times during 
pregnancy to control fetal weight.  
Another study explored a potential role for disturbed imprinting in POCs. Detailed 
analysis of the POC DNA to establish levels of MCC revealed that a large percentage of 
samples (74%) were in fact maternal decidual tissue rather than of fetal origin. Non-
contaminated or partially contaminated POCs were then selected to investigate the status of 
known imprinted genes, including the newly identified maternally expressed gene HLA-C. 
Interestingly, in a number of POCs, known maternally expressed genes were found to be 
paternally expressed and vice versa. In summary, 38% of POCs tested showed an abnormal 
imprinting for HLA-C and 29% of samples showed abnormal imprinting of IGF2. This 
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suggested that some miscarriages might be associated with or even caused by abnormal 
imprinting. 
        Two approaches were then used to study genetic factors associated with RM. The 
first involved a genetic association study with ANXA5, which encodes a placental anti-
coagulant protein. A distinct haplotype (M2) containing four nucleotide substitutions in its 
promoter was genotyped in 500 White European couples with RM and were compared to 250 
normal pregnancy control trios. Carriers of the M2 haplotype were found to exhibit a higher 
RM risk than non-carriers, which was in agreement with previous studies. However, this was 
only true for the patients who suffered with early miscarriages, before the 12
th
 week of 
gestation. 
Next-generation exome sequencing was used to investigate a single family where the 
patient had experienced a total of 29 miscarriages and no successful pregnancies. WES was 
used to search for a rare genetic variant potentially causative of the RM phenotype. Two 
candidate genes were identified, FKBP4 and SERPINB2, which were then further 
investigated by Sanger sequencing in cohorts of Asian RM patients (n=100) and White 
European RM patients (n=120). In FKBP4, which was a very interesting candidate since 
knockout Fkbp4 mice have previously been shown to be infertile, three novel variants 
(p.A16E, p.Q381L, p.R399Q) and one very rare SNP (p.N125S) were identified in four Asian 
patients. Two of these variants are located in the FK506 binding domain of the protein, and 
two are in the tubulin-binding domain. All four were predicted to be damaging by different 
programs designed to predict the functional impact of amino acid substitutions. Future studies 
to investigate these potential mutations will involve laboratory-based functional analysis of 
each variant such as protein-protein interaction studies and pull-down assays.  
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APPENDICES  
 
Appendix A - Imprinted genes highly expressed in the placenta 
 
Locus Gene Origin* Mouse KO Phenotypes Human growth phenotypes 
6q24 PLAGL1 P 
FGR, bone malformation, 
high neonatal lethality  
TNDM (pUPD6, pDup6q24, 
ICR hypomethylation)  
6q25 IGF2R M/biallelic 
Fetal and placental 
overgrowth, organ and 
skeletal abnormalities  
CVS expression positively 
correlated to BW and CRL 
7p12 GRB10 M/P 
Fetal and placental 
overgrowth  
Implicated in SRS 
(mDup7p11.2) 
7q21.3 PEG10 P 
Embryonic lethal due to 
placental malformation  
Hypermethylation at ICR and 
reduced expression in LBW 
cord blood. Upregulated in 
FGR placenta. 
7q32.2 MEST P 
Fetal and placental growth 
restriction, high postnatal 
lethality, abnormal maternal 
behaviour  
Implicated in SRS (mUPD 
7q31-qter)  
11p15 H19 M 
Fetal and placental 
overgrowth  
ICR hypomethylation and 
CNV  in SRS  
 
 IGF2 P 
Fetal and placental growth 
restriction 
CVS expression positively 
correlated to BW and CRL 
BWS, Wilm’s tumor  
 CDKN1C M 
Gestational fetal and 
placental overgrowth  
Mutated in BWS and SRS 
patients  
 SLC22A18 M 
 Implicated in breast and lung 
cancers  
 PHLDA2 M 
Placental overgrowth  Highly expressed in LBW 
and FGR placenta. Promoter 
variant associated with BW 
14q32 DLK1 P 
Pre- and postnatal growth 
restriction, high perinatal 
lethality, obese postnatally  
Associated with T1D, 
UPD14 syndromes,T1D SNP 
correlated to BW 
 MEG3 M 
Postnatal lethal (mat del), 
pre- and postnatal growth 
restriction, high perinatal 
lethality (pat del)  
Associated with T1D, 
Reduced expression in FGR 
placenta  
19q13.4 PEG3 P 
Placental and fetal growth 
restriction, abnormal 
maternal behaviour  
 
 
Origin* = parental origin of the expressed allele, M = maternally expressed, P = paternally 
expressed, Dup = duplication, mat del = maternally inherited deletion, pat del = paternally 
inherited deletion, TNDM = Transient neonatal diabetes mellitus, T1D = type 1 diabetes 
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Appendix B - Demographic characteristics of the CVS cohort 
 
Lab 
ID Parity Gender 
GA  
(days) 
BW  
(g) 
BW  
centile 
MA 
(years) Ethnicity 
MW  
(Kg) 
Height  
(cm) 
BMI  
(kg/m
2)
 Smoking IGF2 IGF2R 
IGF2/ 
IGF2R IGF1R 
IGF2/ 
IGF1R 
IGF1R/ 
IGF2R CLASS 
34 Multip Female 269 2384 2.1 44.6 White 56 162 21.34 no 3.0476 0.1182 25.7777 N/A N/A N/A <10th  
119 Nullip Female 259 3920 99.7 18.1 White 64 167.6 22.64 no 3.7742 0.0742 50.8982 0.2145 17.5917 2.8933 >90th 
124 Multip Male 272 3620 81.1 39.7 White 59 166 21.43 no 3.5323 0.0724 48.7811 0.3222 10.9619 4.4501 10-90th 
142 Multip Female 289 4058 83.7 36 White 64 158 25.44 no 2.1165 0.0909 23.2949 0.3635 5.8221 4.0011 10-90th 
161 Multip Male 273 3632 80 34.5 White 74 157.5 29.63 no 4.2256 0.0987 42.8028 0.4486 9.4190 4.5443 10-90th 
164 Multip Male 293 3180 11.2 31.3 White 59 167.6 21 no 4.7296 0.0952 49.6828 0.4657 10.1561 4.8919 10-90th 
193 Multip Female 273 3482 68.1 33.2 Oriental 60 152 25.97 no 4.0817 0.0679 60.0844 0.2327 17.5441 3.4248 10-90th 
205 Nullip Male 274 2497 2.1 41.9 Asian 51 154.9 21.26 no 4.0383 0.1294 31.1976 N/A N/A N/A <10th  
274 Multip Male 272 3575 77.9 39.7 White 65 160 25.58 no 2.9697 0.1068 27.8009 0.2997 9.9101 2.8053 10-90th 
279 Multip Male 269 2355 1.8 33.4 White 66 162 25.15 no 3.9636 0.1120 35.3781 0.4391 9.0268 3.9192 <10th  
292 Multip Male 278 4001 92.3 40.8 White 59 168 20.9 no 3.2295 0.1005 32.1499 N/A N/A N/A >90th 
333 Nullip Male 270 3340 62.4 38.8 White 57 156 23.42 no 3.9609 0.0659 60.0869 0.3109 12.7400 4.7164 10-90th 
358 Multip Female 295 3660 43.3 43.6 White 85 154.9 35.43 no 6.3346 0.1252 50.6081 0.4504 14.0638 3.5985 10-90th 
363 Nullip Male 296 4230 86.8 33.6 White 68 164 25.28 no 4.2662 0.1057 40.3712 0.4200 10.1568 3.9748 10-90th 
397 Multip Female 281 3859 81.8 28 White 67 164 24.91 no 5.8983 0.1146 51.4703 0.4752 12.4122 4.1468 10-90th 
409 Multip Female 280 3377 42.1 36.7 White 63 172.7 21.12 no 4.4341 0.0979 45.3003 0.3235 13.7047 3.3055 10-90th 
513 Multip Female 289 3670 52.9 27.7 Black 63 162.6 23.83 no 5.4675 0.1119 48.8506 0.3247 16.8384 2.9011 10-90th 
529 Multip Male 266 3510 85.1 38.6 White 64 157.5 25.8 no 8.2091 0.1307 62.8314 0.3706 22.1535 2.8362 10-90th 
605 Multip Female 273 2639 5.3 35.5 White 56 160 21.68 Yes 2.4064 0.0961 25.0412 0.3077 7.8202 3.2021 <10th  
611 Multip Male 292 3940 72 31.9 White 64 163 23.94 no 5.1944 0.1125 46.1594 0.3281 15.8316 2.9156 10-90th 
699 Nullip Female 273 2780 10.2 41.2 White 69 162 26.29 no 5.6531 0.1413 39.9952 0.3872 14.5985 2.7397 10-90th 
733 Multip Male 280 4767 99.9 38.1 White 88 168 31.18 no 2.6283 0.0914 28.7657 0.2604 10.0939 2.8498 >90th 
768 Nullip Female 285 3632 56.3 36.7 White 66 162 25.15 no 2.3531 0.1115 21.1011 0.2521 9.3355 2.2603 10-90th 
771 Nullip Male 277 3600 69.5 38.2 White 70 167.6 24.92 no 5.5179 0.1254 44.0062 0.4052 13.6179 3.2315 10-90th 
807 Multip Female 290 2950 4.9 40.2 White 88 167 31.55 no 4.0941 0.1019 40.1973 0.2129 19.2295 2.0904 <10th  
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Lab 
ID Parity Gender 
GA  
(days) 
BW  
(g) 
BW  
centile 
MA 
(years) Ethnicity 
MW  
(Kg) 
Height  
(cm) 
BMI  
(kg/m
2)
 Smoking IGF2 IGF2R 
IGF2/ 
IGF2R IGF1R 
IGF2/ 
IGF1R 
IGF1R/ 
IGF2R CLASS 
825 Nullip Male 286 3689 59.8 41.6 White 110 180.3 33.84 no 4.9634 0.1214 40.9002 0.4022 12.3394 3.3146 10-90th 
894 Multip Female 276 3796 85.3 40.5 Black 70 167 25.1 no 4.8646 0.0631 77.0368 0.2345 20.7483 3.7129 10-90th 
947 Multip Male 271 4150 98.9 39 White 107 177.8 33.83 no 3.7180 0.1343 27.6765 0.1813 20.5021 1.3499 >90th 
975 Multip Male 275 3859 89.8 39.5 White 65 162.6 24.59 Yes 9.5582 0.0705 135.6521 0.1931 49.5100 2.7399 10-90th 
983 Nullip Male 285 4556 99.1 39.3 White 68 165 24.98 no 3.6286 0.0909 39.9282 0.2597 13.9748 2.8572 >90th 
1002 Nullip Male 287 3660 55.3 38.7 White 54 162.6 20.42 no 5.9873 0.0892 67.1563 0.2960 20.2283 3.3199 10-90th 
1096 Multip Male 259 3288 85 39.6 White 70 162 26.67 no 6.6135 0.1117 59.2105 0.3867 17.1026 3.4621 10-90th 
1143 Multip Male 268 3973 98.1 37.3 White 78 165.1 28.62 no 7.5503 0.0362 208.6736 0.3552 21.2560 9.8172 >90th 
1146 Multip Female 269 3172 48.4 41.8 White 80 162.6 30.26 no 9.5563 0.1717 55.6590 0.4280 22.3284 2.4927 10-90th 
1161 Multip Male 277 3778 82.8 32.2 White 92 164 34.21 no 4.4976 0.0970 46.3811 0.4406 10.2088 4.5432 10-90th 
1194 Multip Male 273 3400 60.5 39.3 White 61 172.7 20.39 Yes 11.4596 0.1169 98.0563 0.3094 37.0356 2.6476 10-90th 
1233 Multip Male 276 4597 99.9 30.9 White 67 162.6 25.23 no 3.9723 0.1051 37.7823 0.3234 12.2834 3.0759 >90th 
1301 Nullip Female 287 3155 14.6 34.5 White 90 147 41.65 no 7.7957 0.1886 41.3257 0.4088 19.0686 2.1672 10-90th 
1353 Nullip Female 282 4160 94.2 36.9 White 63 167 22.59 no 3.8148 0.0970 39.3400 0.1818 20.9847 1.8747 >90th 
1364 Multip Male 278 3810 83.2 27.3 White 71 153 30.33 no 4.0014 0.1245 32.1321 0.2198 18.2036 1.7651 10-90th 
1368 Multip Male 284 3496 45.4 36.5 White 75 157 30.43 Yes 7.3220 0.1118 65.4937 0.2394 30.5797 2.1417 10-90th 
1387 Multip Female 282 3433 43.4 35.5 White 59 160 23.05 no 7.5732 0.1344 56.3468 0.2425 31.2340 1.8040 10-90th 
1438 Multip Female 272 3377 60.8 27.8 White 64 170.2 21.96 Yes 7.3756 0.0927 79.5877 0.3204 23.0190 3.4575 10-90th 
1461 Nullip Male 277 2412 0.9 42.3 White 65 154.9 27.09 no 2.9037 0.0935 31.0474 0.2412 12.0371 2.5793 <10th  
1487 Multip Female 273 3350 55.7 39.9 White 84 173 28.07 no 10.0578 0.1022 98.4380 0.2646 38.0177 2.5893 10-90th 
1525 Multip Female 279 4230 97.2 37.2 White 74 160 28.91 no 3.7899 0.1050 36.0784 0.2403 15.7703 2.2877 >90th 
1541 Multip Female 285 3600 53.3 34.2 White 63 160 24.58 no 3.6972 0.0881 41.9829 0.2723 13.5785 3.0919 10-90th 
1567 Multip Female 274 3575 73.8 40.5 White 64 160 24.84 no 11.4570 0.0866 132.3364 0.2367 48.3962 2.7344 10-90th 
1582 Multip Male 282 3600 59.2 38.6 White 60 167.6 21.36 no 9.9951 0.1093 91.4543 0.2743 36.4384 2.5098 10-90th 
1590 Multip Male 272 3550 76 40.9 White 72 175.3 23.35 no 12.0021 0.0996 120.5172 0.3105 38.6559 3.1177 10-90th 
1664 Multip Female 265 3405 80.2 40.5 White 74 180.3 22.76 no 4.7263 0.0565 83.6192 0.1886 25.0548 3.3374 10-90th 
1679 Nullip Female 284 3377 34.5 41.7 White 70 170.2 24.3 no 6.9710 0.1288 54.1076 0.2263 30.8028 1.7566 10-90th 
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1752 Multip Male 283 3433 41.4 35.3 White 61 170.2 20.99 no 4.4045 0.0857 51.3880 0.2246 19.6116 2.6203 10-90th 
1769 Nullip Female 284 3916 81.1 37.3 White 59 170.2 20.37 no 4.1891 0.1090 38.4282 0.2240 18.7025 2.0547 10-90th 
1777 Multip Female 269 2886 22.3 31 White 70 154 29.52 no 6.6088 0.1095 60.3615 0.4255 15.5319 3.8863 10-90th 
1778 Multip Male 278 3800 82.6 40.1 White 60 170 20.76 no 6.3741 0.1081 58.9643 0.2211 28.8306 2.0452 10-90th 
1811 Multip Female 271 3887 94.7 43.1 White 54 167.6 19.22 no 7.1323 0.1226 58.1651 0.3405 20.9467 2.7768 >90th 
1877 Multip Female 278 3462 54.7 31.1 White 63 165.1 23.11 no 9.5049 0.1166 81.4872 0.2652 35.8339 2.2740 10-90th 
1885 Multip Male 285 3320 28.1 45.7 White 52 154.9 21.76 no 8.0268 0.0765 104.9727 0.2144 37.4460 2.8033 10-90th 
1912 Nullip Male 283 3235 24.5 41.5 White 62 165 22.77 no 6.4167 0.0478 134.2479 0.2536 25.2998 5.3063 10-90th 
1913 Multip Female 285 3820 72.7 41.8 White 75 173 25.06 no 6.2581 0.0697 89.7446 0.2489 25.1440 3.5692 10-90th 
1928 Multip Female 283 3717 67.7 40.3 White 70 167.6 24.92 no 8.3172 0.0996 83.4731 0.1957 42.4902 1.9645 10-90th 
1935 Multip Male 276 3008 19 37.6 White 65 167.6 23.28 no 4.9513 0.0493 100.3984 0.2589 19.1215 5.2506 10-90th 
1937 Multip Female 279 3510 57 41.6 White 70 170.2 24.13 no 8.1568 0.0841 96.9685 0.2606 31.2971 3.0983 10-90th 
1957 Multip Male 273 3140 35.3 42.5 White 54 156 22.19 no 5.1270 0.0601 85.2379 0.3944 12.9988 6.5574 10-90th 
1970 Multip Male 285 3405 35.3 44.6 White 64 175.3 20.7 no 5.2037 0.0974 53.4337 0.3986 13.0535 4.0934 10-90th 
1988 Multip Male 278 3263 35.7 42.5 White 65 157.5 26.2 Yes 6.2364 0.0819 76.1029 0.2598 24.0062 3.1701 10-90th 
2003 Nullip Male 289 3263 18.9 26.7 White 55 157.5 21.97 no 7.0073 0.0718 97.5836 0.1889 37.0920 2.6309 10-90th 
2014 Nullip Female 273 3206 41.5 40.3 White 49 154 20.66 no 5.4832 0.0831 66.0151 0.3401 16.1204 4.0951 10-90th 
2042 Multip Male 280 3260 31.6 39.2 White 62 160 24.22 no 4.8797 0.0705 69.2363 0.3779 12.9140 5.3614 10-90th 
2077 Multip Female 265 2542 8.3 20.9 Black 63 160 24.61 no 4.2418 0.0882 48.1177 0.2766 15.3371 3.1373 <10th  
2261 Multip Female 285 4029 86.4 32.3 White 52 163 19.57 no 4.5895 0.1157 39.6785 0.2164 21.2067 1.8710 10-90th 
2454 Multip Male 293 3664 46.3 40.4 White 53 152.4 22.82 no 2.3972 0.0340 70.5564 0.2357 10.1708 6.9372 10-90th 
2457 Nullip Male 284 3700 64.4 31.4 Black 57 165.1 20.98 no 4.7138 0.0656 71.8765 0.2972 15.8588 4.5323 10-90th 
2512 Nullip Male 282 2865 6.4 30.5 Asian 57 161.5 21.85 no 3.9744 0.0426 93.2993 0.2553 15.5656 5.9939 <10th  
2522 Multip Male 259 3206 79.2 30.3 White 45 157.5 17.94 no 6.1977 0.0506 122.5112 0.1007 61.5392 1.9908 10-90th 
2567 Multip Male 291 3746 56.8 36.4 White 55 160 21.64 no 2.4939 0.0381 65.3876 0.2787 8.9484 7.3072 10-90th 
2570 Nullip Female 290 3508 36.4 25.4 Black 90 163 33.87 Yes 5.6612 0.0574 98.6679 0.2578 21.9586 4.4934 10-90th 
2588 Multip Female 273 2740 8.5 41.6 White 66 167 23.67 no 4.1215 0.0962 42.8292 0.3131 13.1633 3.2537 <10th  
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2593 Nullip Female 287 2710 1.8 39.4 White 65 160 25.39 no 4.7851 0.1352 35.3863 0.2370 20.1928 1.7524 <10th  
2670 Multip Female 259 2781 37.1 42.4 White 57 165.5 20.81 Yes 5.0216 0.0556 90.2987 0.1978 25.3868 3.5569 10-90th 
2697 Multip Female 276 3405 53.8 36.3 White 59 154.9 24.63 no 3.6690 0.0472 77.6776 0.1261 29.0995 2.6694 10-90th 
2702 Multip Male 276 4001 94 33.7 White 70 165.1 25.64 no 3.1498 0.1259 25.0188 0.2170 14.5181 1.7233 >90th 
2713 Nullip Female 273 2856 14 35.6 N/A 65 162 24.77 Yes 5.7443 0.0536 107.1711 0.2412 23.8143 4.5003 10-90th 
2715 Multip Female 268 2912 26.4 29.1 White 51 157 20.69 no 2.0476 0.0368 55.6987 0.3143 6.5148 8.5496 10-90th 
2717 Nullip Male 272 3831 92 29.9 White 90 162.6 34 no 4.6217 0.0556 83.0726 0.1763 26.2186 3.1685 >90th 
2770 Nullip Female 275 2875 12.5 33.6 White 72 165.1 26.41 no 3.5189 0.0600 58.6207 0.2535 13.8835 4.2223 10-90th 
2781 Nullip Male 265 2979 39.9 38.5 White 83 160 32.42 no 3.6425 0.0641 56.7862 0.1810 20.1199 2.8224 10-90th 
2805 Nullip Male 273 3632 80 46 White 55 157.5 22.01 no 4.1331 0.0574 71.9741 0.2269 18.2181 3.9507 10-90th 
2821 Multip Female 282 3660 64.6 41.9 White 78 177.8 24.67 no 3.1851 0.0591 53.8692 0.2119 15.0311 3.5839 10-90th 
2842 Multip Male 261 2752 28.8 41.1 White 70 160 27.34 no 3.8622 0.0972 39.7322 0.1410 27.3868 1.4508 10-90th 
2848 Multip Male 286 3840 72.7 37.1 White 68 170.2 23.47 no 4.9169 0.0754 65.2059 0.2816 17.4612 3.7343 10-90th 
2852 Nullip Female 288 3433 32.9 29.9 White 73 170.2 25.2 no 5.0951 0.1426 35.7320 0.2871 17.7493 2.0132 10-90th 
2869 Nullip Male 286 3348 28.9 36.7 White 52 152.4 22.48 no 3.9502 0.0665 59.4287 0.2294 17.2211 3.4509 10-90th 
2870 Nullip Male 276 3086 24.6 35.7 White 80 163 30.11 no 3.9343 0.0885 44.4543 0.1949 20.1871 2.2021 10-90th 
2882 Multip Male 282 4000 88.3 35.4 White 51 158 20.43 no 4.5656 0.1287 35.4724 0.3129 14.5932 2.4307 10-90th 
2888 Nullip Female 293 3604 40.8 32.5 White 75 165.1 27.51 Yes 3.9915 0.1591 25.0881 0.2674 14.9297 1.6804 10-90th 
2893 Multip Female 268 3176 51.6 36.9 White 62 163 23.34 no 4.1994 0.0845 49.6925 0.2550 16.4651 3.0181 10-90th 
2932 Multip Female 279 2790 5.9 37.2 Black 60 156 24.65 no 4.0278 0.1051 38.3257 0.2562 15.7196 2.4381 <10th  
2956 Multip Male 295 4140 82.7 32.1 White 60 160 23.44 no 2.9295 0.1090 26.8737 0.2526 11.5961 2.3175 10-90th 
2981 Nullip Female 265 2611 11.4 21.4 White 55 172.7 18.27 no 3.7209 0.1156 32.1882 0.3503 10.6205 3.0308 10-90th 
2994 Nullip Male 281 3645 65.3 32.5 White 57 175.3 18.55 no 3.7376 0.1271 29.4175 0.2682 13.9350 2.1111 10-90th 
3047 Multip Female 282 3547 54.2 33.5 White 68 173 22.72 Yes 3.1080 0.1419 21.9060 0.1643 18.9218 1.1577 10-90th 
3051 Multip Male 277 3800 84.1 38.6 Asian 66 161 25.46 no 4.3202 0.1320 32.7391 0.2257 19.1412 1.7104 10-90th 
3063 Nullip Female 281 3240 28.1 31.1 White 60 164 22.31 no 3.0618 0.1017 30.1139 0.2750 11.1355 2.7043 10-90th 
3100 Nullip Female 261 2746 28.3 37.1 White 65 160 25.39 no 5.1837 0.1008 51.4164 0.2881 17.9901 2.8580 10-90th 
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3208 Multip Female 266 3250 64.5 42.6 White 54 162.6 20.46 no 3.9029 0.1504 25.9490 0.1837 21.2429 1.2215 10-90th 
3604 Multip Male 285 3322 28.3 35.7 White 87 165 31.96 no 3.8299 0.1635 23.4211 0.2233 17.1511 1.3656 10-90th 
3623 Multip Male 286 3689 59.8 47 White 54 156 22.19 no 4.0378 0.1380 29.2686 0.3000 13.4601 2.1745 10-90th 
3630 Multip Male 269 3515 79.6 39.1 White 55 160 21.48 Yes 6.8110 0.1302 52.3179 0.3363 20.2501 2.5836 10-90th 
3682 Nullip Male 267 3604 88.6 38 Asian 90 164 33.46 no 4.7284 0.1635 28.9282 0.3243 14.5820 1.9838 10-90th 
3729 Multip Female 298 3220 10.2 40.6 White 65 158 26.04 no 4.1068 0.0838 48.9799 0.3089 13.2962 3.6837 10-90th 
3812 Nullip Male 264 3036 48.6 38.6 White 59 162.6 22.16 no 4.3765 0.1141 38.3501 0.4125 10.6106 3.6143 10-90th 
3820 Multip Male 287 3859 72.7 40.9 White 68 155 28.3 no 4.3202 0.0855 50.5582 0.1589 27.1886 1.8595 10-90th 
3839 Multip Female 289 3832 67.4 40.3 White 59 162 22.48 no 2.6164 0.1001 26.1441 0.2080 12.5774 2.0787 10-90th 
3840 Multip Male 293 5092 99.9 36.8 White 75 175 24.49 no 3.9859 0.1273 31.3205 0.3224 12.3646 2.5331 >90th 
3930 Multip Female 282 3650 63.7 39.2 Asian 54 158 21.63 no 3.6229 0.0805 44.9936 0.2423 14.9548 3.0086 10-90th 
3932 Nullip Female 285 3405 35.3 37.8 White 64 175.3 20.83 no 3.8181 0.0410 93.1295 0.1985 19.2327 4.8422 10-90th 
3933 Nullip Female 264 2700 18.2 31.9 White 53 157 21.5 no 4.6542 0.1046 44.4988 0.3240 14.3637 3.0980 10-90th 
3948 Nullip Male 269 3040 35.4 29.2 White 52 160 20.31 no 4.1622 0.0986 42.2253 0.2705 15.3885 2.7440 10-90th 
3957 Multip Female 266 3200 59.6 41.9 Oriental 53 160 20.7 no 6.3129 0.1137 55.5382 0.2289 27.5755 2.0140 10-90th 
4160 Nullip Male 278 3590 66.6 24.9 White 62 167.6 22.07 no 3.8949 0.1135 34.3153 0.1178 33.0641 1.0378 10-90th 
4185 Multip Male 272 4040 97.3 42.6 White 75 161 28.93 no 4.0462 0.0911 44.4298 0.2583 15.6635 2.8365 >90th 
4204 Multip Male 264 2620 13.2 40.4 N/A 49 147 22.68 no 3.7798 0.1075 35.1554 0.3292 11.4821 3.0618 10-90th 
4210 Multip Female 291 4313 93.2 40.1 White 66 175.3 21.41 no 4.4921 0.0876 51.2555 0.2991 15.0173 3.4131 >90th 
4225 Multip Male 267 3462 80 31.6 White 66 165.1 24.14 no 3.0220 0.1225 24.6689 0.2928 10.3203 2.3903 10-90th 
4234 Multip Male 288 3377 28.3 38.9 White 54 158 21.63 no 7.3944 0.1572 47.0303 0.3066 24.1178 1.9500 10-90th 
4235 Nullip Female 275 2746 7.1 34.9 Asian 59 169 20.66 no 3.7002 0.0748 49.4900 0.2663 13.8966 3.5613 <10th  
4253 Multip Female 273 3160 37.2 35.1 White 52 160 20.31 no 7.0855 0.1249 56.7471 0.1123 63.0749 0.8997 10-90th 
4275 Multip Female 271 3598 81.5 39.8 White 60 157.5 24.19 no 5.7282 0.0993 57.6980 0.0834 68.6658 0.8403 10-90th 
4312 Multip Male 273 3320 52.7 35.9 White 60 152.4 25.83 no 6.1006 0.1032 59.1410 0.2791 21.8544 2.7061 10-90th 
4336 Multip Male 282 3642 63 40.8 White 66 169.5 22.97 no 3.7052 0.0615 60.2505 0.1674 22.1327 2.7222 10-90th 
4338 Nullip Female 293 3547 35.8 38.3 White 60 158 24.03 no 6.4808 0.0970 66.8073 0.1943 33.3620 2.0025 10-90th 
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4347 Multip Female 285 4070 88.4 29.2 White 62 163 23.34 no 4.5965 0.1140 40.3201 0.2011 22.8605 1.7638 10-90th 
4430 Multip Female 285 3400 34.8 38.8 White 83 170.2 28.51 no 4.8618 0.1314 37.0098 0.2649 18.3553 2.0163 10-90th 
4450 Nullip Female 281 3150 21.3 33 White 59 170.2 20.37 no 4.2207 0.0941 44.8645 0.2133 19.7886 2.2672 10-90th 
4454 Nullip Male 263 3462 87.6 25.1 White 67 162.6 25.42 no 5.4406 0.1390 39.1333 0.3213 16.9330 2.3111 10-90th 
4590 Multip Male 278 3645 71.3 25.9 White 57 162.6 21.63 no 5.4691 0.1765 30.9793 0.3383 16.1660 1.9163 10-90th 
4609 Multip Male 284 4040 88 37.9 Oriental 62 165 22.77 no 3.8876 0.1044 37.2532 0.3381 11.4976 3.2401 10-90th 
4640 Multip Male 283 4114 92 37.3 White 83 170.2 28.51 no 5.0188 0.1125 44.5982 0.3205 15.6615 2.8476 >90th 
4719 Multip Male 279 4040 92.8 34.7 White 74 161 28.55 no 4.7571 0.1096 43.3969 0.2580 18.4368 2.3538 >90th 
4722 Multip Female 274 2870 13.5 40.6 White 58 165 21.3 no 4.2268 0.0609 69.4297 0.2818 14.9982 4.6292 10-90th 
4775 Nullip Female 296 1840 0 31.1 N/A 62 162 23.62 no 2.8260 0.1233 22.9238 0.1198 23.5906 0.9717 <10th  
4787 Multip Female 276 3150 29.8 36.1 White 75 164 27.89 no 4.6621 0.0695 67.0416 0.3005 15.5164 4.3207 10-90th 
4800 Multip Female 287 4370 96.5 42.3 White 57 162.6 21.63 no 3.3832 0.0671 50.4464 0.1339 25.2684 1.9964 >90th 
4801 Multip Female 279 2878 8.8 28.9 Black 59 162 22.48 Yes 4.8211 0.0852 56.5814 0.3750 12.8572 4.4007 <10th  
4828 Nullip Male 271 4005 97.2 36.3 White 63 158 25.24 no 2.6075 0.1044 24.9831 0.0955 27.2910 0.9154 >90th 
4833 Multip Female 276 3120 27.3 28.2 Black 52 157 21.1 no 4.9308 0.0983 50.1691 0.3057 16.1288 3.1105 10-90th 
4859 Multip Female 289 3646 50.6 35.8 Black 102 166 37.02 no 3.9628 0.0334 118.5138 0.1714 23.1160 5.1269 10-90th 
4872 Multip Male 278 3316 40.6 39.3 White 60 157 24.34 no 3.7728 0.0640 58.9229 0.2803 13.4610 4.3773 10-90th 
4900 Multip Male 287 3973 80.8 45 White 52 160 20.23 no 4.5420 0.0834 54.4645 0.1710 26.5558 2.0509 10-90th 
4914 Nullip Female 292 3194 12.5 39.6 White 63 166 22.86 no 5.1139 0.0301 170.0574 0.2150 23.7898 7.1483 10-90th 
4990 Nullip Male 281 2853 6.6 34.6 White 66 166 23.95 no 4.5177 0.0497 90.8177 0.3380 13.3656 6.7949 <10th  
4994 Multip Male 286 3490 41.2 42.1 White 54 162.6 20.42 no 4.1273 0.0251 164.6536 0.1629 25.3333 6.4995 10-90th 
5022 Multip Male 294 4060 78.5 28 White 86 163 32.37 no 5.1467 0.1478 34.8117 0.2252 22.8553 1.5231 10-90th 
5025 Nullip Male 283 3402 38.6 36.4 White 62 170 21.45 no 4.4213 0.0489 90.4747 0.1684 26.2554 3.4459 10-90th 
5114 Multip Female 284 2923 7 36.5 White 65 162.6 24.4 no 5.1203 0.0420 122.0060 0.1229 41.6603 2.9286 <10th  
5121 Multip Male 289 4060 83.8 33.9 White 67 170.2 23.03 no 3.5103 0.1148 30.5695 0.1115 31.4941 0.9706 10-90th 
5127 Multip Male 265 3200 62.4 31.8 Asian 53 158 21.23 no 3.3350 0.0285 116.9949 0.0956 34.8864 3.3536 10-90th 
5148 Multip Female 284 3632 58.2 35.2 White 59 165.1 21.65 Yes 3.7573 0.0437 85.9515 0.1593 23.5881 3.6439 10-90th 
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5163 Nullip Male 289 3150 12.6 28.4 White 64 170.2 21.96 no 3.2897 0.0431 76.3413 0.1182 27.8321 2.7429 10-90th 
5181 Multip Female 272 3090 33 40.4 White 76 152.4 32.85 no 4.3884 0.0578 75.9501 0.1215 36.1130 2.1031 10-90th 
5189 Nullip Male 288 3212 16.8 20.8 White 61 167 21.87 no 3.9128 0.0301 130.1199 0.1101 35.5300 3.6623 10-90th 
5209 Multip Female 280 3774 77.6 26.8 White 96 160 37.42 no 3.5216 0.0304 115.6642 0.2699 13.0468 8.8653 10-90th 
5213 Nullip Female 273 3064 28.6 27.7 White 74 155 30.8 no 4.1686 0.0452 92.1657 0.1072 38.8702 2.3711 10-90th 
5270 Multip Male 283 3660 62.7 41.8 White 59 163 22.21 no 3.0488 0.0450 67.6848 0.1317 23.1495 2.9238 10-90th 
5300 Multip Male 282 4143 93.7 35.6 White 95 177.8 30.15 no 3.1997 0.0983 32.5457 0.1614 19.8223 1.6419 >90th 
5308 Nullip Male 281 3730 72.5 27.2 White 83 170 28.58 Yes 4.3742 0.0283 154.6520 0.0966 45.2667 3.4165 10-90th 
5384 Multip Male 273 3200 41 30 Oriental 55 160 21.48 no 6.3888 0.0532 120.0269 0.2681 23.8306 5.0367 10-90th 
5549 Nullip Male 295 4200 86 31.5 White 70 167.6 24.88 no 2.5119 0.1043 24.0920 0.3890 6.4571 3.7311 10-90th 
5557 Nullip Male 269 2680 10 41.4 White 64 156 26.3 no 3.4583 0.1255 27.5626 0.3294 10.4992 2.6252 10-90th 
5566 Multip Male 288 4050 84.3 40.2 White 108 175.3 35.18 no 2.9011 0.1027 28.2419 0.3141 9.2365 3.0576 10-90th 
6161 Multip Male 291 4080 82.9 43.3 White 72 175.3 23.33 no 2.4189 0.1270 19.0420 0.2734 8.8468 2.1524 10-90th 
6252 Multip Male 290 4682 99.2 23.1 White 112 170.2 38.7 no 6.2848 0.0863 72.8515 0.2590 24.2663 3.0022 >90th 
6350 Multip Male 280 4090 93.6 37.3 White 52 164 19.33 no 1.7041 0.0878 19.4006 0.2680 6.3576 3.0516 >90th 
6429 Multip Female 293 4114 82.9 37.6 White 71 172.7 23.81 no 3.2791 0.0978 33.5255 0.2817 11.6421 2.8797 10-90th 
6611 Multip Male 276 2752 6.6 26.2 White 45 154.9 18.75 no 3.4851 0.0770 45.2345 0.2033 17.1425 2.6387 <10th  
6674 Multip Female 262 2500 9.8 32.8 White 47 157.5 18.95 Yes 3.8315 0.1075 35.6468 0.2567 14.9247 2.3884 <10th  
6683 Multip Male 286 4370 96.8 30.4 White 71 167.6 25.2 no 3.7635 0.1128 33.3628 0.2541 14.8133 2.2522 >90th 
6762 Multip Male 294 4034 76.7 26 Asian 55 160 21.48 no 2.2559 0.1107 20.3844 0.2330 9.6802 2.1058 10-90th 
6781 Multip Female 281 4341 98 43.7 White 67 165 24.61 no 3.2795 0.0860 38.1465 0.2021 16.2239 2.3513 >90th 
6792 Multip Male 279 4140 95.5 35.7 White 60 165 22.04 no 2.5241 0.0774 32.6058 0.2042 12.3602 2.6380 >90th 
6797 Multip Male 293 4256 90 31.8 White 104 165.1 38.15 no N/A 0.1078 N/A 0.2520 N/A 2.3385 >90th 
6821 Multip Male 287 4076 86.7 29.2 White 69 171 23.6 no 2.6274 0.1073 24.4832 0.1872 14.0358 1.7443 10-90th 
8827 Multip Female 279 2550 1.6 29.2 White 52 157.5 20.96 no 1.8667 0.0634 29.4255 0.1869 9.9855 2.9468 <10th  
8953 Multip Male 294 4498 96.4 34.7 White 48 160 18.75 no 5.1042 0.1225 41.6817 0.3071 16.6219 2.5076 >90th 
9293 Multip Female 270 2602 6.2 37.8 White 66 170.2 22.78 no 3.8672 0.0976 39.6155 0.3405 11.3566 3.4883 <10th  
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9530 Multip Male 271 2494 3.1 38.8 White 66 164 24.54 no 4.4485 0.0869 51.2187 0.3118 14.2685 3.5896 <10th  
9721 Nullip Female 265 2174 1 40.9 White 61 170 21.11 no 2.8698 0.0799 35.9110 0.1889 15.1943 2.3634 <10th  
9874 Nullip Male 289 2412 0.2 36.6 White 53 154.9 22.13 no 4.1629 0.0725 57.4040 0.2204 18.8870 3.0393 <10th  
36458 Multip Female 273 2639 5.3 34.2 White 81 175.3 26.36 Yes 4.1668 0.1502 27.7361 0.2769 15.0495 1.8430 <10th  
71132 Nullip Female 274 2710 6.7 17.2 Black 55 166 19.96 no 4.7604 0.1105 43.0680 0.3161 15.0617 2.8594 <10th  
71740 Nullip Male 290 4586 98.5 35.5 White 71 171 24.28 no 4.1403 0.1068 38.7526 0.1940 21.3425 1.8157 >90th 
74016 Multip Female 287 4370 96.5 41.4 White 54 162.6 20.42 no 4.4185 0.1204 36.7121 0.3364 13.1355 2.7949 >90th 
74169 Multip Female 260 2740 30.3 37.3 White 56 154.9 23.34 no 2.8981 0.0964 30.0529 0.2837 10.2165 2.9416 10-90th 
74788 Nullip Female 271 2116 0.2 27.3 Oriental 54 165.1 19.81 no 1.6119 0.0698 23.1070 0.2384 6.7606 3.4179 <10th  
77253 Multip Female 277 4256 98.3 41 White 67 157.5 26.89 no 4.2318 0.0669 63.2143 0.1633 25.9120 2.4396 >90th 
77797 Multip Male 291 4820 99.6 32.3 White 79 162.6 29.88 no 8.1644 0.1414 57.7520 0.2980 27.3938 2.1082 >90th 
83552 Multip Female 289 2667 1.1 23.7 White 54 155 22.48 no 3.5012 0.1400 25.0025 0.3465 10.1030 2.4748 <10th  
A0178 Nullip Female 288 4320 95 36.3 White 74 167.6 26.17 no 4.3326 0.0870 49.7768 0.2442 17.7428 2.8055 >90th 
A0700 Nullip Male 293 2355 0.1 40.1 White 60 169 21.01 Yes 3.0125 0.0722 41.7403 0.2755 10.9357 3.8169 <10th  
A0712 Multip Female 263 4313 100 37.6 White 95 177.8 30.05 no 5.5059 0.0948 58.0836 0.2940 18.7272 3.1016 >90th 
A0747 Multip Female 267 2412 3.3 37.2 White 56 162.6 21.16 no 3.3959 0.0904 37.5488 0.2204 15.4086 2.4369 <10th  
A0801 Nullip Female 287 2752 2.3 40 White 60 162.6 22.69 Yes 2.7056 0.0899 30.0978 0.3892 6.9519 4.3294 <10th  
A0989 Multip Female 289 4360 95.4 40 White 64 162.6 24.21 no 5.3485 0.0994 53.8286 0.2908 18.3923 2.9267 >90th 
A1013 Multip Female 264 2667 16 41.8 White 79 170.2 27.27 no 4.4651 0.1042 42.8476 0.3777 11.8223 3.6243 10-90th 
A1125 Nullip Male 285 4300 95.9 35.9 White 63 171 21.55 no 4.4565 0.0979 45.5397 0.2686 16.5940 2.7443 >90th 
A1251 Multip Female 285 4512 98.8 37 White 75 162.6 28.37 no 4.8959 0.1183 41.3731 0.2757 17.7590 2.3297 >90th 
A1253 Multip Female 292 4380 94.6 35.2 White 68 162.6 25.72 no 3.7456 0.1032 36.3024 0.2184 17.1490 2.1169 >90th 
A1466 Nullip Male 279 2580 1.9 29.5 Asian 55 160 21.48 no 2.7935 0.0839 33.3060 0.2524 11.0663 3.0097 <10th  
A1467 Multip Male 271 2600 5.4 27.1 White 84 172.7 28.16 no 3.3562 0.1029 32.6060 0.2950 11.3784 2.8656 <10th  
A1694 Multip Female 286 4455 98 41 White 78 175.3 25.38 no 4.4002 0.0982 44.8212 0.3278 13.4249 3.3387 >90th 
A1786 Nullip Male 275 2506 2 40.5 White 40 159 15.82 no 2.6939 0.0673 40.0466 0.2819 9.5571 4.1903 <10th  
A1816 Nullip Female 291 2724 1.3 37.8 White 50 160 19.53 no 3.0864 0.0798 38.6731 0.2155 14.3219 2.7003 <10th  
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A2096 Nullip Female 288 2750 2 42.5 Asian 65 160 25.39 no 2.3595 0.0977 24.1620 0.3679 6.4129 3.7677 <10th  
A2098 Nullip Female 289 4654 99.1 43.4 White 77 170.2 26.58 no 3.1304 0.1037 30.1867 N/A N/A N/A >90th 
A2099 Multip Male 269 4540 100 42.5 White 83 160 32.42 Yes 3.2235 0.0883 36.4998 0.1931 16.6915 2.1867 >90th 
A2325 Nullip Male 298 4682 98.2 34.5 White 66 163 24.84 no 5.1648 0.1283 40.2448 0.2865 18.0293 2.2322 >90th 
A2345 Nullip Male 278 4313 98.5 35.4 White 74 167.6 26.34 Yes 3.7176 0.1342 27.6970 0.2551 14.5754 1.9003 >90th 
A2394 Multip Female 270 2667 8.4 29.4 White 55 157.5 22.17 Yes 3.1569 0.0969 32.5889 0.2749 11.4836 2.8379 <10th  
A2491 Multip Male 282 4272 96.7 29.4 White 63 152.4 27.13 no 4.4044 0.1347 32.6871 0.2996 14.7002 2.2236 >90th 
A2611 Multip Male 289 4427 96.8 38.3 White 88 160 34.38 no 5.3131 0.1221 43.5228 0.3003 17.6944 2.4597 >90th 
A2742 Multip Male 293 5022 99.9 26.8 White 68 167.6 24.21 no 2.6671 0.1059 25.1733 0.2051 13.0066 1.9354 >90th 
A2744 Nullip Female 265 2710 17.1 41.1 White 65 154.9 27.09 no 2.3195 0.0774 29.9625 0.3113 7.4502 4.0217 10-90th 
A3331 Multip Male 281 4360 98.3 31.4 White 75 162.6 28.37 no 3.7001 0.1273 29.0598 0.1996 18.5373 1.5676 >90th 
A3412 Multip Female 287 4341 95.9 41.3 White 75 175.3 24.41 no 4.6198 0.1129 40.9027 0.3225 14.3255 2.8552 >90th 
A3618 Nullip Male 265 2752 20 28.9 Oriental 67 168 23.74 no 3.3577 0.0921 36.4407 0.2686 12.5025 2.9147 10-90th 
A3633 Nullip Male 290 4380 95.5 39.9 White 95 167.6 33.82 no 3.5643 0.0977 36.4816 0.3546 10.0510 3.6296 >90th 
A3637 Nullip Female 279 2582 1.9 35 White 52 147.3 23.97 no 2.2260 0.0766 29.0481 N/A N/A N/A <10th  
A3731 Nullip Female 259 2150 2.1 41.2 Oriental 60 165.1 21.98 no 2.7607 0.1073 25.7323 0.2759 10.0058 2.5717 <10th  
A3741 Multip Male 281 4586 99.6 36.9 White 105 177.8 33.21 no 3.2537 0.1006 32.3566 0.3137 10.3705 3.1201 >90th 
A3946 Multip Female 277 4341 99 39.8 White 101 172.7 33.86 no 4.3168 0.1130 38.2090 0.3578 12.0665 3.1665 >90th 
A3956 Nullip Male 287 4500 98.3 38.5 White 97 170.2 33.49 no 5.6616 0.1664 34.0191 0.3630 15.5983 2.1809 >90th 
A4139 Nullip Male 289 4940 99.9 32 White 57 165.1 20.91 no 6.8767 0.1061 64.8191 0.2281 30.1472 2.1501 >90th 
A4240 Multip Female 283 2470 0.6 30.6 White 55 152.4 23.68 no 2.3353 0.1005 23.2307 0.3293 7.0915 3.2759 <10th  
A4241 Nullip Male 288 4400 96.6 36.3 White 91 180.3 27.99 Yes 4.4577 0.0957 46.5853 0.2786 16.0001 2.9116 >90th 
A4545 Nullip Female 282 2526 1 24.6 White 96 171 32.83 no 1.6318 0.0727 22.4382 0.2101 7.7650 2.8897 <10th  
A4876 Nullip Male 288 4914 99.9 31.1 White 74 175.3 24.08 no 6.5278 0.1277 51.1325 0.3071 21.2540 2.4058 >90th 
A5328 Multip Male 275 4385 99.5 39.5 White 89 167.6 31.68 no 5.2113 0.1020 51.0841 0.2986 17.4532 2.9269 >90th 
A5590 Multip Male 273 4398 99.7 37.3 White 86 167.6 30.54 no 5.8641 0.1034 56.6982 0.2482 23.6230 2.4001 >90th 
A5647 Multip Male 271 2696 8.6 41 White 98 167.6 34.89 Yes 1.7922 0.0652 27.4927 0.2416 7.4194 3.7055 <10th  
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A5655 Multip Male 280 4400 98.8 34 White 72 165.1 26.41 no 3.7962 0.1013 37.4606 0.2444 15.5300 2.4121 >90th 
A5775 Multip Female 279 2530 1.4 44.3 White 65 170 22.49 no 2.3171 0.0741 31.2659 0.2568 9.0234 3.4650 <10th  
A5795 Nullip Male 290 4345 94.6 35.3 White 70 172.7 23.47 no 5.9438 0.1048 56.7349 0.2690 22.0928 2.5680 >90th 
A5886 Multip Male 273 4800 100 33.5 Oriental 52 155 21.64 no 4.3882 0.0887 49.4838 0.2193 20.0101 2.4729 >90th 
A5920 Nullip Male 274 4341 99.4 17.7 White 75 177.8 23.69 no 7.5266 0.1114 67.5859 0.2036 36.9611 1.8286 >90th 
A6021 Multip Male 279 4290 98 38.9 White 66 172 22.14 no 7.1938 0.1374 52.3383 0.3039 23.6716 2.2110 >90th 
A6302 Multip Female 278 2611 2.6 31.4 White 57 152.4 24.54 no 3.0216 0.1025 29.4823 0.2898 10.4259 2.8278 <10th  
A6435 Nullip Female 273 2130 0.2 25.8 White 55 157.5 22.17 no 3.8766 N/A N/A 0.2990 12.9644 N/A <10th  
A7006 Multip Female 286 2740 2.3 40.2 White 82 173.8 27.15 no 2.6296 0.1213 21.6733 0.3150 8.3489 2.5959 <10th  
A7044 Nullip Male 300 4330 89.1 35.8 Black 82 164 30.49 no 6.4334 0.1268 50.7246 0.2979 21.5931 2.3491 10-90th 
A7272 Nullip Female 275 2724 6.4 19.6 Black 82 168 29.05 no 4.0098 0.1166 34.3917 0.3844 10.4320 3.2968 <10th  
A7380 Multip Male 286 4483 98.3 30.8 White 44 154.9 18.34 no 5.2126 0.1485 35.1046 0.3180 16.3928 2.1415 >90th 
A7549 Nullip Female 269 2354 1.7 33.3 White 54 165.1 19.81 no 3.2881 0.1212 27.1292 0.3326 9.8848 2.7445 <10th  
A7732 Multip Male 290 4852 99.7 40.8 White 74 170.2 25.55 no 3.6056 0.0755 47.7338 0.1479 24.3810 1.9578 >90th 
A7767 Nullip Male 281 2724 3.5 46 White 57 157.5 23.06 no 4.4249 0.1134 39.0226 0.3192 13.8622 2.8150 <10th  
A8186 Multip Male 284 4300 96.4 35.7 White 80 172 27.04 no 5.7246 0.1286 44.4996 0.3427 16.7035 2.6641 >90th 
A8314 Multip Male 284 2724 2.6 26 White 60 160 23.44 no 4.2365 0.1061 39.9115 0.3286 12.8939 3.0954 <10th  
A8315 Multip Male 283 4300 96.8 38.1 White 64 162.6 24.21 no 5.2470 0.1403 37.4065 0.1868 28.0826 1.3320 >90th 
A9235 Nullip Male 261 2164 1.7 24 Black 70 144.8 33.3 no 3.1133 0.1023 30.4322 0.2926 10.6416 2.8597 <10th  
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APPENDIX C – ANXA5 haplotypes of RM and control cohorts 
 
Early miscarriage patients 
 
No 
Lab  
ID Pregnancy 
Early  
Miscarriage 
Late 
Miscarriage 
Live 
Birth APLS FVL LAC 
ANXA5 
Female 
ANXA5 
Male 
1 17 4 3 0 1 NEG WT EQUIV ABN ABN  M1 WT 
2 130 3 3 0 0 NEG WT NEG WT WT 
3 141 5 4 0 1 NEG WT NEG EQUIV WT WT 
4 181 4 4 0 0 NEG WT ABN EQUIV NEG M2 M2* 
5 185 4 3 0 1 NEG POS WT ABN EQUIV NEG M1 WT 
6 227 7 6 0 1 NEG WT NEG WT WT 
7 247 6 6 0 0 NEG WT EQUIV WT M1* 
8 699 4 4 0 N/A NEG WT NEG WT WT 
9 951 N/A E 0 N/A POS N/A NEG M1/M2 WT 
10 1074 3 3 0 0 POS HET NEG WT M2 
11 1081 4 3 0 1 POS WT NEG M2 WT 
12 1098 3 3 0 0 POS WT ABN EQUIV POS WT WT 
13 1225 3 3 0 0 NEG POS WT NEG M1/M2 M1 
14 1255 N/A E 0 N/A POS WT NEG WT WT 
15 1291 N/A E 0 N/A NEG POS WT NEG M1 WT 
16 1299 3 3 0 0 NEG WT NEG WT WT 
17 1303 N/A E 0   POS WT NEG WT M1 
18 1306 5 5 0 0 NEG WT POS NEG POS WT WT 
19 1329 4 4 0 0 NEG POS WT NEG WT M2 
20 1349 5 4 0 1 NEG POS WT NEG WT WT 
21 1353 5 4 0 1 POS WT NEG M2 WT 
22 1364 3 3 0 0 POS WT NEG EQUIV WT WT 
23 1365 6 5 0 1 POS WT NEG M2 M2 
24 1367 4 4 0 0 NEG POS WT NEG M1 WT 
25 1401 3 3 0 0 N/A WT N/A WT M1 
26 1434 4 4 0 0 POS WT NEG WT WT 
27 1435 4 3 0 1 POS WT POS NEG EQUIV M2 WT 
28 1445 3 3 0 0 POS WT EQUIV CLO EQUIV WT WT 
29 1447 3 3 0 0 POS WT NEG WT WT 
30 1448 3 3 0 0 NEG POS WT NEG WT M2 
31 1459 3 3 0 0 NEG WT NEG M1 M2 
32 1482 6 6 0 0 NEG WT ABN NEG NEG  WT WT 
33 1485 3 3 0 0 POS WT NEG NEG EQUIV WT WT 
34 1492 3 3 0 0 POS WT ABN WT WT 
35 1494 N/A E 0 N/A POS WT NEG WT WT 
36 1496 3 3 0 0 NEG WT POS WT WT 
37 1505 4 3 0 1 NEG POS WT NEG M1 WT 
38 1507 3 3 0 0 POS WT ABN EQUIV M1 WT 
39 1510 3 3 0 0 NEG WT NEG M2 M1/M2 
40 1514 5 4 0 0 POS WT NEG WT M2 
41 1515 3 3 0 3 POS WT NEG M2 M2 
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ANXA5 
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42 1516 7 4 0 2 NEG POS WT EQUIV NEG M2 WT 
43 1517 6 4 0 1 POS WT NEG M1 WT 
44 1518 6 5 0 2 NEG POS WT NEG WT WT 
45 1523 6 4 0 2 NEG WT NEG WT WT 
46 1541 N/A E 0 N/A POS WT NEG WT WT 
47 1556 4 3 0 1 NEG WT NEG WT M1/M2 
48 1558 3 3 0 0 NEG HET NEG M2 M1 
49 1559 6 6 0 0 NEG WT NEG EQUIV NEG M2 M2 
50 1570 4 3 0 1 NEG WT NEG WT WT 
51 1572 3 3 0 0 NEG WT POS WT WT 
52 1576 5 4 0 1 POS WT NEG M2* WT 
53 1577 3 3 0 0 POS WT NEG WT WT 
54 1580 6 5 0 1 POS WT ABN ABN NEG WT M2 
55 1583 3 3 0 0 NEG WT NEG M2 M1 
56 1584 4 4 0 0 POS WT NEG POS M2 N/A 
57 1596 8 7 0 1 NEG WT EQUIV WT WT 
58 1597 N/A E 0 N/A NEG WT NEG WT M2* 
59 1600 10 10 0 0 NEG WT EQUIV EQUIV NEG WT M2 
60 1601 3 3 0 0 POS HET NEG WT M2 
61 1604 4 4 0 0 NEG POS WT NEG WT WT 
62 1606 3 3 0 0 POS WT NEG WT M1 
63 1615 N/A E 0 N/A POS WT NEG M1 M2 
64 1616 3 3 0 0 POS WT NEG WT M2 
65 1621 5 4 0 1 POS WT NEG M2 M2 
66 1625 11 10 0 1 NEG POS WT NEG M2 WT 
67 1631 3 3 0 0 NEG WT NEG WT WT 
68 1651 4 3 0 1 POS WT ABN ABN  WT M2* 
69 1663 5 4 0 1 POS WT NEG WT M1 
70 1680 9 8 0 1 NEG POS WT ABN NEG WT WT 
71 1681 3 3 0 0 NEG WT ABN NEG WT M2 
72 1719 4 3 0 1 NEG POS WT NEG WT M2 
73 1733 5 4 0 1 POS WT NEG WT WT 
74 1791 6 5 0 1 NEG POS WT NEG ABN M1 M2* 
75 1797 3 3 0 0 POS WT NEG WT WT 
76 1812 4 3 0 1 POS WT POS WT M2 
77 1822 3 3 0 0 NEG POS WT NEG M1 M2 
78 1857 3 3 0 0 NEG POS WT NEG WT WT 
79 1864 4 3 0 1 POS N/A NEG NEG POS M2 M1/M2 
80 1876 4 4 0 0 POS WT ABN NEG NEG  M2 WT 
81 1892 6 6 0 0 POS WT NEG M2 M2 
82 1899 4 3 0 1 POS WT NEG M1 M1 
83 1900 3 3 0 0 POS HET NEG WT WT 
84 1904 6 6 0 0 POS WT NEG WT M2 
85 1923 5 5 0 0 N/A WT N/A M2 M1 
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Live 
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ANXA5 
Female 
ANXA5 
Male 
86 1957 4 3 0 0 POS HET NEG WT M2 
87 1959 3 3 0 0 POS WT NEG EQUIV NEG WT WT 
88 1962 5 5 0 0 POS WT NEG WT WT 
89 1996 3 3 0 0 POS WT NEG M2 WT 
90 2002 4 3 0 0 POS WT NEG ABN WT M1 
91 2009 3 3 0 0 POS WT NEG EQUIV M1 WT 
92 2015 4 3 0 0 POS WT POS N/A N/A 
93 2017 8 8 0 0 NEG POS WT NEG WT WT 
94 2019 3 3 0 0 POS HET POS WT WT 
95 2356 N/A E 0 N/A POS WT ABN EQUIV WT WT 
96 2516 N/A E 0 N/A NEG WT NEG WT WT 
97 2740 N/A E 0 N/A NEG WT NEG M2 WT 
98 2796 N/A E 0 N/A NEG WT NEG WT WT 
99 2918 N/A E 0 N/A NEG WT NEG WT WT 
100 5427 4 4 0 0 NEG WT NEG WT WT 
101 5435 5 5 0 0 NEG WT NEG M2 WT 
102 5436 5 5 0 0 NEG WT NEG M2 WT 
103 5437 7 5 0 2 POS WT NEG M2 M2 
104 5442 6 5 0 1 N/A N/A NEG M2 M1 
105 5445 4 4 0 0 NEG N/A NEG M1 WT 
106 5446 3 3 0 0 POS WT NEG POS M2 M1 
107 5450 4 3 0 1 NEG WT NEG M1 WT 
108 5453 6 5 0 1 NEG WT NEG WT WT 
109 5461 6 5 0 1 NEG WT NEG POS NEG WT M1 
110 5466 5 5 0 0 NEG HET NEG M1* M2 
111 5469 10 9 0 1 NEG N/A NEG WT N/A 
112 5474 5 5 0 0 NEG WT NEG POS NEG WT WT 
113 5478 3 3 0 0 NEG WT NEG WT WT 
114 5486 7 7 0 0 NEG WT NEG M2 WT 
115 5493 4 4 0 0 POS WT NEG NEG ABN M1 WT 
116 5497 5 5 0 0 NEG WT NEG WT WT 
117 5498 5 5 0 0 NEG WT NEG WT WT 
118 5500 3 3 0 0 NEG WT NEG WT WT 
119 5501 3 3 0 0 NEG POS WT NEG WT WT 
120 5502 4 3 0 1 NEG WT POS N/A M2 
121 5504 5 5 0 0 NEG WT NEG WT WT 
122 5507 5 4 0 1 NEG N/A NEG M1/M2 WT 
123 5512 3 3 0 0 NEG WT N/A WT M2 
124 5514 9 8 0 1 POS WT NEG M2 M1/M2 
125 5515 5 3 0 2 NEG WT NEG WT M2 
126 5524 3 3 0 0 NEG WT NEG WT M2 
127 5528 7 5 0 2 NEG POS WT NEG WT WT 
128 5530 3 3 0 0 NEG WT NEG M1 WT 
129 5538 4 4 0 0 NEG POS WT NEG WT M2 
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130 5541 4 3 0 1 NEG WT NEG WT WT 
131 5545 3 3 0 0 NEG POS WT NEG N/A N/A 
132 5575 7 4 0 3 NEG N/A NEG WT WT 
133 5586 4 4 0 0 NEG POS WT NEG WT WT 
134 5602 5 3 0 2 NEG WT NEG WT WT 
135 5609 5 4 0 1 NEG N/A NEG WT WT 
136 5617 6 5 0 1 NEG POS WT NEG M2 WT 
137 5621 4 4 0 0 NEG WT POS NEG M1 WT 
138 5630 5 4 0 1 NEG WT N/A M2* WT 
139 5637 8 8 0 0 NEG WT POS M1 M2 
140 5638 8 7 0 1 NEG WT NEG WT M1/M2 
141 5641 4 4 0 0 NEG WT NEG M2 WT 
142 5642 5 4 0 1 NEG WT NEG M1 WT 
143 5648 7 7 0 0 NEG WT NEG M2 M2 
144 5658 3 3 0 0 NEG WT NEG M2* WT 
145 5685 4 3 0 1 NEG WT NEG WT WT 
146 5689 5 5 0 0 N/A N/A N/A WT WT 
147 5699 5 5 0 0 NEG WT NEG M1 M2 
148 5717 3 3 0 0 N/A N/A N/A WT WT 
149 5718 4 3 0 1 NEG WT NEG WT WT 
150 5723 4 3 0 1 NEG WT NEG M1 WT 
151 5728 5 4 0 1 NEG WT NEG NEG POS WT WT 
152 5729 5 3 0 2 NEG WT NEG WT M2 
153 5738 3 3 0 0 NEG N/A NEG WT WT 
154 5739 5 5 0 0 NEG WT NEG M2 WT 
155 5741 4 4 0 0 NEG WT POS WT WT 
156 5742 7 7 0 0 NEG WT NEG WT M1 
157 5755 5 3 0 2 NEG WT POS NEG NEG  M1* WT 
158 5775 4 4 0 0 NEG WT POS NEG WT M1 
159 5788 4 3 0 1 N/A N/A N/A WT WT 
160 5789 3 3 0 0 NEG HET NEG WT WT 
161 5790 4 3 0 1 NEG WT NEG M2* WT 
162 5792 5 4 0 1 POS WT NEG M1 M2 
163 5797 3 3 0 0 NEG WT POS WT WT 
164 5799 3 3 0 0 NEG WT NEG M2 WT 
165 5804 4 4 0 0 NEG WT N/A WT M2 
166 5812 3 3 0 0 NEG WT POS NEG M1 WT 
167 5816 6 5 0 1 NEG WT NEG M2 M2 
168 5822 7 7 0 0 NEG WT NEG WT WT 
169 5837 4 4 0 0 NEG POS WT NEG WT M2 
170 5840 4 3 0 1 POS WT NEG WT WT 
171 5841 4 3 0 1 N/A N/A N/A WT WT 
172 5847 5 4 0 1 NEG WT NEG M1 WT 
173 5848 3 3 0 0 NEG WT N/A WT WT 
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Female 
ANXA5 
Male 
174 5849 4 3 0 1 N/A N/A N/A M2 WT 
175 5858 6 5 0 1 NEG WT NEG M2 WT 
176 5860 5 5 0 0 NEG HET NEG M1 WT 
177 5864 4 4 0 0 NEG WT NEG WT M2 
178 5869 9 7 0 2 NEG WT NEG WT M2 
179 5871 4 3 0 1 NEG WT NEG WT WT 
180 5875 4 4 0 0 NEG WT NEG M2 WT 
181 5878 5 4 0 1 NEG WT NEG M2 WT 
182 5879 3 3 0 0 NEG WT NEG WT WT 
183 5882 5 5 0 0 NEG WT NEG M1 WT 
184 5885 4 3 0 1 NEG WT NEG WT M1/M2 
185 5889 11 10 0 1 NEG N/A NEG M1 WT 
186 5896 6 6 0 0 NEG WT NEG WT WT 
187 5907 6 5 0 1 NEG WT N/A WT M1 
188 5909 6 4 0 2 NEG WT NEG M2 M2 
189 5925 4 4 0 0 NEG WT NEG POS NEG M2 M1/M2 
190 5928 5 5 0 0 NEG WT POS NEG N/A WT 
191 5937 8 7 0 1 NEG WT NEG WT WT 
192 5938 3 3 0 0 NEG WT NEG M2 M2 
193 5939 3 3 0 0 NEG WT POS NEG NEG  WT WT 
194 5940 11 9 0 2 NEG N/A NEG WT WT 
195 5941 4 4 0 0 NEG WT POS NEG NEG  WT M2 
196 5948 4 4 0 0 NEG WT NEG WT WT 
197 5949 3 3 0 0 NEG POS WT NEG M2 M2 
198 5950 6 3 0 3 NEG WT POS NEG POS M1 WT 
199 5953 5 5 0 0 NEG WT NEG POS NEG WT WT 
200 5954 4 4 0 0 NEG POS WT NEG M1 WT 
201 5960 4 4 0 0 NEG WT NEG M2 M2 
202 5961 5 5 0 0 NEG WT NEG M2 M1/M2 
203 5967 5 4 0 1 POS WT NEG M2* WT 
204 5977 3 3 0 0 POS WT NEG M2 M2 
205 5979 6 5 0 1 NEG WT NEG M1 WT 
206 5985 5 4 0 1 NEG WT NEG M2 WT 
207 5987 5 5 0 0 NEG WT POS WT WT 
208 5988 8 7 0 1 NEG WT NEG WT WT 
209 5989 4 4 0 0 NEG WT NEG WT M2 
210 5991 4 4 0 0 NEG WT NEG M1/M2 WT 
211 5998 5 4 0 1 NEG POS WT NEG WT WT 
212 5999 4 4 0 0 NEG WT NEG WT WT 
213 6002 6 5 0 1 NEG WT NEG WT M1/M2 
214 6003 3 3 0 0 NEG WT NEG WT M2 
215 6004 3 3 0 0 NEG WT NEG WT M1 
216 6007 9 9 0 0 NEG WT POS M2 M1 
217 6008 14 14 0 0 NEG POS WT POS NEG NEG  WT WT 
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218 6009 5 5 0 0 NEG POS WT NEG M1 WT 
219 6011 4 4 0 0 NEG WT NEG WT WT 
220 6014 3 3 0 0 NEG WT NEG WT M2 
221 6016 4 3 0 1 NEG WT NEG M1 WT 
22 6020 3 3 0 0 POS WT POS NEG NEG  M1 WT 
223 6030 6 4 0 2 NEG POS WT NEG WT WT 
224 6034 8 8 0 0 NEG N/A NEG M1 WT 
225 6035 7 6 0 1 NEG WT NEG WT WT 
226 6036 3 3 0 0 NEG WT NEG WT M1 
227 6037 4 3 0 1 NEG WT NEG WT WT 
228 6038 3 3 0 0 NEG WT NEG WT WT 
229 6039 6 4 0 2 NEG WT NEG WT  N/A 
230 6042 6 6 0 0 NEG WT NEG WT WT 
231 6043 6 5 0 1 NEG POS N/A NEG WT WT 
232 6050 6 5 0 1 NEG WT NEG M1 WT 
233 6051 8 7 0 1 NEG WT NEG WT M2 
234 6061 3 3 0 0 NEG WT NEG WT WT 
235 6063 4 4 0 0 NEG N/A NEG M2 WT 
236 6066 3 3 0 0 NEG POS WT NEG WT M2 
237 6068 4 4 0 0 NEG WT NEG WT WT 
238 6077 3 3 0 0 NEG WT NEG M1/M2 M2 
239 6081 3 3 0 0 NEG WT NEG M1 WT 
240 6083 6 6 0 0 NEG WT NEG WT WT 
241 6084 6 6 0 0 NEG WT NEG WT M1/M2 
242 6086 6 5 0 1 POS WT NEG M2 WT 
243 6087 4 4 0 0 NEG WT NEG WT WT 
244 6089 5 4 0 1 NEG POS N/A NEG WT WT 
245 6096 3 3 0 0 NEG WT NEG M1* M1/M2 
246 6097 4 3 0 1 NEG N/A NEG M2 M1 
247 6101 3 3 0 0 NEG WT N/A WT WT 
248 6102 4 3 0 1 NEG WT NEG WT WT 
249 6106 6 5 0 1 NEG N/A NEG M1 WT 
250 6111 3 3 0 0 N/A N/A N/A WT WT 
251 6116 3 3 0 0 NEG WT NEG WT M1 
252 6119 4 3 0 1 NEG WT N/A WT WT 
253 6123 4 3 0 1 NEG POS WT NEG WT WT 
254 6124 6 6 0 0 NEG WT POS NEG NEG  WT WT 
255 6127 4 3 0 1 NEG POS WT NEG POS  WT WT 
256 6138 4 4 0 0 NEG POS WT NEG M2 WT 
257 6139 5 5 0 0 NEG WT NEG WT M2 
258 6140 3 3 0 0 NEG WT NEG WT WT 
259 6141 3 3 0 0 NEG WT NEG WT WT 
260 6147 6 5 0 1 NEG WT NEG WT M2 
261 6149 4 4 0 0 NEG POS WT POS WT WT 
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262 6160 4 3 0 1 NEG WT NEG M1 M2 
263 6163 4 3 0 1 NEG WT NEG M1 M2 
264 6166 7 6 0 1 NEG WT NEG WT M2* 
265 6171 4 3 0 1 NEG N/A POS NEG WT WT 
266 6183 3 3 0 0 NEG POS HET NEG WT WT 
267 6184 4 3 0 1 NEG WT NEG WT WT 
268 6188 4 4 0 0 NEG WT NEG WT N/A 
269 6191 4 3 0 1 NEG WT NEG M1 M2 
270 6193 3 3 0 0 NEG WT NEG WT WT 
271 6201 4 4 0 0 NEG WT NEG WT M2 
272 6204 3 3 0 0 NEG WT NEG M1 WT 
273 6206 6 5 0 1 NEG WT NEG M2 WT 
274 6208 5 4 0 1 NEG WT NEG WT WT 
275 6219 4 3 0 1 NEG WT NEG WT M1 
276 6220 4 3 0 1 NEG WT NEG WT WT 
277 6224 5 5 0 0 NEG WT NEG WT WT 
278 6231 5 4 0 1 NEG WT NEG M2 M2* 
279 6370 4 4 0 0 NEG WT NEG M2 WT 
280 6373 5 5 0 0 NEG WT NEG POS NEG WT WT 
281 6376 5 5 0 0 NEG WT NEG M2 M2 
282 6378 8 7 0 1 NEG WT NEG M2 WT 
283 6381 3 3 0 0 NEG WT NEG WT WT 
284 6383 5 5 0 0 NEG WT NEG M2 WT 
285 6385 6 6 0 0 NEG POS WT N/A WT M1 
286 6387 5 5 0 0 NEG WT NEG M2 WT 
287 6390 3 3 0 0 NEG WT NEG M1 M1 
288 6391 5 5 0 0 NEG WT NEG M2 M2 
289 6396 4 4 0 0 NEG WT NEG M2 N/A 
290 6399 3 3 0 0 NEG WT NEG M2 M2 
291 6404 4 4 0 0 NEG WT POS WT M1/M2 
292 6410 3 3 0 0 NEG N/A NEG M1/M2 WT 
293 6417 8 7 0 1 NEG WT NEG WT WT 
294 6423 5 4 0 1 NEG WT NEG WT M1 
295 6426 6 6 0 0 NEG WT NEG WT WT 
296 6428 4 4 0 0 NEG WT NEG WT WT 
297 6430 3 3 0 0 NEG WT NEG M1 WT 
298 6434 4 3 0 1 NEG WT NEG WT WT 
299 6438 3 3 0 0 NEG N/A NEG WT WT 
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Late miscarriage patients 
 
No 
Lab  
ID Pregnancy 
Early  
Miscarriage 
Late  
Miscarriage 
Live 
Birth APLS FVL LAC 
ANXA5 
Female 
ANXA5  
Male 
1 222 6 5 1 0 NEG WT EQUIV NEG POS WT WT 
2 235 N/A N/A L N/A NEG WT EQUIV EQUIV NEG WT WT 
3 315 N/A N/A L N/A POS WT EQUIV EQUIV WT WT 
4 324 3 1 1 1 NEG POS HOMO NEG M1 WT 
5 344 N/A N/A L N/A NEG WT NEG WT WT 
6 524 N/A N/A L N/A N/A WT NEG M2 M1 
7 620 2 N/A 2 0 NEG POS WT NEG NEG ABN N/A N/A 
8 626 N/A N/A L N/A POS WT POS M1* M2 
9 628 N/A N/A L N/A POS HET NEG EQUIV EQUIV WT M1 
10 631 3 2 1 0 POS WT NEG WT M2 
11 636 N/A N/A L N/A NEG POS WT NEG WT WT 
12 641 7 3 4 0 NEG WT NEG POS ABN M1 M2* 
13 664 1 N/A 1 0 NEG HET NEG WT WT 
14 681 N/A N/A L N/A NEG WT NEG M2 WT 
15 682 N/A N/A L N/A NEG WT NEG ABN M1 WT 
16 706 4 2 1 1 N/A WT N/A M2 WT 
17 718 3 1 1 1 N/A WT NEG M1/M2 WT 
18 735 7 4 2 1 NEG WT NEG ABN M1 WT 
19 748 2 1 1 0 NEG WT ABN NEG M1/M2 WT 
20 785 N/A N/A L N/A NEG WT NEG WT M2 
21 818 N/A N/A L N/A POS WT POS M1 WT 
22 845 N/A N/A L N/A NEG WT NEG EQUIV WT WT 
23 848 3 N/A 3 0 NEG WT NEG M2* M1 
24 876 6 4 1 1 NEG WT NEG WT WT 
25 896 1 N/A 1 0 NEG POS WT NEG M2 M2 
26 987 N/A N/A L N/A NEG POS WT NEG WT WT 
27 1001 9 8 1 0 POS HET EQUIV M1 WT 
28 1022 5 2 2 1 NEG POS WT ABN POS WT WT 
29 1023 4 2 2 0 NEG POS WT NEG WT WT 
30 1079 N/A N/A L N/A NEG HET NEG WT WT 
31 1097 N/A N/A L N/A NEG WT EQUIV NEG NEG WT WT 
32 1195 3 2 1 0 POS WT NEG M2 WT 
33 1210 N/A N/A L N/A POS WT POS NEG POS WT WT 
34 1227 N/A N/A L N/A POS WT EQUIV NEG M1 WT 
35 1379 N/A N/A L N/A POS WT ABN POS WT M1 
36 1389 N/A N/A L N/A POS WT POS WT M2 
37 1409 N/A N/A L N/A NEG HET NEG M2 M1 
38 1410 5 3 1 1 N/A WT N/A WT WT 
39 1440 2 N/A 2 0 POS WT NEG M1 WT 
40 1458 N/A N/A L N/A N/A N/A N/A WT WT 
41 1478 2 1 1 0 NEG POS WT EQUIV NEG WT WT 
42 1479 N/A N/A L N/A NEG POS WT ABN POS ABN WT WT 
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43 1480 N/A N/A L N/A NEG WT NEG M1 WT 
44 1481 N/A N/A L N/A NEG WT ABN EQUIV WT M1 
45 1484 5 1 3 1 POS WT POS M1 WT 
46 1497 N/A N/A L N/A POS WT NEG M1 M2 
47 1509 3 1 2 0 NEG WT NEG M1 WT 
48 1519 3 1 2 0 NEG WT NEG WT WT 
49 1530 N/A N/A L N/A POS WT EQUIV NEG WT WT 
50 1532 N/A N/A L N/A NEG WT NEG WT WT 
51 1551 N/A N/A L N/A NEG WT EQUIV NEG WT M1 
52 1591 2 N/A 2 0 POS WT NEG WT WT 
53 1602 N/A N/A L N/A NEG POS WT ABN WT WT 
54 1623 2 1 1 0 POS WT NEG WT WT 
55 1624 N/A N/A L N/A POS WT NEG. ABN WT M1 
56 1626 N/A N/A L N/A NEG WT NEG EQUIV NEG WT M2 
57 1645 N/A N/A L N/A NEG POS WT EQUIV WT WT 
58 1648 N/A N/A L N/A NEG POS WT NEG M1 WT 
59 1667 N/A N/A L N/A NEG POS WT NEG NEG ABN WT WT 
60 1670 5 3 1 1 POS WT EQUIV POS WT M2 
61 1679 4 3 1 0 NEG WT NEG WT M2 
62 1684 N/A N/A L N/A POS WT POS WT WT 
63 1701 N/A N/A L N/A NEG POS WT NEG ABN WT WT 
64 1716 N/A N/A L N/A POS WT POS NEG POS M1 M1 
65 1725 5 2 1 2 POS WT ABN NEG WT WT 
66 1747 N/A N/A L N/A POS WT NEG M2* WT 
67 1753 N/A N/A L N/A POS WT POS NEG POS WT WT 
68 1755 4 2 1 1 NEG WT NEG WT WT 
69 1800 5 2 2 1 NEG POS WT POS WT M2 
70 1816 4 2 1 1 POS WT ABN NEG M2 WT 
71 1826 N/A N/A L N/A POS WT POS M1* M1 
72 1827 6 2 2 2 N/A N/A EQUIV EQUIV POS WT M2 
73 1833 N/A N/A L N/A POS N/A NEG WT WT 
74 1880 4 2 1 1 POS WT NEG M1 M2* 
75 1893 N/A N/A L N/A POS WT POS ABN WT M1 
76 1915 4 3 1 0 POS WT NEG M2 WT 
77 1916 N/A N/A N/A N/A POS WT POS NEG NEG WT WT 
78 1928 4 2 2 0 POS N/A NEG WT WT 
79 1942 4 2 2 0 NEG WT NEG EQUIV M2 M1 
80 1949 3 2 1 0 POS WT NEG WT M1/M2 
81 1954 N/A N/A L N/A NEG WT ABN ABN WT M2 
82 1963 7 5 1 1 POS WT NEG NEG EQUIV M2 M2 
83 1970 N/A N/A L N/A POS WT ABN WT WT 
84 2031 N/A N/A L N/A POS WT EQUIV POS NEG M1 WT 
85 2095 N/A N/A L N/A NEG POS WT NEG WT M1 
86 2098 N/A N/A L N/A POS WT NEG WT M1 
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87 2099 N/A N/A L N/A POS WT ABN WT WT 
88 2164 N/A N/A L N/A NEG POS WT ABN POS WT WT 
89 2174 N/A N/A L N/A N/A N/A N/A WT WT 
90 2209 N/A N/A L N/A POS WT NEG M2 WT 
91 2234 N/A N/A L N/A NEG POS HET NEG ABN WT WT 
92 2283 N/A N/A L N/A POS HET NEG M2 M2 
93 2439 N/A N/A L N/A POS WT NEG WT WT 
94 2512 N/A N/A L N/A NEG POS WT NEG WT WT 
95 2856 N/A N/A L N/A NEG WT NEG WT M1 
96 3213 N/A N/A L N/A N/A WT N/A M1 WT 
97 3261 N/A N/A L N/A N/A N/A N/A M1* WT 
98 3401 N/A N/A L N/A POS WT POS NEG M1 M1 
99 4552 2 1 1 0 NEG WT NEG M2 WT 
100 4565 N/A N/A N/A 1SB POS N/A POS WT WT 
101 4568 4 3 1 0 NEG WT NEG WT M1 
102 4573 4 3 1 0 NEG WT NEG M1 WT 
103 4883 N/A N/A N/A 1SB NEG N/A NEG WT M1* 
104 3504 N/A N/A L N/A NEG HET NEG WT N/A 
105 3747 N/A E L 0 NEG WT NEG ABN NEG WT M2 
106 3761 2 0 2 0 NEG WT NEG N/A WT 
107 3792 N/A E L N/A NEG WT EQUIV NEG POS WT WT 
108 3793 N/A E L N/A NEG WT EQUIV EQUIV M1 M2 
109 3837 N/A N/A L N/A NEG N/A NEG WT M1 
110 3839 N/A E L N/A NEG WT POS WT M2 
111 3840 N/A E L N/A NEG WT NEG M1 N/A 
112 3878 N/A E L N/A POS WT NEG WT M1 
113 3885 2 1 1 0 POS WT ABN EQUIV EQUIV WT M2* 
114 3971 4 2 2 0 NEG WT NEG WT M2 
115 3988 3 2 1 0 NEG WT ABN NEG NEG  WT M1 
116 3995 6 4 2 0 NEG WT NEG M2 M2 
117 4002 3 1 2 0 NEG WT EQUIV POS M2 WT 
118 4003 8 2 5 1 NEG WT EQUIV WT M2 
119 4019 3 2 1 0 NEG WT NEG WT WT 
120 4070 2 1 1 0 NEG WT NEG WT WT 
121 4119 4 3 1 0 NEG WT ABN WT WT 
122 4120 2 1 1 0 NEG POS WT N/A M2 N/A 
123 4180 3 2 1 0 NEG WT ABN NEG NEG  M2 WT 
124 4328 10 7 1 2 NEG WT NEG WT WT 
125 4330 3 1 1 1 NEG WT NEG M2 WT 
126 4375 4 3 1 0 NEG POS WT NEG WT M2 
127 4398 4 2 1 1 NEG POS WT NEG WT M1 
128 4411 5 3 1 1 NEG HET NEG WT M1 
129 4444 7 5 1 1 NEG WT NEG WT WT 
130 4445 4 3 1 0 NEG WT EQUIV EQUIV WT WT 
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131 4456 5 3 1 1 NEG WT NEG M1 M2 
132 4511 4 3 1 0 NEG WT NEG M2 WT 
133 4518 4 3 1 0 NEG WT NEG WT WT 
134 4525 5 0 4 1 NEG WT NEG EQUIV POS M1 M1 
135 4528 8 5 2 1 NEG WT NEG WT M1 
136 4535 4 2 1 1 NEG WT NEG M1 M2 
137 4596 3 2 1 0 NEG N/A EQUIV WT WT 
138 4655 3 2 1 0 NEG WT ABN NEG NEG  M1 WT 
139 4675 4 1 2 1 NEG WT N/A WT WT 
140 4682 3 0 2 1 NEG WT POS WT WT 
141 4693 6 4 1 1SB POS WT POS M1 WT 
142 4717 6 4 1 1 NEG WT NEG WT WT 
143 4719 7 5 1 1 NEG WT NEG WT WT 
144 4720 6 4 1 1 NEG WT NEG WT WT 
145 4725 4 3 1 0 NEG POS WT N/A WT WT 
146 4761 3 2 1 0 NEG WT POS NEG NEG WT M2 
147 4796 5 3 1 1 NEG N/A NEG M1 WT 
148 4823 6 4 2 0 N/A N/A N/A WT WT 
149 4855 5 2 1 2 NEG WT NEG M1 WT 
150 4917 5 0 3 2 NEG WT NEG M2 WT 
151 4951 6 4 1 1 POS WT NEG M2 M1 
152 4982 13 6 5 2 NEG N/A NEG WT WT 
153 4996 5 2 2 1 N/A N/A N/A M2 M2 
154 5014 4 1 2 1 NEG WT NEG M2 WT 
155 5159 4 1 2 1 NEG WT NEG WT M2 
156 5182 5 3 1 1 NEG WT NEG M1 WT 
157 5214 8 5 1 2 NEG WT NEG M1 WT 
158 5248 4 3 1 0 NEG WT NEG M2 N/A 
159 5332 3 2 1 0 NEG WT NEG WT WT 
160 5422 4 1 2 1 NEG WT NEG WT M2 
161 5424 7 5 1 1 NEG WT NEG M1 WT 
162 5475 4 1 1 2 NEG WT NEG WT M1 
163 5479 12 5 3 4 NEG WT NEG M1 WT 
164 5480 4 2 1 1 NEG WT NEG WT WT 
165 5516 4 2 1 1 NEG WT NEG M2 WT 
166 5531 6 5 1 0 NEG WT NEG NEG POS NEG WT WT 
167 5612 3 1 2 0 NEG WT NEG WT M2 
168 5631 5 0 3 2 N/A N/A N/A M2 WT 
169 5645 N/A N/A 1 N/A NEG WT POS NEG M2 M2 
170 5646 8 5 2 1 NEG WT NEG WT WT 
171 5740 3 2 1 0 NEG WT NEG M1 WT 
172 5749 5 2 1 2 NEG HET NEG WT M2 
173 5753 6 4 1 1 NEG WT NEG WT M1 
174 5811 2 1 1 0 N/A WT N/A M1 M1 
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175 5846 3 0 3 0 NEG WT NEG WT WT 
176 5890 12 10 1 1 NEG WT POS NEG POS WT WT 
177 5969 4 2 1 1 NEG WT NEG M2 M1 
178 6044 5 1 3 1 NEG POS   NEG WT M2 
179 6076 2 0 1 1 NEG WT NEG WT N/A 
180 6090 3 2 0 1SB NEG WT NEG WT WT 
181 6095 5 4 1 0 NEG POS WT NEG WT WT 
182 6144 6 4 1 1 NEG WT NEG M2 WT 
183 6177 7 4 1 2 NEG WT NEG M2 M1 
184 6182 1 0 1 0 POS WT NEG WT WT 
185 6205 3 2 1 0 NEG WT NEG WT WT 
186 6218 4 3 1 0 NEG WT NEG WT WT 
187 6221 4 3 1 0 NEG WT NEG WT WT 
188 6413 3 2 1 0 NEG WT NEG M1 M2 
189 6437 10 2 5 3 NEG N/A NEG WT WT 
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Moore control cohort 
 
No 
Lab  
ID Pregnancy 
Early 
Miscarriage 
Late 
Miscarriage 
Live 
Birth 
ANXA5 
Female 
ANXA5 
Male 
ANXA5 
Placenta Gender 
1 1 2 0 0 2 M2 WT M2 M 
2 3 1 0 0 1 WT M2 M2 F 
3 5 2 0 0 2 WT M2 M2 M 
4 7 1 0 0 1 WT WT WT F 
5 8 1 0 0 1 WT WT WT M 
6 9 2 0 0 2 WT M1 M1 M 
7 10 1 0 0 1 WT WT WT F 
8 11 1 0 0 1 M1 M2 WT F 
9 14 1 0 0 1 WT M1 M1 M 
10 16 1 0 0 1 WT WT WT M 
11 18 1 0 0 1 WT WT WT F 
12 19 1 0 0 1 WT WT WT M 
13 20 1 0 0 1 WT WT WT M 
14 21 1 0 0 1 WT WT WT F 
15 22 2 0 0 2 M1* M1 M1 M 
16 24 3 0 0 3 M1 WT M1 M 
17 25 1 0 0 1 WT M1 M1 M 
18 26 1 0 0 1 M2 M2 M2* F 
19 38 1 0 0 1 M1 M1 M1 M 
20 39 1 0 0 1 M2 WT M2 F 
21 40 1 0 0 1 WT WT WT M 
22 43 1 0 0 1 WT WT WT M 
23 47 1 0 0 1 WT WT WT F 
24 48 1 0 0 1 WT M1 M1 F 
25 49 1 0 0 1 WT WT WT M 
26 54 1 0 0 1 WT M2 M2 M 
27 57 1 0 0 1 M2 WT M2 M 
28 58 2 0 0 2 WT M2 WT F 
29 64 2 0 0 2 M2 M2 M2 M 
30 66 1 0 0 1 WT M1 M1 F 
31 67 2 0 0 2 WT WT WT M 
32 74 1 0 0 1 WT M2 WT M 
33 79 1 0 0 1 WT M1 M1 F 
34 81 1 0 0 1 WT M2 WT F 
35 82 2 0 0 2 WT WT WT M 
36 83 1 0 0 1 WT M1 M1 F 
37 86 2 0 0 2 WT WT WT F 
38 89 3 0 0 3 WT WT WT M 
39 90 1 0 0 1 WT WT WT M 
40 92 1 0 0 1 WT WT WT F 
41 93 1 0 0 1 WT WT WT F 
42 94 2 0 0 2 M1 M2 M1/M2 M 
43 95 2 0 0 2 M2 WT WT M 
44 96 1 0 0 1 WT WT WT M 
45 97 1 0 0 1 WT WT WT F 
46 100 1 0 0 1 WT WT WT M 
47 102 1 0 0 1 WT M2 M2 M 
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48 106 2 0 0 2 WT M1 M1 F 
49 108 2 0 0 2 WT M1/M2 M2 M 
50 109 1 0 0 1 WT WT WT F 
51 110 1 0 0 1 WT WT WT M 
52 111 3 0 0 3 WT M1 WT F 
53 113 2 0 0 2 WT M1 WT M 
54 115 2 0 0 2 WT WT WT M 
55 117 2 0 0 2 WT WT WT M 
56 118 3 0 0 3 WT WT WT F 
57 119 1 0 0 1 M1 WT M1 M 
58 122 1 0 0 1 WT WT WT F 
59 123 3 0 0 3 WT M2 M2 M 
60 126 1 0 0 1 WT WT WT F 
61 127 3 0 0 3 M1* WT M1 M 
62 129 2 0 0 2 WT WT WT M 
63 131 1 0 0 1 M1* M1 M1* M 
64 134 1 0 0 1 WT M2 WT F 
65 143 1 0 0 1 WT WT WT M 
66 145 1 0 0 1 WT WT WT F 
67 149 2 0 0 2 M2 M1 M1/M2 M 
68 154 2 0 0 2 WT WT WT F 
69 156 1 0 0 1 WT M1 WT M 
70 157 2 0 0 2 M1 WT WT M 
71 158 2 0 0 2 M2* WT M2 F 
72 161 3 0 0 3 M2 WT WT M 
73 162 3 0 0 3 M1* WT M1 F 
74 167 1 0 0 1 WT WT WT M 
75 169 2 0 0 2 M1 WT M1 M 
76 170 2 0 0 2 M1 WT M1 M 
77 176 1 0 0 1 WT WT WT F 
78 178 2 0 0 2 WT WT WT F 
79 179 2 0 0 2 M2 WT M2 F 
80 185 1 0 0 1 M2 WT M2 M 
81 186 2 0 0 2 WT WT WT F 
82 191 2 0 0 2 WT WT WT F 
83 192 2 0 0 2 WT WT WT M 
84 194 2 0 0 2 WT M1 M1 M 
85 197 1 0 0 1 WT M1 M1 M 
86 198 1 0 0 1 WT M1 M1 M 
87 199 2 0 0 2 M1 M1 WT F 
88 200 2 0 0 2 WT M1 M1 M 
89 201 1 0 0 1 WT WT WT M 
90 202 1 0 0 1 WT WT WT M 
91 205 3 0 0 3 WT WT WT F 
92 211 3 0 0 3 WT WT WT F 
93 222 2 0 0 2 WT WT WT M 
94 223 2 0 0 2 WT M2 WT F 
95 224 1 0 0 1 WT WT WT M 
96 228 3 0 0 3 WT WT WT F 
97 240 1 0 0 1 WT WT WT F 
98 243 1 0 0 1 M1 WT M1 F 
99 245 1 0 0 1 WT WT WT M 
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Male 
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100 249 3 0 0 3 M1 WT WT M 
101 250 4 0 0 4 WT WT WT M 
102 251 3 0 0 3 WT WT WT F 
103 252 2 0 0 2 M1 WT M1 F 
104 253 2 0 0 2 WT M2 WT F 
105 257 1 0 0 1 M2 WT M2 M 
106 260 1 0 0 1 WT M1 M1 M 
107 262 1 0 0 1 WT WT WT M 
108 264 1 0 0 1 M1 WT M1 M 
109 268 3 0 0 3 WT WT WT F 
110 269 2 0 0 2 WT WT WT F 
111 273 1 0 0 1 WT M1 WT F 
112 274 1 0 0 1 M2 M1 M1 M 
113 275 1 0 0 1 M1 M1 M1 F 
114 276 2 0 0 2 WT M1 WT F 
115 283 1 0 0 1 WT WT WT M 
116 287 2 0 0 2 M1* WT M1 F 
117 288 1 0 0 1 WT M1 WT M 
118 289 1 0 0 1 WT M2 M2 M 
119 290 1 0 0 1 M2 M2 M2* M 
120 291 1 0 0 1 WT WT WT M 
121 294 1 0 0 1 M2 WT M2 F 
122 295 1 0 0 1 WT WT WT M 
123 304 1 0 0 1 WT WT WT F 
124 306 1 0 0 1 WT WT WT M 
125 307 3 0 0 3 M2 WT M2 M 
126 308 1 0 0 1 WT WT WT F 
127 N03 1 0 0 1 M1 WT M1 F 
128 N07 1 0 0 1 WT WT WT M 
129 N13 2 0 0 2 WT M1 M1 F 
130 N15 1 0 0 1 WT WT WT F 
131 N18 4 0 0 4 WT WT WT M 
132 N25 2 0 0 2 WT WT WT F 
133 N26 3 0 0 3 M2 WT M2 M 
134 N29 2 0 0 2 M2 M2 M2 F 
135 N30 1 0 0 1 WT WT WT M 
136 N32 1 0 0 1 M2 WT M2 F 
137 N33 3 0 0 3 M2 WT M2 M 
138 N43 2 0 0 2 M1 M1 WT F 
139 N47 1 0 0 1 WT M2 M2 M 
140 N50 3 0 0 3 M2* WT M2 F 
141 N51 2 0 0 2 WT WT WT M 
142 N58 1 0 0 1 WT WT M1 F 
143 N59 2 0 0 2 M2 WT M2 F 
144 N61 1 0 0 1 WT M1* M1 M 
145 N65 2 0 0 2 M2 M2 M2 F 
146 N69 2 0 0 2 M1/M2 WT M2 M 
147 N71 2 0 0 2 M1 M1 M1 F 
148 N75 1 0 0 1 WT WT WT M 
149 b00250 2 0 0 2 WT M2 WT M 
150 b00251 1 0 0 1 WT WT WT M 
151 b00293 1 0 0 1 WT WT WT F 
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152 b00296 1 0 0 1 WT M1 WT M 
153 b00302 3 0 0 3 M1 WT WT F  
154 b00371 1 0 0 1 M1 M2 M1 M 
155 b00375 1 0 0 1 M1 WT M1 F 
156 b00376 1 0 0 1 WT WT WT M 
157 b00391 1 0 0 1 WT WT WT M 
158 b00392 2 0 0 2 WT WT WT M 
159 b00399 2 0 0 2 M2* M2 M2* M 
160 b00400 1 0 0 1 M1 M1 M1 F 
161 b00401 1 0 0 1 WT M2 WT F 
162 b00402 3 0 0 3 WT WT WT M 
163 b00480 2 0 0 2 WT WT WT F 
164 b00482 1 0 0 1 WT WT WT M 
165 b00483 1 0 0 1 WT WT WT F 
166 b00486 1 0 0 1 WT M2 M2 F 
167 b00563 1 0 0 1 M2* WT M2 F 
168 b00571 2 0 0 2 WT WT WT M 
169 b00573 2 0 0 2 M2 WT M2 M 
170 b00578 1 0 0 1 WT M2 M2 F 
171 b00581 1 0 0 1 M2 WT M2 F 
172 b00582 2 0 0 2 WT M2 M2 F 
173 b00589 1 0 0 1 WT WT WT M 
174 b00590 1 0 0 1 M2 M2 M2* M 
175 b00593 2 0 0 2 M2 WT WT M 
176 b00701 1 0 0 1 M1 WT M1 F 
177 b00708 1 0 0 1 WT M1 WT M 
178 b00742 1 0 0 1 WT WT WT F 
179 b00794 1 0 0 1 WT WT WT M 
180 b00802 1 0 0 1 M1 WT M1 F 
181 b00806 2 0 0 2 WT WT WT F 
182 b00808 1 0 0 1 WT WT WT M 
183 b00844 1 0 0 1 WT M2 WT M 
184 b00847 2 0 0 2 M2 WT M2 M 
185 b00850 2 0 0 2 WT WT WT M 
186 b00913 3 0 0 3 WT WT WT F 
187 b00948 2 0 0 2 WT M2 WT M 
188 b00952 3 0 0 3 WT WT WT F 
189 b00955 2 0 0 2 M1 WT M1 F 
190 b00996 1 0 0 1 M2 WT WT F 
191 b01006 1 0 0 1 M2 M2 WT F 
192 b01010 1 0 0 1 M2 WT M2 M 
193 b01015 2 0 0 2 M1 WT WT F 
194 b01016 3 0 0 3 M2 WT M2 F 
195 b01038 2 0 0 2 WT WT WT F 
196 b01040 2 0 0 2 WT M2* M2 F 
197 b01043 1 0 0 1 M1 WT WT F 
198 b01044 1 0 0 1 M2 WT M2 M 
199 b01047 1 0 0 1 WT WT WT F 
200 b01050 1 0 0 1 WT M1 M1 F 
201 b01082 1 0 0 1 M1 M1 WT F 
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202 b01083 2 0 0 2 WT WT WT M 
203 b01084 1 0 0 1 WT WT WT M 
204 b01085 1 0 0 1 M2 M2 M2* F 
205 b01086 1 0 0 1 WT WT WT M 
206 b01090 1 0 0 1 WT M1* M1 M 
207 b01134 1 0 0 1 WT WT WT F 
208 b01135 2 0 0 2 WT WT WT M 
209 b01144 1 0 0 1 M2 WT WT M 
210 b01180 3 0 0 3 M1 M1 WT F 
211 b01181 2 0 0 2 WT WT WT M 
212 b01236 2 0 0 2 WT WT WT F 
213 b01237 1 0 0 1 M2 M1/M2 M2 F 
214 b01238 1 0 0 1 M2 M2 M2 M 
215 b01240 1 0 0 1 M2 WT M2 F 
216 b01241 1 0 0 1 M1 M2 M1 M 
217 b01301 2 0 0 2 M1 WT WT M 
218 b01302 1 0 0 1 WT WT WT M 
219 b01321 1 0 0 1 WT WT WT F 
220 b01328 1 0 0 1 WT WT WT F 
221 b01348 1 0 0 1 WT M2 WT F 
222 b01354 1 0 0 1 WT WT WT F 
223 b01388 1 0 0 1 WT M2 WT M 
224 b01394 3 0 0 3 M1 WT M1 M 
225 b01423 1 0 0 1 M1 M2 WT F 
226 b01434 2 0 0 2 WT M2* M2 F 
227 b01451 1 0 0 1 WT WT WT F 
228 b01452 1 0 0 1 M1 WT WT F 
229 b01460 2 0 0 2 WT WT WT F 
230 b01487 1 0 0 1 WT WT WT F 
231 b01513 1 0 0 1 WT WT WT M 
232 b01532 1 0 0 1 M1 WT M1 F 
233 b01533 3 0 0 3 WT WT WT M 
234 b01536 1 0 0 1 WT M1 M1 F 
235 b01539 1 0 0 1 WT WT WT F 
236 b01540 1 0 0 1 WT WT WT F 
237 b01541 2 0 0 2 WT M1 WT M 
238 b01544 1 0 0 1 WT WT WT M 
239 b01545 1 0 0 1 M2 WT M2 F 
240 b01550 1 0 0 1 WT WT WT F 
241 b01553 1 0 0 1 M2 WT M2 M 
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Appendix D - A list of genes prioritized using Ingenuity 
 
A list of variants and genes were prioritized using the software program Ingenuity. This table 
lists all the genes that passed the “Genetic Analysis” filter. Indicated in red are the genes we 
chose to further investigate. 
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APPENDIX E – Variants found in RM patients and controls in gene SERPINB2 
 
No 
 
Region Coordinates Subst 
Asians 
RM 
White 
Europ. 
RM 
Bangladeshi 
controls 
Protein 
change 
SNP type and 
SNP frequency 
WT chromatogram HET chromatogram 
 
1 
 
5’UTR 18:61554966 G>A 
13 het 
2 homo 
2 het 11 het  
rs2288288 
 
0.035 in Europ. 
0.256 in Asians 
  
 
2 
 
Exon 4 18:61564364 C>G 
Patient 
(exome) 
 
 
NONE 
 
 
NONE L110V 
Missense 
 
NOVEL 
  
 
 
3 
 
 
Exon 5 18:61565014 C>T 2 het 
 
 
1 het 
 
 
NONE D157D 
Synonymous 
rs6106 
 
793 in 13006 
alleles   
 
4 
 
Exon 5 18:61565062 C>G 
17 het 
3 homo 
 
 
14 het 
 
 
15 het 
2 homo 
V173V 
Synonymous 
rs6105 
 
575 in 13006 
alleles   
 
5 
 
Exon 6 18:61569091 G>C 1 het 
 
 
NONE 
 
 
2 het G218A 
Missense 
rs143202684 
 
10 in 13006 
alleles   
 
 
6 
 
Exon 7 18:61569697 A>G 1 het 
 
 
NONE 
 
 
2 het I246M 
Missense 
rs138446596 
 
20 in 13006 
alleles   
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7 Exon 8 18:61570470 T>G 
22 het 
4 homo 
 
30 het 
6 homo 
 
37 het 
3 homo 
P393P 
Synonymous 
rs6102 
 
2648 in 13006 
alleles   
8 Exon 8 18:61570473 T>C 1 het 
 
 
NONE 
 
 
 
 
NONE 
 
 
 
 
F394F 
 
 
Synonymous 
 
NOVEL 
  
9 Exon 8 18:61570503 C>G 
31 het 
8 homo 
 
30 het 
6 homo 
 
35 het 
15 homo 
N404K 
Missense 
rs6103 
 
3501 in 13006 
alleles 
  
10 Exon 8 18:61570529 C>G 
31 het 
8 homo 
 
32 het 
6 homo 
 
35 het 
10 homo 
S413C 
Missense 
rs6104 
 
3493 in 13006 
alleles  
 
11 3’UTR 18:61570546 G>A 
 
3 het 
 
 
 
NONE 
 
 
1 het  
 
 
NOVEL 
 
   
12 3’UTR 18:61570982 G>A 4 homo 
 
1 het 
5 homo 
 
1 het 
13 homo 
 
rs12102 
 
0.336 in Europ. 
0.488 in Asians 
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APPENDIX F – Variants found in RM patients and controls in gene FKBP4 
 
No 
 
Region Coordinates Subst 
Asians 
RM 
White 
Europ. 
RM 
Bangladeshi 
controls 
Protein 
change 
SNP type and 
SNP frequency 
WT chromatogram HET chromatogram 
 
1 
 
Exon 1 12:2904352 C>A 
Patient 
(exome) 
NONE NONE A16E 
Missense 
 
NOVEL 
  
 
2 
 
 
Exon 3 12:2907013 C>A 1 het NONE 1 het P123P 
Synonymous 
 
NOVEL 
  
 
3 
 
 
Exon 3 12:2907018 A>G 1 het NONE NONE N125S 
Missense 
rs145385559 
 
2 in 13006 
alleles   
 
4 
 
 
Exon 5 12:2908280 A>C 3 het 1 het 1 het K181Q 
Missense 
Reported SNP 
but rs unknown 
5 in 7632 alleles 
  
 
5 
 
 
Exon 5 12:2908330 C>A 1 het 8 het 
NONE 
 
N197K 
Missense 
rs56196860 
 
289 in 13006 
alleles   
 
6 
 
 
Exon 9 12:2910390 G>A 1 het NONE NONE L380L 
Synonymous 
Reported SNP 
but rs unknown 
 
1 in 13006 
alleles  
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7 Exon 9 12:2910392 A>T 1 het NONE NONE Q381L 
Missense 
 
NOVEL 
  
8 Exon 9 12:2910446 G>A 1 het NONE NONE R399Q 
Missense 
 
NOVEL 
  
9 3’UTR 12:2912469 C>T 1 het NONE NONE  
rs1803818 
 
203 in 12806 
alleles 
  
10 3’UTR 12:2912477 
C 
indel 
2 het NONE NONE  
NOVEL 
 
  
11 3’UTR 12:2913025 C>T 1 het NONE NONE  
rs116573718 
 
3 in 118 alleles 
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